#### (19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 January 2001 (11.01.2001)

#### (10) International Publication Number WO 01/02561 A2

C12N 15/12. (51) International Patent Classification?: C07K 14/705, G01N 33/50, 33/53, A61K 38/17, C12N 15/11, C12Q 1/68, C07K 16/28

British Columbia V6S 1M1 (CA). BAILLIE, David, L. [CA/CA]; 698 Millbank, Vancouver, British Columbia

- (21) International Application Number: PCT/CA00/00794
- (25) Filing Language:

English

(26) Publication Language:

(22) International Filing Date:

**English** 

(30) Priority Data: 09/346,794

2 July 1999 (02.07.1999)

4 July 2000 (04.07.2000)

- (71) Applicant (for all designated States except US): NEU-ROMED TECHNOLOGIES, INC. [CA/CA]; 3250 East Mall, Vancouver, British Columbia V6T 1W5 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SNUTCH, Terrance, P. [CA/CA]; 3963 West 24th Avenue, Vancouver,

V5Z 3Z3 (CA).

(81) Designated States (national): AU, CA, IL, JP, NO, US.

(74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Suite 2200, 650 West Georgia Street, Box

11560, Vancouver, British Columbia V6B 4N8 (CA).

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

#### Published:

Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

10

15

20

25

30



### TECHNICAL FIELD

The invention relates to T-type calcium channel encoding sequences, expression of these sequences, and methods to screen for compounds which antagonize calcium channel activity. The invention is also related to molecular tools derived from knowledge of the molecular structure of T-type calcium channels.

RELATED PROBES, CELL LINES AND METHODS

#### **BACKGROUND OF THE INVENTION**

The rapid entry of calcium into cells is mediated by a class of proteins called voltage-gated calcium channels. Calcium channels are a heterogeneous class of molecules that respond to depolarization by opening a calcium-selective pore through the plasma membrane. The entry of calcium into cells mediates a wide variety of cellular and physiological responses including excitation-contraction coupling, hormone secretion and gene expression. In neurons, calcium entry directly affects membrane potential and contributes to electrical properties such as excitability, repetitive firing patterns and pacemaker activity. Miller, R.J. (1987) "Multiple calcium channels and neuronal function." Science 235:46-52. Calcium entry further affects neuronal functions by directly regulating calcium-dependent ion channels and modulating the activity of calcium-dependent enzymes such as protein kinase C and calmodulin-dependent protein kinase II. An increase in calcium concentration at the presynaptic nerve terminal triggers the release of neurotransmitter. Calcium entry also plays a role in neurite outgrowth and growth cone migration in developing neurons and has been implicated in long-term changes in neuronal activity.

In addition to the variety of normal physiological functions mediated by calcium channels, they are also implicated in a number of human disorders. Recently, mutations identified in human and mouse calcium channel genes have been found to account for several disorders including, familial hemiplegic migraine, episodic ataxia type 2, cerebellar ataxia, absence epilepsy and seizures. Fletcher, et al. (1996) "Absence epilepsy in tottering mutant mice is associated with calcium channel defects." Cell 87:607-617; Burgess, et al. (1997) "Mutation of the Ca2+ channel

10

15

20

25

30



β subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse." Cell 88:385-392; Ophoff, et al. (1996) "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4." Cell 87:543-552; Zhuchenko, O. et al. (1997) "Autosomal dominant cerebellar ataxia (SCA6) associated with the small polyglutamine expansions in the α<sub>1A</sub>-voltage- dependent calcium channel." Nature Genetics 15:62-69.

The clinical treatment of some disorders has been aided by the development of therapeutic calcium channel antagonists. Janis, et al. (1991) in Calcium Channels:

Their Properties. Functions, Regulation and Clinical Relevance. CRC Press, London.

Native calcium channels have been classified by their electrophysiological and pharmacological properties as T, L, N, P and Q types (for reviews see McCleskey, et al. (1991) "Functional properties of voltage-dependent calcium channels." Curr. Topics Membr. 39: 295-326, and Dunlap, et al. (1995) "Exocytotic Ca2+ channels in mammalian central neurons." Trends Neurosci. 18:89-98.). T-type (or low voltageactivated) channels describe a broad class of molecules that activate at negative potentials and are highly sensitive to changes in resting potential. The L. N. P and O-type channels activate at more positive potentials and display diverse kinetics and voltage-dependent properties. There is some overlap in biophysical properties of the high voltage-activated channels, consequently pharmacological profiles are useful to further distinguish them. L-type channels are sensitive to dihydropyridine (DHP) agonists and antagonists, N-type channels are blocked by the Conus geographus peptide toxin, @-conotoxin GVIA, and P-type channels are blocked by the peptide o-agatoxin IVA from the venom of the funnel web spider, Agelenopsis aperta. A fourth type of high voltage-activated Ca channel (O-type) has been described. although whether the Q- and P-type channels are distinct molecular entities is controversial (Sather et al. (1993) "Distinctive biophysical and pharmacological properties of class A (B1) calcium channel a<sub>1</sub> subunits." Neuron 11:291-303; Stea, et al. (1994) "Localization and functional properties of a rat brain  $a_{1A}$  calcium channel reflect similarities to neuronal Q- and P-type channels." Proc Natl Acad Sci (USA) 91:10576-10580; Bourinet, E. et al. (1999) Nature Neuroscience 2:407-415). Several types of calcium conductances do not fall neatly into any of the above categories and there is variability of properties even within a category suggesting that additional calcium channels subtypes remain to be classified.



Biochemical analyses show that neuronal high-threshold calcium channels are heterooligomeric complexes consisting of three distinct subunits ( $\alpha_1$ ,  $\alpha_2\delta$  and  $\beta$ ) (reviewed by De Waard, *et al.* (1997) in *Ion Channels*, Volume 4, edited by Narahashi, T. Plenum Press, New York). The  $\alpha_1$  subunit is the major pore-forming subunit and contains the voltage sensor and binding sites for calcium channel antagonists. The mainly extracellular  $\alpha_2$  subunit is disulphide-linked to the transmembrane  $\delta$  subunit and both are derived from the same gene and are proteolytically cleaved *in vivo*. The  $\beta$  subunit is a non-glycosylated, hydrophilic protein with a high affinity of binding to a cytoplasmic region of the  $\alpha_1$  subunit. A fourth subunit,  $\gamma$  is unique to L-type Ca channels expressed in skeletal muscle T-tubules. The isolation and characterization of  $\gamma$ -subunit-encoding cDNAs is described in U.S. Patent No. 5,386,025 which is incorporated herein by reference.

Molecular cloning has revealed the cDNA and corresponding amino acid sequences of six different types of  $\alpha_1$  subunits ( $\alpha_{1A}$ ,  $\alpha_{1B}$ ,  $\alpha_{1C}$ ,  $\alpha_{1D}$ ,  $\alpha_{1E}$  and  $\alpha_{1S}$ ) and four types of  $\beta$  subunits ( $\beta_1$ ,  $\beta_2$ ,  $\beta_3$  and  $\beta_4$ ) (reviewed in Stea, A., Soong, T.W. and Snutch, T.P. (1994) "Voltage-gated calcium channels." in *Handbook of Receptors and Channels*. Edited by R.A. North, CRC Press). A comparison of the amino acid sequences of these  $\alpha_1$  subunits is included in this publication, which is incorporated herein by reference. PCT Patent Publication WO 95/04144, which is incorporated herein by reference, discloses the sequence and expression of  $\alpha_{1E}$  calcium channel subunits.

As described in Stea, A. et al. (1994) (supra), the  $\alpha_1$  subunits are generally of the order of 2000 amino acids in length, ranging from 1873 amino acids in  $\alpha_{1S}$  derived from rabbit to 2424 amino acids in  $\alpha_{1A}$  derived from rabbit. Generally, these subunits contain 4 internal homologous repeats (I-IV) each having six putative alpha helical membrane spanning segments (S1-S6) with one segment (S4) having positively charged residues every 3rd or 4th amino acid. There are a minority of a splice variant exceptions. Between domains II and III there is a cytoplasmic domain which is believed to mediate excitation-contraction coupling in  $\alpha_{1S}$  and which ranges from 100-400 amino acid residues among the subtypes. The domains I-IV make up roughly 2/3 of the molecule and the carboxy terminus adjacent to the S6 region of domain IV is believed to be on the intracellular side of the calcium channel. There is a consensus motif (QQ-E-L-GY-WI-E) in all of the subunits cloned and described in Stea, A. et al.

10

15

20



(supra) downstream from the domain I S6 transmembrane segment that is a binding site for the B subunit.

PCT publication WO 98/38301, which describes the work of the inventors herein, and which is incorporated herein by reference, reports the first description of the molecular composition of T-type calcium channel  $\alpha_1$  subunits. The present application describes full-length genes for 3 mammalian subtypes,  $\alpha_{1G}$ ,  $\alpha_{1H}$ , and  $\alpha_{1I}$  associated with T-type calcium channels.

In some expression systems the high threshold α<sub>1</sub> subunits alone can form functional calcium channels although their electrophysiological and pharmacological properties can be differentially modulated by coexpression with any of the four β subunits. Until recently, the reported modulatory affects of β subunit coexpression were to mainly alter kinetic and voltage-dependent properties. More recently it has been shown that β subunits also play crucial roles in modulating channel activity by protein kinase A, protein kinase C and direct G-protein interaction. (Bourinet, et al. (1994) "Voltage-dependent facilitation of a neuronal α1C L-type calcium channel." *EMBO J.* 13: 5032-5039; Stea, et al. (1995) "Determinants of PKC- dependent modulation of a family of neuronal calcium channels." *Neuron* 15:929-940; Bourinet, et al. (1996) "Determinants of the G-protein-dependent opioid modulation of neuronal calcium channels." *Proc. Natl. Acad. Sci. (USA)* 93: 1486-1491.)

Because of the importance of calcium channels in cellular metabolism and human disease, it would be desirable to identify the remaining classes of  $\alpha_1$  subunits, and to develop expression systems for these subunits which would permit the study and characterization of these calcium channels, including the study of pharmacological modulators of calcium channel function.

25

30

#### DISCLOSURE OF THE INVENTION

The present invention provides sequences for a novel mammalian calcium channel subunits of T-type calcium channels, which we have labeled as  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  subunits. Knowledge of the sequences of these calcium channel subunits may be used in the development of probes for mapping the distribution and expression of the subunits in target tissues. In addition, as the molecular structure of the  $\alpha_1$  subunits of these T-type calcium channels has been elucidated, it is possible to identify those

10

15

25

30



portions which reside extracellularly and thus to design peptides to elicit antibodies which can be employed to assess the location and level of expression of T-type calcium channels. In addition, these subunits, either alone or assembled with other proteins, can produce functional calcium channels, which can be evaluated in model cell lines to determine the properties of the channels containing the subunits of the invention. These cell lines can be used to evaluate the effects of pharmaceuticals and/or toxic substances on calcium channels incorporating  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  subunits. The resulting identified compounds are useful in treating conditions where undesirable T-type calcium channel activity is present. These conditions include epilepsy, sleep disorders, mood disorders, cardiac hypertrophy and arrythmia and hypertension, among others. In addition, antisense and triplex nucleotide sequences can be designed to inhibit the production of T-type calcium channels.

In some embodiments of the methods and products of this invention, the  $\alpha_1$  subunits are other than those encoded by SEQ ID NO: 17; or, alternatively, are other than those encoded by SEQ ID NO: 17 and by the full length sequences of which SEQ ID NO: 19 and 21 are part. Other embodiments of the methods and products of this invention exclude probes representing portions of or all of SEQ ID NO: 13-21; or, alternatively, exclude probes representing portions of or all of SEQ ID NO: 1-22.

### 20 BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1A and B show a comparison of the waveforms and current voltage relationship for  $\alpha_{1G}$ :

Figs. 2A and B show a comparison of the waveforms and current voltage relationship for  $\alpha_{11}$  calcium channels.

Fig. 3 shows a comparison of the steady state inactivation profiles of the  $\alpha_{IG}$  and  $\alpha_{II}$  calcium channels.

Figs. 4A-C show a comparison of the inactivation kinetics of the  $\alpha_{1G}$  and  $\alpha_{1J}$  calcium channels.

Figures 5A and 5B show the construction of the human  $\alpha_{1G}$  cDNA complete sequence from partial clones.

Figure 6 shows the nucleotide and deduced amino acid sequence of human T-type calcium channel  $\alpha_{1G}$ .

15

20

25

30



Figure 7 shows a comparison of the waveforms and current voltage relationship for human  $\alpha_{1G}$  calcium channel.

Figure 8 shows the characteristic pore pattern for T-type channels.

### 5 MODES OF CARRYING OUT THE INVENTION

The present invention includes the following aspects for which protection is sought:

novel mammalian (including human) calcium channel subunits and (a) DNA sequences encoding such subunits. Specifically, the invention encompasses an at least partially purified DNA molecule comprising a sequence of nucleotides that encodes an a<sub>1</sub> subunit of a T-type calcium channel, and such a<sub>1</sub> subunits per se. It will be appreciated that polymorphic variations may be made or may exist in the DNA of some individuals leading to minor deviations in the DNA or amino acids sequences from those shown which do not lead to any substantial alteration in the function of the calcium channel. Such variations, including variations which lead to substitutions of amino acids having similar properties are considered to be within the scope of the present invention. Thus, in one embodiment, the present application claims DNA molecules which encode at subunits of mammalian T-type calcium channels, and which hybridize under conditions of medium (or higher) hybridization stringency with one or another of the specific sequences disclosed in this application. This level of hybridization stringency is generally sufficient given the length of the sequences involved to permit recovery of the subunits within the scope of the invention from mammalian DNA libraries.

Alternatively, the T-type calcium channels of the invention are recognized by their functional characteristic of low voltage gating along with defined structural characteristics which classify them as  $\alpha_1$  calcium channel subunits and also characterize them as of the T-type. By virtue of the present invention, these characteristics have been elucidated as follows:

One distinguishing feature of the  $\alpha_{IG}$ ,  $\alpha_{IH}$  and  $\alpha_{II}$  T-type channels over other types of calcium channels and sodium channels is that the pore region (P-region) in each of the four structural domains contains a diagnostic amino acid sequence implicated in channel permeability. Figure 8 shows that the T-type channels contain the residues glutamate/glutamate/aspartate/asparate (single letter amino acid code:

10

15

20

25

30



EEDD) in their P-regions (in domains I-IV). In contrast, figure 8 shows that in sodium (Na) channels the P-region of the four domains contains the residues: aspartate/glutamate/lysine/alanine (single letter amino acid code: DEKA), while high threshold calcium channels such as the L-type channel contain the residues: glutamate/glutamate/glutamate/glutamate (single letter amino acid code: EEEE). The  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  T-type channels are also distinct in this region compared to other types of ion channels including the *C. elegans* C11D2.6 and C27F2.3 and the rat NIC-channel (Figure 8).

A second distinguishing characteristic of the  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  T-type channels compared to other types of calcium channels is that they do not contain a  $\beta$  subunit binding consensus sequence in the cytoplasmic linker separating domains I and II. In contrast, all high threshold calcium channels contain a consensus sequence (single letter amino acid code: QQ-E-L-GY-WI-E) shown to physically interact with the calcium channel  $\beta$  subunit (Pragnell, M., De Waard, M., Mori, Y., Tanabe, T., Snutch, T.P. & Campbell, K.P., 1994, Nature 368:67-70). Thus, it appears the presence of a  $\beta$  subunit does not modify activity, nor is its presence required.

A third distinguishing characteristic of the ( $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  T-type channels is that they do not possess an EF-hand calcium binding motif in the region carboxyl to domain IV S6. In contrast, all high threshold calcium channels contain a consensus sequence that is closely related to the EF-hand domain found in certain calcium binding proteins (de Leon, M., Wang, Y., Jones, L., Perez-Reyes, E., Wei, X., Soong, T.W., Snutch, T.P. & Yue, D.T., 1995, Science270: 1502-1506).

Thus, as defined herein, "T-type calcium channel  $\alpha_1$  subunits" refers to subunits which contain these structural characteristics.

Alternatively, the T-type  $\alpha_1$  subunit molecules can be defined by homology to the human and rat nucleotide and amino acid sequences described herein. Thus, T-type  $\alpha_1$  subunits will typically have at least 50% and preferably 70% homology in terms of amino acid sequence or encoding nucleotide sequence to the sequences set forth in SEQ ID NOS. 23-28 herein or those shown in Figure 6. Preferably, the homology will be at least 80%, more preferably 90%, and most preferably 95%, 97%, 98% or 99%.

10

15

20

25

30



Relative homology may also be defined in terms of specific regions; as set forth above, certain regions of T-type channel  $\alpha_1$  subunits have very high homologies while other regions, such as the cytoplasmic region between domains II and III have less homology. Thus, T-type  $\alpha_1$  subunits will have over 75% homology, preferably over 85% or over 95% homology, more preferably over 98% homology in domains I-IV to those of SEQ ID NO: 23-28 or Figure 6. The degree of homology in the cytoplasmic region between domains II and III may be substantially less, *e.g.*, only 25% homology, preferably 50% homology or more preferably 60% homology. Similarly, the intracellular region downstream of domain IV may be less homologous than those within domains I-IV.

- (b) polynucleotide sequences useful as probes in screening human cDNA libraries for genes encoding these novel calcium channel subunits. These probes can also be used in histological assay to determine the tissue distribution of the novel calcium channel subunits.
- As set forth above, the elucidation herein of the structural features of T-type subunits permits the selection of appropriate probes by selecting portions of the encoding nucleotide sequence that are particularly characteristic of this type. As set forth above, for example, T-type subunits have particular patterns of amino acids in the pore forming units as set forth in Figure 8. Alternatively, multiple probes might be used to distinguish other subunits, such as probes which represent the  $\beta$ -binding domain missing from the T-type  $\alpha_1$  subunits combined with a probe representing a consensus sequence for calcium channel  $\alpha$  subunits in general.
- (c) at least partially purified  $\alpha_1$  subunits and related peptides for mammalian T-type calcium channels. These proteins and peptides can be used to generate polyclonal or monoclonal antibodies to determine the cellular and subcellular distribution of T-type calcium channel subunits.

Again, by virtue of the elucidation of the amino acid sequence of T-type  $\alpha_1$  subunits, it is well within the ordinary skill in the art to determine which regions of the channel are displayed extracellularly and to select these regions for the generation of antibodies.

(d) eukaryotic cell lines expressing the novel calcium channel subunits.
These cell lines can be used to evaluate compounds as pharmacological modifiers of the function of the novel calcium channel subunits.

10

15

20

25

30



- (e) a method for evaluating compounds as pharmacological modifiers of the function of the novel calcium channel subunits using the cell lines expressing those subunits alone or in combination with other calcium channel subunits.
- (f) Use of the compounds identified as set forth above for the treatment of conditions which are associated with undesired calcium channel activity.

These diseases include, but are not limited to; epilepsy, migraine, ataxia, schizophrenia, hypertension, arrhythmia, angina, depression and Parkinson's disease; characterization of such associations and ultimately diagnosis of associated diseases can be carried out with probes which bind to the wild-type or defective forms of the novel calcium channels.

T-type channels in particular are responsible for rebound burst firing in central neurons and are implicated in normal brain functions such as slow-wave sleep and in neurological disorders such as epilepsy and mood disorders. They are also important in pacemaker activity in the heart, hormone secretion and fertilization, and are associated with disease states such as cardiac hypertrophy and hypertension.

As used in the specification and claims of this application, the term "T-type calcium channel" refers to a voltage-gated calcium channel having a low activation voltage, generally less than -50 mV, and most commonly less than -60 mV. T-type calcium channels also exhibit comparatively negative steady-state inactivation properties and slow deactivation kinetics. The terms " $\alpha_1$  subunit" or " $\alpha_1$  calcium channel" refer to a protein subunit of a calcium channel which is responsible for pore formation and contains the voltage sensor and binding sites for calcium channel agonists and antagonists. Such subunits may be independently functional as calcium channels or may require the presence of other subunit types for complete functionality.

As used in the specification and claims of this application, the phrase "at least partially purified" refers to DNA or protein preparations in the which the specified molecule has been separated from adjacent cellular components and molecules with which it occurs in the natural state, either by virtue of performing a physical separation process or by virtue of making the DNA or protein molecule in a non-natural environment in the first place. The term encompasses cDNA molecules and expression vectors.

10

15

20

25

30



In accordance with the present invention, we have identified mammalian DNA sequences which code for novel T-type calcium channel  $\alpha_1$  subunits. These subunits are believed to represent new types of  $\alpha_1$  subunits of mammalian voltage-dependent calcium channels which have been designated as types  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$ .

A Bacterial Artificial Chromosome (BAC) sequence (bK206c7) was identified from sequences in Sanger Genome Sequencing Center (Cambridge, U.K.) and the Washington University Genome Sequencing Center (St. Louis. MO) that contains a nucleotide sequence encoding the α<sub>11</sub> subunit of human T-type calcium channel. The rationale for this identification is set forth in WO 98/38301, incorporated herein by reference. The relevant nucleotide sequence and the translated amino acid sequence containing 1854 amino acids are set forth in SEQ ID NO:17 and 18.

As described in WO 98/38031, using PCR cloning techniques to identify relevant sequences within a human brain total RNA preparation, we confirmed that the novel  $\alpha_{11}$  calcium channel subunit is present in human brain. Subcloning of the 567 nt PCR product (Seq. ID No. 19, amino acids Seq. ID No. 20) and subsequent sequencing thereof showed that this product corresponds to the derived sequence from the bK206c7 BAC genomic sequence, the nucleotide sequence of which is given as SEQ ID No. 17 (amino acid sequence Seq. ID No. 18). The same experiment was performed using a rat brain RNA preparation and resulted in recovery of a substantially identical PCR product. (SEQ ID. No. 21). The protein encoded by the rat PCR product (SEQ ID No. 22) is 96% identical to the human PCR product (Seq. ID No. 20).

These sequences, which encode a partial subunit were used as a basis for constructing full length human or rat  $\alpha_{11}$  clones. Briefly, the subcloned  $\alpha_{11}$  PCR product is radiolabeled by random hexamer priming according to standard methods (See, Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning, A Laboratory Manual*. Cold Spring Harbor Press) and used to screen commercial human brain cDNA libraries (Stratagene, La Jolla, CA). The screening of cDNA libraries follows standard methods and includes such protocols as infecting bacteria with recombinant lambda phage, immobilizing lambda DNA to nitrocellulose filters and screening under medium hybridization stringency conditions with radiolabeled probe. cDNA clones homologous to the probe are identified by autoradiography. Positive clones are purified by sequential rounds of screening.

10

15

20

25

30



Following this protocol, most purified cDNA's are likely to be partial sequence clones due the nature of the cDNA library synthesis. Full length clones are constructed from cDNA's which overlap in DNA sequence. Restriction enzyme sites which overlap between cDNAs are used to ligate the individual cDNA's to generate a full-length cDNA. For subsequent heterologous expression, the full-length cDNA is subcloned directly into an appropriate vertebrate expression vector, such as pcDNA-3 (Invitrogen, San Diego, CA) in which expression of the cDNA is under the control of a promoter such as the CMV major intermediate early promoter/enhancer. Other suitable expression vectors include, for example, pMT2, pRC/CMV, pcDNA3.1 and pCEP4.

Following these protocols, full length mammalian  $\alpha_{IG}$ ,  $\alpha_{IH}$  and  $\alpha_{II}$  calcium channel subunit cDNAs were isolated by using the 567 base pair human fragment (Seq. ID No. 19) to screen a rat brain cDNA library. Sequencing of the recovered sequences identified the three distinct classes of calcium channel subunits which have been denominated herein as  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  subunits. For each class of subunit, complete sequencing of the largest cDNA confirmed that it represented only a portion of the predicted calcium channel coding region. Complete sequences for the three new subunits were obtained by rescreening the rat brain cDNA library with probes derived from the partial length cDNAs to obtain overlapping segments. These segments were combined to form a complete gene by restriction digestion and ligation. The complete cDNA sequences of the rat  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  subunits are given by Sequence ID Nos. 23, 25 and 27, respectively. Corresponding amino acid sequences are given by Sequence ID Nos. 24, 26 and 28. The same techniques are employed to recover human sequences by screening of a human or other mammalian library. Thus, for example, partial length human sequences for  $\alpha_{IG}$  and  $\alpha_{IH}$  T-type calcium channels have been recovered using the same probe (Seq. ID No. 19) and the full length rat all cDNA (Seq. ID. No. 27) has been used to recover a partial length DNA encoding a human  $\alpha_{11}$  T-type calcium channel. The DNA and amino acid sequences for these partial length human calcium channels are given by Seq. ID Nos. 30-35. A complete coding sequence for human a<sub>1G</sub> was obtained and is set forth, along with the deduced amino acid sequence, in Figure 6.

Once the full length cDNA is cloned into an expression vector, the vector is then transfected into a host cell for expression. Suitable host cells include *Xenopus* 

10

15

20

25

30



oocytes or mammalian cells such as human embryonic kidney cells as described in International Patent Publication No. WO 96/39512 which is incorporated herein by reference and Ltk cells as described in US Patent No. 5,386,025 which is incorporated herein by reference. Transfection into host cells may be accomplished by microinjection, lipofection, glycerol shock, electroporation calcium phosphate or particle-mediated gene transfer. The vector may also be transfected into host cells to provide coexpression of the novel  $\alpha_1$  subunits with other subunits, such as an  $\alpha_2\delta$  subunit or a  $\gamma$  subunit.

To confirm that the three full length cDNAs (sequence ID Nos. 23, 25 and 27) encoded functional calcium channels, the  $\alpha_{1G}$  and  $\alpha_{1I}$  cDNAs were transiently transfected into human embryonic kidney cells and evaluated using electrophysiological recording techniques. The results are consistent with a role of these subunits in native T-type channels in nerve, muscle and endocrine cells. Similarly, a full length clone encoding human  $\alpha_{1G}$  T-type subunit was recovered and verified to have the characteristic properties of T-type channels.

The resulting cell lines expressing functional calcium channels including the novel α<sub>1</sub> subunits of the invention can be used test compounds for pharmacological activity with respect to these calcium channels. Thus, the cell lines are useful for screening compounds for pharmaceutical utility. Such screening can be carried out using several available methods for evaluation of the interaction, if any, between the test compound and the calcium channel. One such method involves the binding of radiolabeled agents that interact with the calcium channel and subsequent analysis of equilibrium binding measurements including but not limited to, on rates, off rates, K<sub>d</sub> values and competitive binding by other molecules. Another such method involves the screening for the effects of compounds by electrophysiological assay whereby individual cells are impaled with a microelectrode and currents through the calcium channel are recorded before and after application of the compound of interest. Another method, high-throughput spectrophotometric assay, utilizes the loading the cell lines with a fluorescent dye sensitive to intracellular calcium concentration and subsequent examination of the effects of compounds on the ability of depolarization by potassium chloride or other means to alter intracellular calcium levels. Compounds to be tested as agonists or antagonists of the novel all calcium channel subunits are combined with cells that are stably or transiently transformed with a

WO 01/02561

5

10

15

20

25

30



DNA sequence encoding the  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  calcium channel subunits of the invention and monitored using one of these techniques.

Compounds which are shown to modulate the activity of calcium channels can then be used in pharmaceutical compositions for the treatment associated with inappropriate T-type calcium channel activity. Such conditions may also include those with inappropriate calcium channel activity in general since such activity may be modified by enhancing or decreasing T-type channel activity. Conditions appropriate for such treatment include those set forth above. The compounds identified are formulated in conventional ways as set forth in Remington's "Pharmaceutical Sciences," latest edition, Mac Publishing Co., Easton, PA. Modes of administration are those appropriate for the condition to be treated and are within the ordinary skill of the practitioner.

In addition, the regulation of expression of T-type calcium channels can be achieved by constructing expression systems encoding antisense sequences or sequences designed for triplex binding to interrupt the expression of nucleotide sequences encoding the T-type calcium channels of the invention.

DNA fragments with sequences given by SEQ ID Nos. 13-17 and 19, or polynucleotides with the complete coding sequences as given by Sequence ID Nos. 23, 25 and 27 or Figure 6, or distinctive portions thereof which do not exhibit non-discriminatory levels of homology with other types of calcium channel subunits may also be used for mapping the distribution of  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  calcium channel subunits within a tissue sample. This method follows normal histological procedures using a nucleic acid probe, and generally involves the steps of exposing the tissue to a reagent comprising a directly or indirectly detectable label coupled to a selected DNA fragment, and detecting reagent that has bound to the tissue. Suitable labels include fluorescent labels, enzyme labels, chromophores and radio-labels.

Heterologous Expression of Mammalian T-type Calcium Channels in Cells

A. Transient Transfection in Mammalian Cells

Host cells, such as human embryonic kidney cells, HEK 293 (ATCC# CRL 1573) are grown in standard DMEM medium supplemented with 2 mM glutamine and 10% fetal bovine serum. HEK 293 cells are transfected by a standard calcium-phosphate-DNA co-precipitation method using a full-length mammalian  $\alpha_1$  T-type

#### WO 01/02561

5

10

15

20

25

30



calcium channel cDNA (for example, Seq. ID. No. 27) in a vertebrate expression vector (for example see Current protocols in Molecular Biology). The  $\alpha_{11}$  calcium channel cDNA may be transfected alone or in combination with other cloned subunits for mammalian calcium channels, such as  $\alpha 2\delta$  and  $\beta$  or  $\gamma$  subunits, and also with clones for marker proteins such the jellyfish green fluorescent protein.

Electrophysiological Recording: After an incubation period of from 24 to 72 hrs the culture medium is removed and replaced with external recording solution (see below). Whole cell patch clamp experiments are performed using an Axopatch 200B amplifier (Axon Instruments, Burlingame, CA) linked to an IBM compatible personal computer equipped with pCLAMP software. Microelectrodes are filled with 3 M CsCl and have typical resistances from 0.5 to 2.5 M ohms. The external recording solution is 2 mM BaCl<sub>2</sub> 1 mM MgCl<sub>2</sub>, 10 mM HEPES, 40 mM TEACl, 10 mM Glucose, 92 mM CsCl, (pH 7.2). The internal pipette solution is 105 mM CsCl, 25 mM TEACI, 1 mM CaCl<sub>2</sub>, 11 mM EGTA, 10 mM HEPES (pH 7.2). Currents are typically elicited from a holding potential of -100 mV to various test potentials. Data are filtered at 1 kHz and recorded directly on the harddrive of a personal computer. Leak subtraction is carried out on-line using a standard P/5 protocol. Currents are analyzed using pCLAMP versions 5.5 and 6.0. Macroscopic current-voltage relations are fitted with the equation  $I = \frac{1}{1 + \exp(-(V_m - V_h)/S)} \times G - (V_m - E_{rev})$ , where  $V_m$  is the test potential, V<sub>h</sub> is the voltage at which half of the channels are activated, and S reflects the steepness of the activation curve and is an indication of the effective gating charge movement. Inactivation curves are normalized to 1 and fitted with I =  $(1/1 + \exp((V_m - V_b)/S))$  with  $V_m$  being the holding potential. Single channel recordings are performed in the cell-attached mode with the following pipette solution (in mM): 100 BaCl<sub>2</sub>, 10 HEPES, pH 7.4 and bath solution: 100 KCl, 10 EGTA, 2 MgCl<sub>2</sub>, 10 HEPES, pH 7.4.

#### B. Transient Transfection in Xenopus Oocytes

Stage V and VI Xenopus oocytes are prepared as described by Dascal et al (1986), Expression and modulation of voltage-gated calcium channels after RNA injection into Xenopus oocytes. Science 231:1147-1150. After enzymatic dissociation with

#### WO 01/02561

5



collagenase, oocytes nuclei are microinjected with the human a<sub>11</sub> calcium channel cDNA expression vector construct (approximately 10 ng DNA per nucleus) using a Drummond nanoject apparatus. The α<sub>11</sub> calcium channel may be injected alone, or in combination with other mammalian calcium channel subunit cDNAs, such as the α2-δ and β1b and γ subunits. After incubation from 48 to 96 hrs macroscopic currents are recorded using a standard two microelectrode voltage-clamp (Axoclamp 2A, Axon Instruments, Burlingame, CA) in a bathing medium containing (in mM): 40 Ba(OH)2,, 25 TEA-OH, 25 NaOH, 2 CsOH, 5 HEPES (pH titrated to 7.3 with methan-sulfonic acid). Pipettes of typical resistance ranging from 0.5 to 1.5 M ohms are filled with 2.8M CsCl, 0.2M CsOH, 10mM HEPES, 10mM BAPTA free acid. Endogenous Ca (and Ba) -activated Cl currents are suppressed by systematically injecting 10-30 nl of a solution containing 100mM BAPTA-free acid, 10mM HEPES (pH titrated to 7.2 with CsOH) using a third pipette connected to a pneumatic injector. Leak currents and capacitive transients are subtracted using a standard P/5 procedure.

15

20

25

30

10

## Construction of Stable Cell Lines Expressing Mammalian T-type Calcium Channels

Mammalian cell lines stably expressing human α11 calcium channels are constructed by transfecting the all calcium channel cDNA into mammalian cells such as HEK 293 and selecting for antibiotic resistance encoded for by an expression vector. Briefly, a full-length mammalian T-type calcium channel a<sub>1</sub> subunit cDNA (for example Seq. ID No. 27) subcloned into a vertebrate expression vector with a selectable marker, such as the pcDNA3 (InvitroGen, San Diego, CA), is transfected into HEK 293 cells by calcium phosphate coprecipitation or lipofection or electroporation or other method according to well known procedures (Methods in Enzymology, Volume 185, Gene Expression Technology (1990) Edited by Goeddel. D.V.). The an calcium channel may be transfected alone, or in combination with other mammalian calcium channel subunit cDNAs, such as the α2-δ and β1b subunits, either in a similar expression vector or other type of vector using different selectable markers. After incubation for 2 days in nonselective conditions, the medium is supplemented with Geneticin (G418) at a concentration of between 600 to 800 ug/ml. After 3 to 4 weeks in this medium, cells which are resistant to G418 are visible and can be cloned as isolated colonies using standard cloning rings. After growing up



each isolated colony to confluency to establish cell lines, the expression of  $\alpha_{11}$  calcium channels can be determined at with standard gene expression methods such as Northern blotting, RNase protection and reverse-transcriptase PCR.

The functional detection of  $\alpha_{11}$  calcium channels in stably transfected cells can be examined electrophysiologically, such as by whole patch clamp or single channel analysis (see above). Other means of detecting functional calcium channels include the use of radiolabeled <sup>45</sup>Ca uptake, fluorescence spectroscopy using calcium sensitive dyes such as FURA-2, and the binding or displacement of radiolabeled ligands that interact with the calcium channel.

10

15

20

25

30

5

### EXAMPLE 1

### Partial Rat and Human Subunits

In order to recover mammalian sequences for novel calcium channels, the 567 base pair partial length human brain  $\alpha_{11}$  cDNA described in WO 98/3801 was gelpurified, radio-labelled with <sup>32</sup>P dATP and dCTP by random priming (Feinberg et al., 1983, Anal. Biochem. 132: 6-13) and used to screen a rat brain cDNA library constructed in the phase vector Lambda Zapp II. (Snutch et al., 1990, Proc Natl Acad Sci (USA) 87: 3391-3395). Screening was carried out at 62°C in 5XSSPE (1XSSPE=0.18 M NaCl; 1mM EDTA; 10 mM sodium phosphate, pH=7.4 0.3% SDS, 0.2 mg/ml denatured salmon sperm DNA). Filters were washed at 62°C in 0.2X SSPE/0.1% SDS. After three rounds of screening and plaque purification, positive phages were transformed into Bluescript phagemids (Stratagene, La Jolla, CA) by in vivo excision.

Double stranded DNA sequencing on the recombinant phagemids was performed using a modified dideoxynucleotide protocol (Biggin *et al.*, 1983, *Proc Natl Acad Sci (USA)* 80:3963-3965) and Sequenase version 2.1 (United States Biochemical Corp.). DNA sequencing identified three distinct classes of calcium channel  $\alpha_1$  subunits: designated as  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  calcium channel subunits.

For each class of calcium channel  $\alpha_1$  subunit, the largest cDNA was completely sequenced and determined to represent only a portion of the predicted calcium channel coding region. In order to isolate the remaining portions of  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channel subunits, the  $\alpha_{1G}$  clone was digested with HindIII and SpeI. The resulting 540 base pair fragment was gel purified, radiolabeled with <sup>32</sup>P dATP and dCTP by random priming and used to rescreen the rat brain cDNA library as described above. The sequence of the 540 base pair  $\alpha_{1G}$  screening probe used is given

10

15

20

25

30



by Seq. ID No. 29. Other sequences spanning regions of distinctiveness within the sequences for the subunits could also be employed.

Double-stranded DNA sequencing of the purified recombinant phagemids showed that additional  $\alpha_{1G}$ ,  $\alpha_{1H}$  and  $\alpha_{1I}$  calcium channel subunit cDNAs overlapped with the original partial length cDNAs and together encoded complete protein coding regions as well as portions of their respective 5' and 3' non-coding untranslated regions.

To recover further human sequences for the novel  $\alpha_{IG}$  and  $\alpha_{IH}$  calcium channels, the 567 base pair partial length human brain α1 cDNA (Seq. 19) was radiolabelled with <sup>32</sup>P dATP and dCTP by random priming and used to screen a commercial human thalamus cDNA library (Clontech). Hybridization was performed overnight at 65 °C in 6 X SSPE; 0.3% SDS; 5X Denhardt's. Filters were washed at 65 °C in 0.1 X SSPE/ 0.3% SDS. After four rounds of screening and plaque purification, positive phages were selected, DNA prepared and the insert cDNA excised from the lambda vector by digestion with Eco R1 restriction enzyme. The excised cDNA was subcloned into the plasmid Bluescript KS (Stratagene, La Jolla, CA) and the DNA sequence determined using a modified dideoxynucleotide protocol and Sequence version 2.1. The partial length  $\alpha_{1G}$  cDNA isolated consisted of 2212 base pairs of which 279 base pairs were 5' noncoding and 1,933 base pairs were coding region representing 644 amino acids (Seq. ID Nos. 30, 31). The partial  $\alpha_{1H}$ cDNA isolated consisted of 1,608 base pairs of which 53 base pairs were 5' noncoding and 1.555 were coding region representing 518 amino acids (Seq. ID Nos. 32, 33).

To recover further human sequences for the novel α<sub>11</sub> calcium channel, the full-length rat brain α<sub>11</sub> cDNA (Seq. 27; see example 2) was radio-labelled <sup>32</sup>P dATP and dCTP by random priming and used to screen a commercial human hippocampus cDNA library (Stratagene). Hybridization was performed overnight at 65°C in 6 X SSPE; 0.3% SDS; 5X Denhardt's. Filters were washed at 65° C in 0.1 X SSPE/ 0.3% SDS. After four rounds of screening and plaque purification, positive phages were transformed into Bluescript phagemids (Stratagene, LA Jolla, CA) by *in vitro* excision. The excised cDNA DNA sequence was determined using a modified dideoxynucleotide protocol and Sequenase version 2.1. The partial α<sub>11</sub> cDNA isolated

10

15

20

25

30



consisted of 1,080 base pairs of coding region representing 360 amino acids (Seq. ID Nos. 34, 35).

#### **EXAMPLE 2**

#### Full Length Rat Subunits

Double-stranded DNA sequencing of the purified recombinant phagemids from rat brain showed that additional  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channel cDNAs overlapped with the original partial length cDNAs and together encoded complete protein coding regions as well as portions of their respective 5' and 3' non-coding untranslated regions. (Seq. ID Nos. 23 and 27, respectively) In addition to the  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channel classes, DNA sequencing of the recombinant phagemids also identified a third class of calcium channel  $\alpha_{1}$  subunit: designated as the  $\alpha_{1H}$  calcium channel subunit. The partial length  $\alpha_{1H}$  calcium channel cDNAs overlapped and together encoded a complete  $\alpha_{1H}$  coding region as well as portions of the 5' and 3' untranslated regions (Seq. ID. No. 25).

Electrophysiological studies were performed on transiently-transfected human embryonic kidney cells (HEK-tsa201) prepared using the general protocol above. Transfection was carried out by standard calcium phosphate precipitation. (Okayama et al., 1991, Methods in Molec. Biol., Vol. 7, ed. Murray, E.J.). For maintenance, HEK-tsa201 cells were cultured until approximately 70% confluent, the media removed and cells dispersed with trypsin and gentle trituration. Cells were then diluted 1:10 in culture medium (10% FBS, DMEM plus L-glutamine, pen-strp) warmed to 37°C and plated onto tissue culture dishes. For transfert transfection, 0.5 mM CaCl<sub>2</sub> was mixed with a total of 20 µg of DNA (consisting of 3µg of either rat brain α<sub>1G</sub> or α<sub>11</sub> calcium channel cDNA, 2 μg of CD8 plasmid marker, and 15 μg of Bluescript plasmid carrier DNA). The DNA mixture was mixed thoroughly and then slowly added dropwise to 0.5 ml of 2 times HeBS (274 mM NaCl, 20mM D-glucose, 10mM KCl, 1.4 mM Na<sub>2</sub>HPO<sub>4</sub>, 40 mM Hepes (pH=7.05). After incubation at room temperature for 20 min, 100 µl of the DNA mixture was slowly added to each dish of HEK-tsa201 cells and then incubated at 37°C for 24 to 48 hours in a tissue culture incubator (5% CO<sub>2</sub>).

Positive transfectant cells were identified visually by addition of 1 µl of mouse CD8 (Lyt2) Dynabeads directly to the recording solution and gentle swirling to mix. Whole cell patch clamp readings were carried out with an Axopatch 200A amplifier

10

15

20

25

30



(Axon Instruments) as described previously. (Zamponi et al., 1997, Nature 385: 442-446). The external recording solution was 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, 40 mM TEA-Cl, 10 mM glucose, 92 mM CsCl, pH=7.2 with TEA-hydroxide. The internal pipette solutions was 105 mM CsCl, 25 mM TEA-Cl, 1mM CaCl<sub>2</sub>, 11 mM EGTA, 10 mM HEPES, pH 7.2 with NaOH.

For determination of current-voltage (I-V) relationships, cells were held at a resting potential of -100 mV and then stepped to various depolarizing test potentials. For steady-state inactivation, cells were held at varius potentials for 20 sec. and currents recorded during a subsequent test pulse to the peak potential of the I-V. Leak currents and capacitative transients were subtracted using a P/5 procedure.

Figs. 1-4 show the results obtained for HEK cells transfected with and expressing the cDNA of sequences ID Nos. 23 and 27, which correspond to the subunits designated as  $\alpha_{1G}$  and  $\alpha_{1I}$ . Figs. 1A and B and 2A and B shows a comparison of the waveforms and current- voltage relationship for the two channel subunit types. In the presence of recording solution containing 2mM  $Ca^{2+}$ , both the  $\alpha_{1G}$  and  $\alpha_{1I}$  channel subunits exhibit activation properties consistent with native T-type calcium currents. Figs 1 A and 2A show the subunit calcium current from a cell held at -120 mV and depolarized to a series of test potentials. Figs 1B and 2B show the magnitude of the calcium current. From a holding potential of -110 mV, both channel first activate at approximately -70 mV and peak currents are obtained between -40 and -50 mV. Upon depolarization to various test potentials, the current waveforms of the  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channels exhibit an overlapping pattern characteristic of native T-type channels in nerve, muscle and endocrine cells.

Fig. 3 shows steady-state inactivation profiles for the  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channels in HEK 293 cells transiently transformed with full length cDNAs (SEQ ID Nos 23 or 27) for  $\alpha_{1G}$  or  $\alpha_{1I}$  subunits. Steady state inactivation properties were determined by stepping from -120 mV to prepulse holding potentials between -120 mV and -50 mV for 15 sec.. prior to a test potential of -30 mV. The data are plotted as normalized whole cell current versus prepulse holding potential and show that  $\alpha_{1G}$  exhibits a V<sub>50</sub> of approximately -85 mV and  $\alpha_{1I}$  a V<sub>50</sub> of approximately -93 mV. Thus, consistent with native T-type calcium channels, both of the  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channels exhibit pronounced steady-state inactivation at negative potentials.

10

15

20

25

30



Figs. 4A-C show a comparison of the voltage-dependent deactivation profiles of the  $\alpha_{1G}$  and  $\alpha_{1I}$  calcium channels. HEK 293 cells were transiently transfected with either an  $\alpha_{1G}$  or  $\alpha_{1I}$  subunit cDNA (Seq. ID No. 23 or 27). The deactivation properties of  $\alpha_{1G}$  were determined by stepping from a holding potential of -100 mV to -40mV for 9 msec, and then to potentials between -120 mV and -45 mV. The deactivation properties of  $\alpha_{1I}$  were determined by stepping from a holding potential of -100 mV to -40 mV for 20 msec, and then to potentials between -120 mV and -45 mV. Both channels exhibit slow deactivation kinetics compared to typical high-threshold channels, and is consistent with the  $\alpha_{1G}$  and  $\alpha_{1I}$  subunits being subunits for T-type calcium channels

#### Example 3

# Cloning of a Full Length cDNA for the Human $\alpha 1_G$ T-Type Calcium Channel Subunit

#### Materials and Methods:

A full length cDNA encoding the human  $\alpha_{1G}$  subunit was constructed from 5 overlapping clones (Figure 1B) isolated from a human thalamus cDNA library constructed in  $\lambda gt11$  vector (Clontech, Cat#HL5009b).

Three Agt11 cDNA clones were isolated by conventional filter hybridization.

Clone 1 was identified by hybridization to a 567 bp cDNA probe (SEQ ID NO: 19) containing the transmembrane region S4 to S6 of domain I of the previously cloned human neuronal  $\alpha_{11}$  T-type calcium channel subunit. Clones HG10-1112 and HG5-1211 were identified by hybridization to a 1265 bp cDNA probe of the rat  $\alpha_{1H}$  T-type calcium channel subunit spanning domain II and part of the II-III intracellular loop. cDNA probes were <sup>32</sup> P-dCTP labelled by random priming using a Multiprime DNA labeling system (Amersham Pharmacia). Plaque lifts using H-bond nylon membranes were done in duplicate following the standard protocols supplied by manufacturer (Amersham Pharmacia). Hybridization was performed for at least 16hrs at 65°C for clone 1 and for at least 16hrs at 58°C, clones HG10-1112 and HG5-1211. Membranes were washed in 0.1X SSC/0.3% SDS at 62°C for clone 1 and 0.2X SSC/0.1% SDS at 58°C clones HG10-1112 and HG5-1211. Blots were exposed to BioMax MS Kodak film with Kodak HE intensifying screens for at least 48hrs at -80°C. Double positive plaques were isolated and re-screened to isolate single clones

10

15

20

25

30



according to the procedure above. Bacteriophage DNAs were then isolated according to the  $\lambda$ gt11 library User Manual (Clontech). Clone 1 cDNA insert was excised with EcoRI (NEB) and subcloned into pBluescriptKS (Stratagene). Clones HG10-1112 and HG5-1211 cDNA inserts were excised from  $\lambda$ DNA with Not I (NEB) and subcloned into the Not I site of pBluescriptKS. Plasmids with cDNA inserts were transformed by electroporation into XL-I E.Coli host strain bacteria and sequenced using universal reverse and forward primers according to Sanger double stranded DNA sequencing method in combination with automatic sequencing ABI 100 PRISM model 377 Version3.3 (PE Biosystems).

Clone 1 was identified as a human  $\alpha_{1G}$  subunit containing the 5'UTR and 1933 bp of the in-frame coding region, including part of the intracellular I-II loop. Clone HG10-1112 was identified as a human  $\alpha_{1G}$  subunit of 3915 bp, spanning Domain I (IS5-IS6) to the III-IV loop. Clone HG5-1211 was identified as human  $\alpha_{1G}$  subunit of 3984 bp containing the I-II linker and C-terminus.

For expression in HEK cells, removal of 5' UTR from clone 1 was achieved by replacing 5'UTR DNA fragment flanked by Hind III/SacII restriction sites with 5'end - 291 bp cDNA fragment, containing translation start site and an incorporated Hind III site for subsequent cloning into pcDNA3.1 (Invitrogen). Following PCR conditions were used: 94°C -30 sec, 45°C -30 sec, 72°C -30 sec for 5 cycles and followed by 94°C -30 sec, 48°C -30 sec, 72°C -30 sec for 20 cycles (Bio-rad Gene Cycler). The cDNA fragment was subcloned into p-Gem-T-Easy plasmid vector (Promega) and the DNA sequence determined.

The remaining region of the 3'  $\alpha_{1G}$  subunit cDNA was obtained using the PCR method on a human thalamus cDNA library with primers MD19-sense (5'GCG TGG AGC TCT TTG GAG 3') and G26- antisense (5' GCA CCC AGT GGA GAA AGG TG 3'). The PCR protocol used was 94°C -30 sec, 58°C -30 sec, 72°C -30 sec for 25 cycles (Bio-rad Gene Cycler). A cDNA fragment of 1617 bp was subcloned into p-Gem-T-Easy plasmid vector (Promega) and sequenced. The 3'PCR cDNA was identified as a human  $\alpha_{1G}$  subunit spanning from Domain IV-S5 to the carboxyl terminus including the stop codon.

Unique restriction sites (Figures 5A and B) of the partial cDNA clones were used to construct the full length human  $\alpha_{1G}$  T-type calcium channel in pcDNA3.1 Zeo

10

15

20

25



(+) (Invitrogen) mammalian expression vector.

The complete nucleotide and amino acid sequences are shown in Figure 6. In order to determine the functional properties of the human  $\alpha_{1G}$  channel standard calcium-phosphate transfection was used to transiently express the channel in HEK ts201 cells. Cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum, 200 U/ml penicillin and 0.2 mg/ml streptomycin at 37°C with 5% CO<sub>2</sub>. At 85% confluency cells were split with 0.25% trypsin/1 mM EDTA and plated at 10% confluency on glass coverslips. At 12 hours the medium was replaced and the cells transiently transfected using a standard calcium phosphate protocol and the  $\alpha_{IG}$  calcium channel cDNA. Fresh DMEM was supplied and the cells transferred to 28°C/5% CO<sub>2</sub>. Cells were incubated for 1 to 2 days prior to whole cell recording. Whole cell patch recordings were performed using an Axopatch 200B amplifier (Axon Instruments) linked to an IBM compatible personal computer equipped with pCLAMP version 7.0 software. The intrapipette solution contained (in mM): 105 CsCl, 25 CsCl, 1 CaCl<sub>2</sub>, 11 EGTA, 10 HEPES, pH 7.2. The extracellular solution contained (in mM): 40 TEA-Cl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 92 CsCl, 10 glucose, 10 HEPES, pH 7.2.

Figure 7 shows that the human  $\alpha_{1G}$  cDNA encodes a calcium channel with typical properties of a T-type current. The left panel illustrates representative current traces obtained from a holding potential of -100 mV to test pulses potentials of -90 mV to +20 mV. The traces show a typical crossover pattern and considerable inactivation during the test pulse, both of which are consistent with native T-type channels. The right panel shows a plot of the peak whole current at various test potentials and indicates that the human  $\alpha_{1G}$  cDNA first activates near -60 mV with maximal current near -40 mV, which is also consistent with native low-threshold T-type calcium channels.

#### Claims

- 1. A DNA molecule which comprises an expression cassette wherein said expression cassette comprises a nucleotide sequence encoding a T-type calcium channel  $\alpha_1$  subunit, said encoding sequence operably linked to control sequences to effect its expression.
- 2. The DNA molecule of claim 1 wherein said  $\alpha_1$  subunit is  $\alpha_{1G}$ ,  $\alpha_{1H}$ , or  $\alpha_{1I}$ .
- 3. The DNA molecule of claim 2 wherein said  $\alpha_1$  subunit is derived from a mammal.
- 10 4. Recombinant host cells modified to contain the DNA molecule of any of claims 1-3.
  - 5. The cells of claim 4 which are mammalian cells.
- 6. A method to effect production of a functional calcium channel which method comprises culturing the cells of claim 4 or 5 under conditions wherein said
   15 functional calcium channels are produced.
  - 7. A method to identify a compound which is a modulator for T-type mammalian calcium channels, which method comprises contacting the cells employed in the method of claim 6 with said compound and assessing the effect of said compound on said cells.
- 20 8. A T-type calcium channel modulator identified by the method of claim 7.
  - 9. A method to treat conditions characterized by undesirable levels of T-type calcium channel activity which method comprises administering to a subject in need of such treatment an effective amount of the modulator of claim 8.



- 10. The method of claim 9 wherein said condition is cardiac hypertrophy, cardiac arrythymia, hypertension, a sleep disorder, or epilepsy.
- 11. A DNA molecule which comprises an expression system for a nucleotide sequence which is complementary to the nucleotide sequence encoding a
   5 T-type calcium channel α<sub>1</sub> subunit or which forms a triple helix with DNA comprising said encoding sequence.
  - 12. A method to treat a condition characterized by an undesirable level of T-type calcium channel activity which method comprises administering to a subject in need of such treatment an effective amount of the DNA molecule of claim 11.
- 10 13. The method of claim 12 wherein said condition is cardiac hypertrophy, cardiac arrythmia, hypertension, a sleep disorder, or epilepsy.
  - 14. An oligonucleotide which consists essentially of a nucleotide sequence characteristic of a T-type calcium channel  $\alpha_1$  subunit, said oligonucleotide coupled to or comprising a detectable label.
- 15. A method to map the distribution of T-type calcium channels in a tissue which method comprises contacting said tissue with the oligonucleotide of claim 14.
  - 16. Antibodies specifically immunoreactive with the extracellular portions of a T-type calcium channel.
- 20 17. A method to map the distribution of T-type calcium channels in a tissue which method comprises contacting said tissue with the antibodies of claim 16.



1/18




FIG. 1A




FIG. 1B




FIG. 2A







FIG. 2B




SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)

71 131 27 191 47 251 67 311 107 431 127 491 167 6611 GGG GAG GAC GAC D D AGC S S S TTC TTC Y TAC Y TAC Y TAC G CGG CTC AAC GAC CTG T R L N D L S C CCG GGC AGC GCG GAC T P G S A D S T TTC TTC TAC TTG AGC C P W F E R I P W F E R I S C CCC TGG TTT GAG CGC A P W F E R I F R C E D F I F A C D D F I F A C ATC TTT GGG AAA AAG T I F G K K C I F G K K C C ATC TTT GGG AAA AAG T I F G K K C I F G K K C I F G K K C I F G K K C I A G M L E 3 ACA GTC CGT GTG CTG C aagcttgcttgcccctctccggatcgcccggggccccggctggccagagg ATG ATG
M
GAC
D
GTT
V
AAC
N
ATG
M
TTT
F
GGC
G
G
G
G
R
AGG F AAG K GTG V TGT C GGC GGC A A TTG I L ATC A A TC A A TC A A TC A A A TC A A A TC A A A TC A A A TC A A A TC A A AGC
S
GAA
E
CCG
CCG
V
V
CTG
CAG
Q
A
TTC
F
F CGG
R
GCA
GCC
A
ACG
T
T
CTG
L
L
L
TTTT
TTTT
F
S CCC P TCA S S CTG CTG V V ATC ATC D N GAC GAC F TTC F CAG Q GGG GCG CTC CTC CGG K AAGC S TCG S GGG GGG GGC TGG W CTC L CGC CGC N N AAC GAG E CCG P CCG S S CTT L CAG M ATG GAG E CGG CGG CTG L L TTCC S GAG GAG T ACT 600 600 600 600 600 600 7 600 800 800 600 600 600 L TGT C GCC A A GGA G A GCC A GCG A AGC S ATG 192 48 252 68 88 108 432 312 372 TITUTE SHEET (RULE 26)

FIG. 6/

71	7.0	31	7.7	31	17	51	57	11	37	71	11	)31	Li	91	13	.51	1.5	111	387
9	2	7	2	7	5	ထ်	2(	9	28	9	3	10	32	10	34	Π	36	12	38
					Œı														
					Z														
CTG	ᆸ	TIC	뚀	GAG	[sc]	GAT	Ω	GTG	Λ	TAC	<b>&gt;</b>	909	r C	ATC	н	GAT	Д	TTC	Ľz.,
CTG	ıı	ATC		CCI	വ	GAG	团	AGC	ഗ	ည္ဟ	æ	TCA	လ	16G	×	ATG	Σ	TIC	Ľz.,
TTG	ᆸ	TTC	ഥ	CTA	ᄓ	AAC	z	AGA	<b>~</b>	GAG	臼	TGC	ပ	ည္ဟ	Æ	GTG	Λ	TCC	Ś
					ᄄ														
					ပ														
					~														
					z														
ည္ပ	<b>~</b>	TGC	ပ	9	<b>¤</b>	TAT	×	9	ტ	TGC	ပ	CAG	Ø	GAC	۵	GAC	Ω	CTC	ц
					ы														
AGC	ഗ	CTG	ц	CTG	ы	GAG	ы	GAG	田	CCA	വ	TGG	æ	AAC	z	7GG	<b>3</b>	ATC	<b>⊢</b>
					ၒ														
GTG	>	GIC	Λ	GCA	¥	GAC	<b>Q</b>	CCA	പ	GGT	ဗ	GTC	^	ည္ဟ	Æ	GAG	Œ	TAC	>-
999	~	AAC	z	$\mathbb{I}$ GG	S	GTG	Λ	CAG	O	ည္သမ္မ	ტ	TGT	ပ	ည္ဟမ္	ග	CIG	ı⊐	ATC	<b>—</b>
AAC	z	ည္ဟ	ဗ	CTG	-7	AGC	ß	1CC	လ	999	ບ	ACC	H	AAG	×	ACG	Ė	TIC	드니
					Õ														
ည္ပ	æ	ATG	Σ	GTC	>	ည္ဟ	Д	ATC	н	999	ഗ	AAC	×	ည္သ	Д	GIC	>	TAC	<b>&gt;</b> -
					g														
CIC	H	CTG	ы	GTC	>	AGC	ഗ	ည္ဟ	Д	CTG	ᄓ	ICC	S	CAC	Ħ	TTC	ſΞι	ICC	ഗ
					228														
						S	UBS'	TITU	STE	SHE	ET (	(RUL	E 2	6)					

CAG
CTG
L
L
L
L
ATC
S
CAC
N
N
N
N
TCT
S
TTTA
L
L
ACT GAG GCC GCC GTG V V V S CCT GAG GAG GAG S AACC CCC CCC CCC CCC CCC AACC CCCC AACC CCCC AACC CCCC AACC CCCC AACC ACG
TTC
F
CGG
CGG
CGG
CGG
TC
TC
CCAC
F
CCAC
F
CCAC
F
CCAC
F
CCA GTG
V
CGT
Y
Y
CAG
Q
GGC
G
G
CAC
H
H
A
A
G
G
G
CCC
CCC
CCC
CCC GTG CAG GGG GGG GGG CTC L L CTC CTC S S S CTG

L

CTG

S

CTG

L

L

CTC

L

CTC

T

AGG

AGG

R

R

CCC

CCC

CCTC TGC CGG GGC GGC CCC CCC CGC GGGG GGG N CTG L GAG GCC GCC CCA CCCA CGC G GGG GGG 1212 388 388 1272 408 1332 448 1452 468 468 1572 508 1632 508 1632 508 1632 508 SUBSTITUTE SHEET (RULE 26)

F1G. 6



1871 607 1931 627 1991 647 2051 2111 687 2111 707 2231 727 2231 747 2291																			
CTA	ь <del>,</del>	999	ഗ	$\mathbf{ICI}$	ഗ	TGC	ນ	GAC	۵	GAC	Ω	ည္ဟ	A	999	24	CAG	0	ည္သ	A
GCA	ø;	ည္ပ	ρ.,	AGC	တ	AGC	တ	SCI	മം	999	<b>~</b>	CTG	П	399	G	GAG	压	TTT	[z.,
AAG	~	CCA	٠,	CAA	ŏ	GAC	Ω	AIG	E	CIC	ы	GTG	>	TTT	[±4	CAC	E	CIC	ᆔ
GAG	떠	ATC	<b>  </b>	TGC	ပ	SS	Д	GAA	田	GAC	Q	TCT	S	TAC	<b>&gt;</b> -	TAC	5-1	AGC	
AAG	×	AAC	Z	ည္ဟ	Æ	GGT	ဗ	CGT	24	AGC	S	AGC	S	AAG	<b>×</b>	GAA	ы	ACC J	E
CIG	ᆸ	CIC	П	GGT	ဗ	IGT	ပ	GAC	D	CAC	н	ည္သ	വ	AGC	တ	ATC	Н	TTC	Gen
ACG	E	AGC	മ	ACA	E⊸	ည္ဟ	A	ည္ဟ	A	CAG	Õ	GAG	E	GAC	Ω	ည္ဟမ္မ	හ	GIC	
GAG	떠	ACC	₽	AGT	S	GGA	ტ	CIC	ᆸ	ည္ဟ	Æ	SCA	sat.	STG	. <del></del>	4TG	-	ATC	_
ည္သ	4	CIC	д	CAG	ø	AGT	S	GAG	四	GAT	Ω	SAT (	0	ATT (	_	196	<b>FO</b>	AAC A	
CCA	<b>Q</b> 4	ACC	₽	ACA	E	GAC	Ω	GTG	Λ	CAG	 	SCA (	_ _	AAG 1	· · ·	7, 21,	. 7	16C 1	<i>5</i> 0
CCI	Д	CCA	а	GAG	드	GCA	Æ	GAG	阳	ACA	E-	395	כיז	CGA 1	~ ~	ACA (		ATC ?	<u></u>
AGC	လ	ည္သ	Дι	CTG	1	AAA	×	999	ဗ	TTC	تعا	CTG		LTC (	(Tru	AAC 1		AAA 1	
ACC	E	999	ຶ່	CTG	ᆸ	TTG	H	GCA	¥	GAG	E)	AGC (	Ś	200		STC 1		TA (	
CAC	z	TCT	လ	AAG	×	TGC	U	999	ຶ່ບ	TAT	<b>≻</b> ₁	993	ο <b>.</b>	SAC /		CTG (	ے	ည္ဟ	
GTG	^	AGC	တ	CAC	=	CCT	Д	ည္ဟ	A	GTT	` ^	CAA (	 	IGT (	_	AIC (		AAC (	7
ACC	Ę⊣	ည္ဗ	Æ	ATG	Σ	AGC	S	555	~	GCA	et.	990	œ.	ATC :		200		700	
ပ္ပ	<u>а</u>	GCT	A	ŢĊĊ	တ	TCC	S	၁၁၅	Ø	GAG	Œ	) වූපු	~	CTA /	· ·	ATC (	~	TT 1	. 7
TAT	¥	GTG	<b>&gt;</b>	AGC	တ	ATC	н	TGT	ບ	AGC	S	AGC (	 	4GG (	~: ~:	ATG 7	<u></u>	SAG (	~- ~-
GTG	>	GAG	臼	TAC	×	AAG	×	TAC	>	GAC .		CAC	 br:	. 99J	·=	ATC 1	_	adg (	E-3
AAG	×	GTA	Λ	ည္ပ	Д	TGC	ບ	ည္ဟ	<u>а</u> ,	TCA	Ś	ည္တ	Q.	IIC	ſ <b>-</b> ,	SGA S	<i>r</i> n	ည္လ	٥.
1812	588	1872	809	1932	628	1992	648	2052	899	2112	889	2172	108	2232	728	2292 (	748 (	2352 (	768 1
									UTE							•		. •	



2471	807	2531	827	2591	847	2651	867	2711	887	2771	907	2831	927	2891	947	2951	196	3011	987
TAC	<b>&gt;</b>	999	G	TIC	또	ACC	₽	TIC	[z.,	GAC	Q	AAA	×	CTC	ы	TTC	بحزا	CTG	ы
ည္ပ	പ	CAG	ŏ	9	~	ည္ဟ	K	CTC	ы	TTT	لعبا	AAC	z	ည္ဟ	A	၁၅၅	ပ	CAG	ŏ
AAT	z	CAG	ŏ	GTG	Λ	GTG	>	CAT	==	AAT	2	TGG	3	ATT	Н	GAG	ص	ATT	ш
AAG	×	ည္ဟမ္	5	CTG	ц	AAC	z	ATG	Z	AAG	×	GAC	Q	TTC	נבי	GTG	<b>^</b>	IGI	. ئ
									ტ										
									н										
၁၅၅	ຶ່	GAG	덟	GTG	>	ACC	₽	ATC	Н	CCA	д	ACC	H	ည	Æ	ည္ဟ	Æ	CAG	ð
									လ										
									ſ×ι										
									<b>-</b>										
									[z.										
									н										
									ᄄ										
									П										
									Z										
									П										
									ы										
									E										C+3
GAG	Œ	ATC	н	ညဗ္ဗ	U	900	D.	TGC	ບ	IGC	ບ	TIG	LI	CIC	· 	ည္မွ	F-1	වූදුල	
									<u>ب</u>										 C
2412	788	2472	808	2532	828	2592	848	2652	898	2712	888	2772	806	2832	928	2892	948	2952 (	896
									HTF										

3071	1007	3131	1027	3191	1047	3251	1067	3311	1087	3371	1107	3431	1127	3491	1147	3551	1167	3611.	1187
	လ																		
TTC	Ľx.,	GGA	ပ	ACA	E→	<b>1</b> 76	ഗ	9	Д	AGG	<b>~</b>	GGA	G	TCA	ဟ	999	ρς,	ACT	₽
TIC	[ <del>Z</del>	CIG	ᆸ	ටුටු	Æ	වුටු	Æ	TCA	တ	AGC	တ	AGT	လ	AGC	တ	GAG	Œ	ည္ပ	œ
	Ω																		
	Ω,																		
	ᇤ																		
	လ																		
GAA	ᇤ	TTG	ᆸ	ATC	<b>⊢</b> i	GAG	臼	ည္ဟ	Æ	GCA	Æ	AAG	<b>&gt;</b>	CAG		CAC	z	CIG (	>
	လ																		
	×																		
	z																		
	ø																		
	Q																		
	ຶ່ນ																		
	ဟ																		
CAG	Õ	GGT	ניז	990	~ ~	AAG	<b>5</b> 4	AGC (	m	ICT (	ro	) 29t	7	rrg .	. 7	) ) )		TT (	
	ß																		
GAC	Ω	CTG		3AG (	(±3	OTG (	ت ت	AGC 7	ro.	290	α.	266	~	ည		993	~	GT 1	<b>7</b> 0
STC (	^	) 25 4	ro	92	_ م	921	ro	ACC J		ည္ဟ	~	360		. 99 .1	~	iAG (	F. 7	AG A	02
CT.	م	200	0.	CAC (		ATG ?	~	360.7	~	) DS(	**	100 N	50	366	~	AG G	E	7 225	
	886																		
ĕ	٥,	3	1(	Ω	1(											34		35	
						3	0D2	FTI	/ I E	JUE	ET (	l KUL	E Z	D)					



										••,	•								
3671	1207	3731	1227	3791	1247	3851	1267	3911	1287	3971	1307	4031	1327	4091	1347	4151	1367	4211	1387
ည္ဟ	<b>~</b>	GAG	মে	13c	ບ	CIC	П	TTC	[æ4	ည္ဟ	<b>p</b>	GTG	>	AAC	Z	TCT	တ	ည္သ	~
999	ဗ	GAC	Ω	ည	æ	ည္ဟ	<b>~</b>	ATC	<b>-</b>	GAA	드리	ACA	₽	TGG	3	GTC	^	CTG	П
TCA	လ	GAT	0	CCI	ф	TTC	[ <del></del> -	ATC	н	GCT	¥	ATG	Σ	AGT	လ	ATG	Σ	ACC	₽
GCI	Æ	ည္ဟ	Æ	CIC	ı	AGG	~	GTC	>	AGC	တ	GAA	되	AGC	တ	TCC	လ	990	~
TCG	တ	GAC	۵	CGA	α,	$\mathbf{ICC}$	တ	CTT	ı	CAC	E	GCT	A	995	<b>~</b>	GTG	>	CTG	ᆸ
AAG	×	GAT	Ω	ည္ဟ	Æ	CAG	Ø	GTC	Λ	ည္သ	Д	CTG	ы	CTG	П	CTG	ᆸ	CTG	H
ටුලු	9	666	G	CGA	ፙ	CCT	വ	GTG	^	GAC	Q	TTT	ᄄ	TAC	×	ATT	Н	990	<b>84</b>
AAT	z	GAT	Ω	ATC	н	CCT	М	CAG	<b>=</b>	ATT	Н	GIC	>	වුටුව	ø	GAC	0	CIG	-
TGC	ပ	CTG	H	$\mathbf{TGG}$	3	TIC	드	GAC	Ω	AAA	<b>×</b>	GCA	Æ	CAG	O <sub>1</sub>	ATC	н	GTG	^
GAC	Ω	CCA	ؠڡ	පුරුල	Ą	ATC	Н	TIC	اعدا	ည္သ	ρı	ACC	E	GAG	ഥ	GTC	^	AGG	<b>~</b>
CAG	ø	ည္သ	Δ4	ည္သည	~	TAC	<b>&gt;</b> 4	ATG	X	၁၅၁	<b>∝</b>	TTC	[±4	999	ຶ	$\mathbb{I}^{\mathbb{C}^{\mathbb{C}}}$	တ	CTG	ы
CAC	H	GAC	Ω	GTC	>	ည္သ	A	AAG	×	GAG	E	ATC	Н	TTC	드	ATC	<del>  </del>	ATG	Σ
GAG	田	GAT	Ω	990	œ	TCA	ဟ	CAC	z	ATG	×	TAC	<b>∀</b>	$\mathbf{TGC}$	ပ	CIC	ᆸ	299	ဗ
TCT	ß	CCI	٠Δ.	GAA	떠	TGG	Z.	ACC	E+	ည္ဟ	A	AAT	z	TGG	Z	$\mathtt{GTG}$	Λ	CIG	ц
GCT	A	990	œ	999	Ŋ	TCC	လ	ATC	H	ATC		TCC	လ	299	ტ	TTG	ᆸ	ATC	H
TCI	လ	CTG	ы	AAA	×	GAC	Q	ATC	Н	ACC	E	CIC	П	CTG	<b>⊢</b> 1	CIG	ᆸ	AAG	×
999	ဗ	ည္ဟ	K	AGC	വ	CGA	<b>~</b>	SSS	<b>~</b>	ATC	Н	ACC	<del>[</del> 1	GCA	A	.555	ဗ	ACC	E-1
			∞.															ည္ဟမ္ပ	ტ
266	ტ	ည္ဟ	Æ	AAC	z	CIC	ь	TGT	ပ	AAC	z	TTC	[zu	GTG	^	CTG	П	AGC	S
AGT	S	CTG	ы	399	ტ	TAC	<del>∑</del>	CTG	ı	CTT	ᆸ	ATC	<b>—</b>	AAG	×	GTG	Λ	GAC	Ω
			1208																
						9	SUBS	TIT	UTE	SHE	ET	(RUL	.E 2	6)					



<b>~</b>	427 4331 4331 4431 4451 1467 4511 1507 4631 1527 4691 1547 1587																		
427	140	433	142	439	144	445	146	451	148	457	150	463	152	469	154	475	156	481	158,
ICC	ß	ည	ტ	AGG	84	TAC	<b>&gt;</b> 4	GGT	Ŋ	ATG	×	TTT	[z.	CAG	O	AGA	<b>~</b>	CAC	Н
ATG	Σ	TIC	드	ACC	₽	AAG	×	GAT	Ω	ATC	ь	TTC	Ĺъц	CAC	×	AAG	×	GTC	>
CTG	П	ATT	н	GAT	Ω	CAC	Σ	AAG	×	ည္ဟ	а	ည္ဟ	ø	CAG	Õ	AAA	×	CIC	ы
									လ										
									A										
GTG	^	TTC	لتا	CAG	Ø	$\mathbf{TGG}$	3	$\mathbf{TTG}$	h	GAC	Ω	CIC	ı	AAG	×	AGA	<b>~</b>	TTC	[Eq.
GTG	>	ည	Æ	IGC	ပ	990	~	GTT	^	GTG	Λ	CTG	П	CAC	н	CGA	8	ည္ပ	×
C TGT C TGT C GTG C TGT C TGT C TTC																			
CTG AAG L K ATC TGC I TTT TTC F GCC AGT A S TCC CTG S L GCT GTG A V A V A V A N A N A N A N A N A N A N A N A N A N														7					
CIG	П	ATC	н	TTT	드	ည္ဟ	A	<b>1</b> 50	ഗ	GCT	Ą	ATC	H	GAG	园	AAG	×	GAC	Ω
									Σ										
									ᄓ										
									A										
									Ø										
									ຶ										
									н										
									z										
									۵										æ
									[z-i										×
									z										<b>~</b>
4212	1388	4272	1408	4332	1428	4392	1448	4452	1468	4512	1488	4572	1508	4632	1528	4692	1548	4752	1568
						9	SUBS	TIT	UTE	SHE	EΤ	(RU	LE 2	26)					

FIG. 6F



CTG L GTG V V GTG CTG CTG CTG CTG GGG GCT AATT L L CCTG CCTG CCTG V CAT H H V GAT D TTTC F CTG S CTG L CTG L CTG CTG CTG ATC
I
CAG
QAG
GAG
QA
V
V
V
ATT
TTT
F
CGA
GAG
CGA
R
R H GAG E T T T T T T A A GAC B M GAC D D GAC ATG
M
TAC
Y
Y
CGT
R
ATG
M
ATC
CTT
L
CGC
G
CTT
L
L
L
L
TTT
F L
AACC
AAC
N
TTC
F
ATC
I
ATC
V
GGGA
GGAC
D H GTC C C G G G TCC S ACC T 1588 4872 1608 4932 1628 4992 1648 1648 5052 5112 1688 SUBSTITUTE SHEET (RULE 26)

FIG. 61



5471 1807 5531 1827 5591 1847 5651 1867 5771 1907 5831 1947 5951 1967																			
5471	1807	5531	1827	5591	1847	5651	1867	5711	1887	5771	1907	5831	1927	5891	1947	5951	1967	6011	1987
			Λ																
ACG	E	AAC	Z	GAG	[±]	TCG	S	ည္သ	۵,	GAG	(±1)	999	~	666	ဌာ	299	<sub>ნ</sub>	AAA	×
AAC	[Z-1	GTC	>	GAG	[ <del>2</del> ]	CAC	æ	AGC	മ	CIG	H	GTG	Λ	CAT	&	TCA	S	ည္ဟ	д
TAC	>-	CTA	H	AAG	×	ည္ပ	വ	GAC	Q	ICC	လ	ACT	₽	995	<b>8</b> 4	CAG	ŏ	CIT	, <u>, , , , , , , , , , , , , , , , , , </u>
<b>1</b> GC	ပ	GTG	Λ	ည္ဟ	W	CAG	ŏ	ည္ပ	Ω,	TIT	[ <del>z</del> i	CTG	H	IGI	ບ	GCT	Æ	CAG	Ø
ACC	₽	TIC	Œı	GAG	드	ည္ပ	Д	AGC	လ	CAC	H	TTA	ᆸ	ATG	X	AAA	×	CTG	·
ICC	လ	CAG	ð	AAG	×	AGC	ß	GAC	۵	ICC	<b>က</b> ်	GAC	_	TAC	×	ည္သ	صر	ATC	<b>H</b>
GAG	压	ည္ဟ	¥	AAC	z	CIC	П	ည္သ	Д	၁၁၅	A	CCA	Δ.	AGC	တ	CIC	ᄓ	TAC	<b>&gt;</b>
GAC CAG D Q CTG ACG L T GAG AGC K T GAG GGC K T GAG GGC K T CCA GGA R S CCA GGA N D N D N D N D N D N D N D N D N D N D														တ					
GAC	Q	CTG	ᆸ	GAG	ᇤ	AAG	×	GAG	[±]	AGA	24	CCA	<u>а</u> ,	AAT	z	$\mathbb{I}^{\mathbb{G}}$	Z	ACC	E
TGT	ပ	GTG	>	GAG	(±1)	ATG	Z	GTC	Λ	909	Ø	CTG	ц	င္ပင္ပ	Д	၁၅	හ	GAT	Q
GAC	Д	TTC	ſΞŧ	CTG	П	GAG	闰	999	ტ	CAC	H	GAG	[±]	CIG	ᆸ	AGG	<b>~</b>	GCA	K
99	<b>~</b>	TCC	တ	CAC	æ	CTG	ı	CCI	വ	ည	A	ACG	E→	TCT	S	CAC	<b>=</b>	CCA	ф
CTC	ц П	GTG	>	AAG	×	GAG	ഥ	TGG	z	<u> </u>	Æ	ည္သ	Д	CAC	Z	GGA	<sub>ග</sub>	CAG	Ö
ACC	E	TTT	Ē	ATG	Z	CIG	口	CTC	Ţ	CCA	Ωı	CAC	H	ACG	E	CTG	П	ICC	S
			<b>&gt;</b>																
			н																
ATG	Σ	CCT	Ω,	ည္ဟ	Æ	GAG	闰	AGC	လ	GCT	A.	ATG	Σ	GIC	^	GAG	匞	ICC	ഗ
ATT	Н	TCG	တ	ATC	<b>  </b>	CTA	ıП	299	ഗ	999	හ	ACG	₽	999	ტ	ည္ဟ	Æ	TTG	ы
GGC GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG											TCT	S	ACT	E→	GIC	>			
5412	1788	5472	1808	5532	1828	5592	1848	5652	1868	5712	1888	5772	1908	5832	1928	5892	1948	5952	1968
											EET								

FIG. 6.




6071 2007 2007 6131 2027 2047 6251 2087 6431 6431 6431 6551 2167 2167 ACC T CTC L L E GAG GAG CCC CCC CCC CCC CCC T I CCT P CCAG O GCC A A H H H ATT I I I AAG K GGG GGC GGG L S GTT CTG L L N N TGG N CTG CTG CTG H GGA GGA L CCG CCG S CCG CGG W W 1988 6072 2008 6132 2028 6192 2048 6252 SUBSTITUTE SHEET (RULE 26)

FIG. 6K

6671	2207	6731	2227	6791	2247	6851	2267	6892
			S					
GAG	E	1 2 2	လ	ည္ည	လ	ည္ဟ	Д	
ပ္ပ	Д	ည	<u>а</u>	ပ္ပ	ы	GAC	Ω	
ပ္ပ	Ы	GCT	R A	1 <u>C</u> G	လ	CIG	ᆸ	
GAC	Ω	AGG	<b>~</b>	ည္တ	A	GAC	Ω	
ATA	Н	AGG	R R	GCI	A	GCA	æ	
ACC	E-+	වුදුට	<b>~</b>	ATG	X	CCA	പ	
			н					
AGT	മ	1GC	ပ	GAC	Ω	TCI	လ	
CCI	Д	ATC	н	CCI	а	ICC	ഗ	ည္ထ
922	ф	GGT	ŋ	ည	а	TTA	1	gggt
AGC	လ	CCI	م	ည္ဟ	ပ	GGT		cact
CTC	ы	AGC	മ	TCI	လ	TCC	လ	tctc
AAA	×	ည	ф	ည္ဟ	æ	CIC	Ы	cctt
AAA	×	999	م	TIG	ы	AGT	တ	ctca
AAG	×	ACC	₽	8	Д	CTG	ы	ccca
8	Ď,	99	24	GAT	Ω	GTG	>	cttt
995	α,	CCI	Δı	AAG	×	GAT	Ω	ccca
AGC	တ	GGI		1 <u>3</u> 2	ഗ	AAA	×	ctgc
999	ပ	CAA	Q	GAC	Ω	AAG	×	gtc
6612	2188	6672	2208	6732	2228	6792	2248	6852 gtcctgccccactttcccactcacctttctccactgggtgc

FIG. 61








FIG. 7
SUBSTITUTE SHEET (RULE 26)

		. •	, • `			
	NIC-1 (C11D2.6)	NIC-2 (C27F2.3)	Rat -NIC	L-Type Ca Channel	T-Type Ca Channel	Na Channels
	DWNDI				NWNGI	QITTS A GWDGL
2	ഥ	团	团	囝	О	K
	RCLTG	RSVTG	RIVTG	RCATG	RVSTG	OILLS
	ETLSF K GWNVI	ETLSY K GWNVV	GWVEV	TVSTF K GWPEL	VLASK D GWVDI	QVATF K GWMDI
Ħ	×	X	×	ᅜ	Ω	×
	ETLSF	ETLSY	EVLSL	TVSTF	VLASK	QVATE
	GWTDF		GWVDV	DWNSV	DWNKV	WIETM
Ħ	田	围	田	田	田田	回
	QIIIQ	QIIIQ	<b>OILIQ</b>	OILTG	QILIQ	RVLCG
	GWVYV	GWVYV	GWVFL	GWTDV	GWVDI	FWENL
Н	臼		团	闰		Ω
STITU	H LAASE	E LAASO	EASSO	E OCILM	TI ON IL	S RIMTO

F/G. 8

#### SEQUENCE LISTING

```
<110> Snutch, Terry P.
     Baillie, David L.
<120> NOVEL HUMAN CALCIUM CHANNELS AND RELATED PROBES, CELL
      LINES AND METHODS
<130> NMED.P-001-2(CIP)
<140>
<141>
<150> 09/030,482
<151> 1998-02-25
<150> 60/039,204
<151> 1997-02-28
<160> 35
<170> PatentIn Ver. 2.0
<210> 1
<211> 24
<212> DNA
<213> rat
<220>
<223> oligonucleotide probe for locating calcium channel
<400> 1
gtcaaaactc aggccttcta ctgg
                                                                    24
<210> 2
<211> 24
<212> DNA
<213> rat
<220>
<223> oligonucleotide probe for locating calcium channel
<400> 2
aacgtgttct tggctatcgc ggtg
                                                                    24
<210> 3
```

<210> 7

<211>								
<212>				•				
<213>	rat							
<220>								
	oligonucleotide genes	probe	for	locating	calcium	channel	•	
<400>								
gtgaaa	gcac agagetteta	ctgg						24
<210>	4							
<211>	•							
<212>								
<213>	rat							
<220>			_					
<223>	oligonucleotide genes	probe	for	locating	calcium	channel	•	
<400>								
aacgtt	ttct tggccattgc	tgtg						24
<210>								
<211>				•				
<212>								
<213>	rat							
<220>				_				
<223>	oligonucleotide genes	probe	for	locating	calcium	channel		
<400>	5							
gttaa	atcca acgtetteta	ctgg						24
<210>	6							
<211>	24							
<212>								
<213>	rat							
<220>				0				
<223>	oligonucleotide genes	probe	for	locating	calcium	channel		
<400>	6							
aatgt	gttct tggccattgo	ggtg						24

. WO 01/02561							CA00/00794
<211> <212> <213>	DNA		. <u>-</u>				
<220> <223>	oligonucleotide	probe i	for	locating	calcium	channel	
	genes						
<400> gtgaag	7 Jictg tcacgittta	ctgg					24
<210>							
<211><212>							
<213>							
<220>							
<223>	oligonucleotide genes	probe 1	for	locating	calcium	channel	
<400>	8						
aagete	ettet tggccattge	tgta				•	24
<210>				٠			
<211>							
<212>							
<213>	rat						
<220>							
<223>	oligonucleotide genes	probe :	for	locating	calcium	channel	
<400>	9						
gtcaa	gtcgc aagtgttcta	ctgg					24
<210>							
<211>							
<212>							
<213>	rat						
<220>							
<223>	oligonucleotide genes	probe	for	locating	calcium	channel	
<400>	10						
aatgt	attct tggctatcgc	tgtg					24

<210> 11

)	01/02561		A00/0079	94
	<211>	21		
	<212>			
	<213>			
	<220>			
	<223>	oligonucleotide probe for locating calcium o	hannel	
		genes		
	<400>			
	atctay	ygcyr tsatyggsat g		21
	010	10		
	<210>			
	<211>			
	<212>			
	<213>	rat		
	<220>			
		oligonucleotide probe for locating calcium o	hannal	
	1000	genes	ameı	
		<b>3-</b>		
	<400>	12		
	atggad	caayt tygastaytc		20
	<210>	12		
	<211>	, <del></del>		
	<212>			
		HUMAN		
	(6437	TALEMAN TO SERVICE STATE OF THE SERVICE STATE STATE OF THE SERVICE STATE OF THE SERVICE STATE STATE STATE STATE STATE STATE STATE STATE		
	<220>			
	<223>	expressed sequence tag H55225		
	<400>			
	gtgate	cacto tggaaggotg ggtggagato atgtactacg tgatgg	atgc tcactccttc	60
	tacaa	cttca totacttcat cotgettate ataccoctet tgeett	gcac cccatatggt	120
	cttcc	cagag tgageteate cacetegtea tgeetgaete gaegtt	ca	168
	<210>	14		
	<211>			
	<212>		•	
		HUMAN		
	-413/	ALMA MERCH		
	<220>			
	<223>	expressed sequence tag H55617		
		14	•	
	<400>			
	gatgg	tegag tactecetgg acetteagaa cateaacetg teagee tgagg ceceteaaag ceateaaceg egtgeeca		
	Carre	canal contragg contragera ratifica		98

```
WO 01/02561
                                                                 A00/00794
     <210> 15
     <211> 94
     <212> DNA
     <213> HUMAN
     <220>
     <223> expressed sequence tag H55223
     <400> 15
     catgctggtg atcctgctga actgcgtgac acttggcatg taccagccgt gcgacgacat 60
     ggactgcctg tccgaccgct gcaagatcct gcag
     <210> 16
     <211> 123
     <212> DNA
     <213> HUMAN
     <220>
     <223> expressed sequence tag H55544
     <400> 16
     gtatctctgg ttactttagt agccaacact cttggctact cagaccttgg tcccattaaa 60
     tecetgegaa eettgagage actaagaeet etaagagett tgtetagatt tgaaggaatg 120
     <210> 17
     <211> 5562
     <212> DNA
     <213> HUMAN
     <220>
     <223> human alpha-I partial sequence from BAC bK206c7
     <400> 17
     atgtttttcg tctcagccaa tccctgggtg agtttcacca gttttgattt aaacgtggcc 60
     aatatggaca acttettege eecegtttte accatgggea aatattatae geaaggegae 120
     aaggtgctga tgccgctggc gattcaggct ctgaaacagc tgatgttcaa attggtggcc 180
     actgttgctc gaacacatgc tacaccgtca cacatcacgg gtggtcctgg aacagggatg 240
     cacacgggca ccttccagga aggagetgag cctggttcat ctcagcaccc tgaggcacag 300
     gccacgtata cagcagggtg caccccagcc cccacgggcg atcccacctg ctgctttgtc 360
     cttgacttgg tgtgcacgtg gtttgaatgt gtcagcatgc tggtgatcct gctgaactgc 420
     gtgacacttg gcatgtacca gccgtgcgac gacatggact gcctgtccga ccgctgcaag 480
     atcetgeagg tetttgatga etteatettt atettetttg ceatggagat ggtgeteaag 540
```

atggtggccc tggggatttt tggcaagaag tgctacctcg gggacacatg gaaccgcctg 600 gatttettea tegtcatggc aggcaacate aacctgtcag ccatecgcae egtgegegte 660 etgaggeccc teaaagecat caaccgegtg eccagtatge ggatectggt gaacctgete 720 etggacacac tgcccatget ggggaatgte etgetgetet gettetttgt ettetteate 780 tttggcatca taggtgtgca getetgggeg ggeetgetge gtaaccgetg ettectggag 840



					ggaggaggat	
					ctgccatgag	
atccccccgc	tcaaggagca	gggccgtgag	tgctgcctgt	ccaaggacga	cgtctacgac	1020
tttggggcgg	ggcgccagga	cctcaatgcc	agcggcctct	gtgtcaactg	gaaccgttac	1080
tacaatgtgt	gccgcacggg	cagcgccaac	ccccacaagg	gtgccatcaa	ctttgacaac	1140
					ggtggagatc	
atgtactacg	tgatggatgc	tcactccttc	tacaacttca	tctacttcat	cctgcttatc	1260
ataagtgagc	tcatccacct	cgtcatgcct	gactgcagct	tcagcacagc	acagtcccca	1320
aaatgtcaag	gtgattcact	cccaggagtc	gctgctgaat	ccctgctgct	gcgagactct	1380
agctcctcag	tcatcactga	tgaggctgca	gccatggaga	acctcctggc	gggcacctcc	1440
aagggggatg	aaagctatct	gctcaggctg	gccggcagcc	aagttcactc	ccaggctcag	1500
					gcccactcg	
					gcctctcccc	
					cctcgttgtc	
					ggagcagcgg	
cagcgctacc	tgtcctccag	cacggtggcc	agctacgccg	agcctggcga	ctgctacgag	1800
gagatettee	agtatgtctg	ccacatcctg	cgcaaggcca	agegeegege	cctgggcctc	1860
taccaggccc	tgcagagccg	gcgccaggcc	ctgggcccgg	aggccccggc	ccccgccaaa	1920
					atcgattctt	
gggaggcaag	cagaagaatg	cacgctcaga	gctgccgccc	accegteete	gggtgccagc	2040
catccaggcg	tgggctcgga	ggaggcccca	gagetgtgee	cgcaacatag	cccctggat	2100
gcgacgcccc	acaccctggt	gcagcccatc	cccgccacgc	tggcttccga	tcccgccagc	2160
					caccgactcg	
ggccaggagg	gctcgggctc	cgggagctcc	gctggtggcg	aggacgaggc	ggatggggac	2280
					ggaggaggag	
gagcaggcgg	atggggcggt	ctggctgtgc	ggggatgtgt	ggcgggagac	gcgagccaag	2400
ctgcgcggca	tcgtggacag	caagtacttc	aaccggggca	tcatgatggc	catcctggtc	2460
aacaccgtca	gcatgggcat	cgagcaccac	gagcaggcca	gtgcagcgca	gccgggccgg	2520
gcctgcggga	gaggacaaaa	tccagacctt	tgcatgaccc	tcaaggcccc	ttgtctctgt	2580
cacaacgtcc	cttcaccagg	ccagggtgtc	ctgtcccatc	cagtgactcc	accccataca	2640
gccccatggc	gcatggagac	aggaaagcag	ggacacggat	gtgaagaagg	accaggacaa	2700
cgaagcagtg	acatgtttgc	cctggagatg	atcctgaagc	tggctgcatt	tgggctcttc	2760
					cagcatctgg	
					gctgctgcgc	
gtgctgaaac	tggtgcgctt	catgcctgcc	ctgcggcgcc	agctcgtggt	gctcatgaag	2940
					catcttcagc	
					tggagacacg	
					gttccagatc	
					ttctccctgg	
					caacctgctg	
					agaggaagca	
					gggagggctg	
					tgaggtgggt	
					agagtttgat	
aagctccagg	aaggcctgga	cagcagcgga	gatcccaagc	tctgcccaat	ccccatgacc	3540
					tgctggggct	
					cctgggctcc	
cgaaagagca	gcgtcatgtc	tctagggagg	atgagctatg	accagcgctc	cctggtgggt	3720



```
ggtettagag ceacageggg ggtgeagget geetttggge acetggtgee ceageegtgg 3780
gtgtgcctgt ggggcgctga cccgaacggg aactcettcc agtccagetc ccggagetcc 3840
tactacgggc catggggccg cagcgggcc tgggccagcc gtcgctccag ctggaacagc 3900
ctcaagcaca ageegeegte ggeggageat gagteeetge tetetgegga gegeggegge 3960
ggcgcccggg tetgcgaggt tgccgcggac gaggggccgc cgcgggccgc acccctgcac 4020
accecacaeg cecaceaegt teatcaeggg ceccatetgg egeacegeea eegecaceae 4080
egeeggaege tgteeetega eaacagggae teggtggaee tggeegaget ggtgeeegeg 4140
gtgggegeee acceeeggge egeetggagg geggeaggee eggeeeeegg geatgaggae 4200
tgcaatggca ggatgcccag catcgccaaa gacgtcttca ccaagatggg cgaccgcggg 4260
ctgaccctgt gcttccgcgt ccgcaagatg atcgacgtct ataagcccga ctggtgcgag 4380
gteegegaag actggtetgt etacetette tetecegaga acaggeteag ggatetggge 4440
tgggtaagcc tcgagtgcca gggaaaggtg ggtgacctcg tggtgtgggt gtatggtcag 4500
aggaggeage gecagaceat tattgeecae aaactetteg actaegtegt cetggeette 4560
atetttetca actgeateae categeeetg gageggeete agategagge eggeageace 4620
gaacgcatct ttctcaccgt gtccaactac atcttcacgg ccatcttcgt gggcgagatg 4680
acattgaagg tagteteget gggeetgtae tteggegage aggegtaeet acgeageage 4740
tggaacgtgc tggatggctt tcttgtcttc gtgtccatca tcgacatcgt ggtgtccctg 4800
gcctcagccg ggggagccaa gatcttgggg gtcctccgag tcttgcggct cctgcgcacc 4860
ctacgccccc tgcgtgtcat cagccgggcg ccgggcctga agctggtggt ggagacactc 4920
atctectece teaageeeat eggeaacate gtgeteatet getgtgeett etteateate 4980
tttggcatcc tgggagtgca gctcttcaag ggcaagttct accactgtct gggcgtggac 5040
accegeaaca teaceaaceg eteggaetge atggeegeea actacegetg ggtecateac 5100
aaatacaact tegacaacet gggeeagget etgatgteee tetttgteet ggeatecaag 5160
gatggttggg tgaacatcat gtacaatgga ctggatgctg ttgctgtgga ccagcagcct 5220
gtgaccaacc acaacccctg gatgctgctg tacttcatct ccttcctgct catcgtcagc 5280
ttctttgtgc tcaacatgtt tgtgggtgtc gtggtggaga acttccacaa gtgccggcag 5340
caccaggagg ctgaagaggc acggcggcgt gaggagaagc ggctgcggcg cctggagaag 5400
aagegeegga aggeeeageg getgeeetae tatgeeacet attgteacae eeggetgete 5460
atccactcca tgtgcaccag ccactacctg gacatettca tcacettcat catetgcctc 5520
aacgtggtca ccatgtccct ggagcactac aatcagccca cg
<210> 18
<211> 1854
<212> PRT
<213> HUMAN
<220>
<223> human alpha-I partial sequence from BAC bK206c7
<400> 18
Met Phe Phe Val Ser Ala Asn Pro Trp Val Ser Phe Thr Ser Phe Asp
                                    10
Leu Asn Val Ala Asn Met Asp Asn Phe Phe Ala Pro Val Phe Thr Met
```

Gly Lys Tyr Tyr Thr Gln Gly Asp Lys Val Leu Met Pro Leu Ala Ile

CA00/00794

Gln Ala Leu Lys Gln Leu Met Phe Lys Leu Val Ala Thr Val Ala Arg 50 55 60

Thr His Ala Thr Pro Ser His Ile Thr Gly Gly Pro Gly Thr Gly Met 65 70 75 80

His Thr Gly Thr Phe Gln Glu Gly Ala Glu Pro Gly Ser Ser Gln His

Pro Glu Ala Gln Ala Thr Tyr Thr Ala Gly Cys Thr Pro Ala Pro Thr 100 105 110

Gly Asp Pro Thr Cys Cys Phe Val Leu Asp Leu Val Cys Thr Trp Phe 115 120 125

Glu Cys Val Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr Leu Gly 130 135 140

Met Tyr Gln Pro Cys Asp Asp Met Asp Cys Leu Ser Asp Arg Cys Lys 145 150 155 160

Ile Leu Gln Val Phe Asp Asp Phe Ile Phe Ile Phe Phe Ala Met Glu
165 170 175

Met Val Leu Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr 180 185 190

Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Met Ala Gly
195 200 205

Asn Ile Asn Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu 210 215 220

Lys Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Asn Leu Leu 225 230 235 240

Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Cys Phe Phe
245 250 255

Val Phe Phe Ile Phe Gly Ile Ile Gly Val Gln Leu Trp Ala Gly Leu 260 265 270

Leu Arg Asn Arg Cys Phe Leu Glu Glu Asn Phe Thr Ile Gln Gly Asp 275 280 285

Val Ala Leu Pro Pro Tyr Tyr Gln Pro Glu Glu Asp Asp Glu Met Pro

290 295 300

Phe Ile Cys Ser Leu Ser Gly Asp Asn Gly Ile Met Gly Cys His Glu 305 310 315 320

Ile Pro Pro Leu Lys Glu Gln Gly Arg Glu Cys Cys Leu Ser Lys Asp 325 330 335

Asp Val Tyr Asp Phe Gly Ala Gly Arg Gln Asp Leu Asn Ala Ser Gly
340 345 350

Leu Cys Val Asn Trp Asn Arg Tyr Tyr Asn Val Cys Arg Thr Gly Ser 355 360 365

Ala Asn Pro His Lys Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala 370 375 380

Trp Ile Val Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Glu Ile 385 390 395 400

Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe 405 410 415

Ile Leu Leu Ile Ile Ser Glu Leu Ile His Leu Val Met Pro Asp Cys
420 425 430

Ser Phe Ser Thr Ala Gln Ser Pro Lys Cys Gln Gly Asp Ser Leu Pro 435 440 445

Gly Val Ala Ala Glu Ser Leu Leu Leu Arg Asp Ser Ser Ser Val
450 455 460

Ile Thr Asp Glu Ala Ala Ala Met Glu Asn Leu Leu Ala Gly Thr Ser 465 470 475 480

Lys Gly Asp Glu Ser Tyr Leu Leu Arg Leu Ala Gly Ser Gln Val His
485
490
495

Ser Gln Ala Gln Gln Met Leu Gly Arg Gly Leu Gly Pro Glu Ser Leu 500 505 510

Glu Thr Gly Glu Glu Pro His Ser Trp Ser Pro Arg Ala Thr Arg Arg 515 520 525

Trp Asp Pro Gln Cys Gln Pro Gly Gln Pro Leu Pro Leu His Phe Met 530 535 540

Gln Ala Gln Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val Val



545 550 555 560

Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu His Arg Leu Met 565 570 575

Leu Glu Gln Arg Gln Arg Tyr Leu Ser Ser Ser Thr Val Ala Ser Tyr
580 585 590

Ala Glu Pro Gly Asp Cys Tyr Glu Glu Ile Phe Gln Tyr Val Cys His 595 600 605

Ile Leu Arg Lys Ala Lys Arg Arg Ala Leu Gly Leu Tyr Gln Ala Leu 610 615 620

Gln Ser Arg Arg Gln Ala Leu Gly Pro Glu Ala Pro Ala Pro Ala Lys 625 630 635 640

Pro Gly Pro His Ala Lys Glu Pro Arg His Tyr Pro Leu Thr Val Trp
645 650 655

Glu Ser Ile Leu Gly Arg Gln Ala Glu Glu Cys Thr Leu Arg Ala Ala 660 665 670

Ala His Pro Ser Ser Gly Ala Ser His Pro Gly Val Gly Ser Glu Glu 675 680 685

Ala Pro Glu Leu Cys Pro Gln His Ser Pro Leu Asp Ala Thr Pro His 690 695 700

Thr Leu Val Gln Pro Ile Pro Ala Thr Leu Ala Ser Asp Pro Ala Ser 705 710 715 720

Cys Pro Cys Cys Gln His Glu Asp Gly Arg Arg Pro Ser Gly Leu Gly
725 730 735

Ser Thr Asp Ser Gly Gln Glu Gly Ser Gly Ser Gly Ser Ser Ala Gly 740 745 750

Gly Glu Asp Glu Ala Asp Gly Asp Gly Ala Arg Ser Ser Glu Asp Gly 755 760 765

Ala Ser Ser Glu Leu Gly Lys Glu Glu Glu Glu Glu Glu Gln Ala Asp
770 780

Gly Ala Val Trp Leu Cys Gly Asp Val Trp Arg Glu Thr Arg Ala Lys
785 790 795 800

Leu Arg Gly Ile Val Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Met





B15

- Ala Ile Leu Val Asn Thr Val Ser Met Gly Ile Glu His His Glu Gln 820 825 830
- Ala Ser Ala Ala Gln Pro Gly Arg Ala Cys Gly Arg Gly Gln Asn Pro 835 840 845
- Asp Leu Cys Met Thr Leu Lys Ala Pro Cys Leu Cys His Asn Val Pro 850 855 860
- Ser Pro Gly Gln Gly Val Leu Ser His Pro Val Thr Pro Pro His Thr 865 870 875 880
- Ala Pro Trp Arg Met Glu Thr Gly Lys Gln Gly His Gly Cys Glu Glu 885 890 895
- Gly Pro Gly Gln Arg Ser Ser Asp Met Phe Ala Leu Glu Met Ile Leu 900 905 910
- Lys Leu Ala Ala Phe Gly Leu Phe Asp Tyr Leu Arg Asn Pro Tyr Asn 915 920 925
- Ile Phe Asp Ser Ile Ile Val Ile Ile Ser Ile Trp Glu Ile Val Gly
  930 935 940
- Gln Ala Asp Gly Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg 945 950 955 960
- Val Leu Lys Leu Val Arg Phe Met Pro Ala Leu Arg Arg Gln Leu Val 965 970 975
- Val Leu Met Lys Thr Met Asp Asn Val Ala Thr Phe Cys Met Leu Leu 980 985 990
- Met Leu Phe Ile Phe Ile Phe Ser Ile Leu Gly Met His Ile Phe Gly 995 1000 1005
- Cys Lys Phe Ser Leu Arg Thr Asp Thr Gly Asp Thr Val Pro Asp Arg 1010 1015 1020
- Lys Asn Phe Asp Ser Leu Leu Trp Ala Ile Val Thr Val Phe Gln Ile 1025 1030 1035 1040
- Leu Thr Gln Glu Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala Ser 1045 1050 1055
- Thr Ser Pro Trp Ala Ser Leu Tyr Phe Val Ala Leu Met Thr Phe Gly



1060 1065

- Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly Phe 1075 1080 1085
- Gln Ala Glu Val Thr Val Val Leu Ala Glu Glu Ala Pro Pro Gln Gly 1090 1095 1100
- Leu Arg Lys Thr Gly Arg Gly Arg Gly Gly Leu Asp Gly Gly Gly Leu 1105 1110 1115
- Gln Phe Lys Leu Leu Ala Gly Asn Leu Ser Leu Lys Glu Gly Val Ala 1125 1130 1135
- Asp Glu Val Gly Asp Ala Asn Arg Ser Tyr Ser Asp Glu Asp Gln Ser 1140 1145 1150
- Ser Ser Asn Ile Glu Glu Phe Asp Lys Leu Gln Glu Gly Leu Asp Ser 1155 1160 1165
- Ser Gly Asp Pro Lys Leu Cys Pro Ile Pro Met Thr Pro Asn Gly His 1170 1180
- Leu Asp Pro Ser Leu Pro Leu Gly Gly His Leu Gly Pro Ala Gly Ala 1185 1190 1195 1200
- Ala Gly Pro Ala Pro Arg Leu Ser Leu Gln Pro Asp Pro Met Leu Val 1205 1210 1215
- Ala Leu Gly Ser Arg Lys Ser Ser Val Met Ser Leu Gly Arg Met Ser 1220 1225 1230
- Tyr Asp Gln Arg Ser Leu Val Gly Gly Leu Arg Ala Thr Ala Gly Val 1235 1240 1245
- Gln Ala Ala Phe Gly His Leu Val Pro Gln Pro Trp Val Cys Leu Trp 1250 1255 1260
- Gly Ala Asp Pro Asn Gly Asn Ser Phe Gln Ser Ser Ser Arg Ser Ser 1265 1270 1275 1280
- Tyr Tyr Gly Pro Trp Gly Arg Ser Ala Ala Trp Ala Ser Arg Arg Ser 1285 1290 1295
- Ser Trp Asn Ser Leu Lys His Lys Pro Pro Ser Ala Glu His Glu Ser . 1300 1305 1310
- Leu Leu Ser Ala Glu Arg Gly Gly Gly Ala Arg Val Cys Glu Val Ala



1315 1320 1325

- Ala Asp Glu Gly Pro Pro Arg Ala Ala Pro Leu His Thr Pro His Ala 1330 1335 1340
- His His Val His His Gly Pro His Leu Ala His Arg His Arg His His 1345 1350 1355 1360
- Arg Arg Thr Leu Ser Leu Asp Asn Arg Asp Ser Val Asp Leu Ala Glu 1365 1370 1375
- Leu Val Pro Ala Val Gly Ala His Pro Arg Ala Ala Trp Arg Ala Ala 1380 1385 1390
- Gly Pro Ala Pro Gly His Glu Asp Cys Asn Gly Arg Met Pro Ser Ile 1395 1400 1405
- Ala Lys Asp Val Phe Thr Lys Met Gly Asp Arg Gly Asp Arg Gly Glu 1410 1415 1420
- Asp Glu Glu Glu Ile Asp Tyr Val Ser Gly Gly Gly Ala Glu Gly Asp 1425 1430 1435 1440
- Leu Thr Leu Cys Phe Arg Val Arg Lys Met Ile Asp Val Tyr Lys Pro 1445 1450 1455
- Asp Trp Cys Glu Val Arg Glu Asp Trp Ser Val Tyr Leu Phe Ser Pro 1460 1465 1470
- Glu Asn Arg Leu Arg Asp Leu Gly Trp Val Ser Leu Glu Cys Gln Gly 1475 1480 1485
- Lys Val Gly Asp Leu Val Val Trp Val Tyr Gly Gln Arg Arg Gln Arg
- Gln Thr Ile Ile Ala His Lys Leu Phe Asp Tyr Val Val Leu Ala Phe 1505 1510 1515 1520
  - Ile Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu Arg Pro Gln Ile Glu
    1525 1530 1535
  - Ala Gly Ser Thr Glu Arg Ile Phe Leu Thr Val Ser Asn Tyr Ile Phe 1540 1545 1550
  - Thr Ala Ile Phe Val Gly Glu Met Thr Leu Lys Val Val Ser Leu Gly 1555 1560 1565
  - Leu Tyr Phe Gly Glu Gln Ala Tyr Leu Arg Ser Ser Trp Asn Val Leu



1575

1580

- Asp Gly Phe Leu Val Phe Val Ser Ile Ile Asp Ile Val Val Ser Leu 1585 1590 1595 1600
- Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu Arg Val Leu Arg 1605 1610 1615
- Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Pro Gly
  1620 1625 1630
- Leu Lys Leu Val Val Glu Thr Leu Ile Ser Ser Leu Lys Pro Ile Gly 1635 1640 1645
- Asn Ile Val Leu Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu 1650 1655 1660
- Gly Val Gln Leu Phe Lys Gly Lys Phe Tyr His Cys Leu Gly Val Asp 1665 1670 1675 1680
- Thr Arg Asn Ile Thr Asn Arg Ser Asp Cys Met Ala Ala Asn Tyr Arg 1685 1690 1695
- Trp Val His His Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met
  1700 1705 1710
- Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asn Ile Met Tyr 1715 1720 1725
- Asn Gly Leu Asp Ala Val Ala Val Asp Gln Pro Val Thr Asn His 1730 1735 1740
- Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ser 1745 1750 1760
- Phe Phe Val Leu Asn Met Phe Val Gly Val Val Glu Asn Phe His 1765 1770 1775
- Lys Cys Arg Gln His Gln Glu Ala Glu Glu Ala Arg Arg Glu Glu 1780 1785 1790
- Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg Lys Ala Gln Arg Leu 1795 1800 1805
- Pro Tyr Tyr Ala Thr Tyr Cys His Thr Arg Leu Leu Ile His Ser Met 1810 1815 1820
- Cys Thr Ser His Tyr Leu Asp Ile Phe Ile Thr Phe Ile Ile Cys Leu





1830

1835

1840

Asn Val Val Thr Met Ser Leu Glu His Tyr Asn Gln Pro Thr 1845 1850

<210> 19

<211> 567

<212> DNA

<213> HUMAN

<220>

<223> human alpha-I partial sequence

<400> 19

atgeggate teggtgaacet geteetggae acactgecea tgetggggaa tgteetgetg 60 etetgettet ttgtettett cacetttgge ateataggtg tgeagetetg ggegggeetg 120 etgegtaace getgetteet ggaggagaac tteaceatae aaggggatgt ggeettgeee 180 ecatactace ageeggagga ggatgatgag atgeeettea tetgeteeet gtegggegae 240 aatgggataa tgggetgeea tgagateeee eeggteeaag ageagggeeg tgagtgetge 300 etgteeaagg aegaegteta egaetttggg geggggegee aggaeeteaa tgeeagegge 360 etetgtgtea actggaaceg ttactacaat gtgtgeegea egggeagege caaceceeae 420 aagggtgeea teagetttga caacateggt tatgettgga ttgteatett eeggtgate 480 actetggaag getgggtgee gateatgtae taegtgatgg atgeeteete ettetacaae 540

<210> 20

<211> 189

<212> PRT

<213> HUMAN

<220>

<223> human alpha-I partial sequence

ttcgtctact tcatcctgct tatcata

<400> 20

Met Arg Ile Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu Gly
1 10 15

Asn Val Leu Leu Cys Phe Phe Val Phe Phe Thr Phe Gly Ile Ile 20 25 30

Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu 35 40

Glu Asn Phe Thr Ile Gln Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gln 50 55 60

Pro Glu Glu Asp Asp Glu Met Pro Phe Ile Cys Ser Leu Ser Gly Asp

65

75

Asn Gly Ile Met Gly Cys His Glu Ile Pro Pro Leu Lys Glu Gln Gly 85 90 95

Arg Glu Cys Cys Leu Ser Lys Asp Asp Val Tyr Asp Phe Gly Ala Gly
100 105 110

Arg Gln Asp Leu Asn Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr
115 120 125

Tyr Asn Val Cys Arg Thr Gly Ser Ala Asn Pro His Lys Gly Ala Ile 130 135 140

Ser Phe Asp Asn Ile Gly Tyr Ala Trp Ile Val Ile Phe Gln Val Ile 145 150 155 160

Thr Leu Glu Gly Trp Val Ala Ile Met Tyr Tyr Val Met Asp Ala Leu 165 170 175

Ser Phe Tyr Asn Phe Val Tyr Phe Ile Leu Leu Ile Ile 180 185

<210> 21

<211> 567

<212> DNA

<213> rat

<220>

<223> rat alpha-I partial sequence

<400> 21

atgeggatec tegteact getetegae acgetecca tegetegggaa egteteete 60 etetetete tegtetete cateteege ateategee tegeagetete geagetete 120 etacggaace geteteet ggaagaaaa tetategee tegeagetete ggeectegee 180 etatatee aaccagagga ggatgaegag atgecettea tetgeteeet gaetegggae 240 aatggeatea tegegetee eggateee eggaatgeteg 300 etgtecaaag atgatgta tegaeteegg gegggegee aggaeetea eggeagege 360 etgtegegea actggaaceg etactacaac gtetgeegea egggeaaceg eaacceteae 420 aagggegeea teaacttega egategtega teaacttega egeteggate teaacttega egeteggate teaacttega egeteggate teateateae teaacttega egetegate teateatae teaacttega eaccatte teateatae 540 eaccatteaet teateatae

<210> 22

<211> 189

<212> PRT

<213> rat



<220>

<223> rat alpha-I partial sequence

<400> 22

Met Arg Ile Leu Val Asn Leu Leu Asp Thr Leu Pro Met Leu Gly
1 5 10 15

Asn Val Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile Ile 20 25 30

Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu 35 40 45

Glu Asn Phe Thr Ile Gln Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gln
50 55 60

Pro Glu Glu Asp Asp Glu Met Pro Phe Ile Cys Ser Leu Thr Gly Asp 65 70 75 80

Asn Gly Ile Met Gly Cys His Glu Ile Pro Pro Leu Lys Glu Gln Gly 85 90 95

Arg Glu Cys Cys Leu Ser Lys Asp Asp Val Tyr Asp Phe Gly Ala Gly
100 105 110

Arg Gln Asp Leu Asn Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr 115 120 125

Tyr Asn Val Cys Arg Thr Gly Asn Ala Asn Pro His Lys Gly Ala Ile 130 135 140

Asn Phe Asp Asn Ile Gly Tyr Ala Trp Ile Val Ile Phe Gln Val Ile 145 150 155 160

Thr Leu Glu Gly Trp Val Glu Ile Met Tyr Tyr Val Met Asp Ala His 165 170 175

Ser Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile 180 185

<210> 23

<211> 7540

<212> DNA

<213> rat

<400> 23





ccgtctctgg	cgcggagcgg	gacgatgctg	accccttaga	tcctgctcca	gctgcgccga	60 <sup>.</sup>
gggaagaggg	ggcgcccctc	cccggacccc	cgccctccat	cgggtggccc	cttttttc	120
tcttcctctc	gggggctgct	tegeegaagg	tagcgcctgt	tacgggcaac	cggagcctgg	180
gcgcgaacga	agaagccgga	acaaagtgag	gggaagccgc	ccggctagtc	ggggagcccc	240
			caggcggggc			
			gctgagctga			
			cccaccggg			
			tcggaccccc			
			ccgaggagtc			
			gcggcagggg			
			ctgccgtacc			
			cggagctggt			
			attettetca			
			tcccagcgct			
			gaaatggtgg			
			acttggaacc			
			ctgcagaacg			
			attaaceggg			
			ctgggcaacg			
			cagetgtggg			
			ctgagcgtgg			
			tgctctcagc			
tectaraga	atataccac	actocotogo	gaaggcggtg	ataacccacc	ctgcagtctg	1380
			accacctgtg			
			ttcaaaggcg			
			atcacactgg			
tacttcgtaa	togacoctca	ctccttctac	aacttcatct	acttcattct	tctcatcatc	1620
			ctggtggtga			
			gagcagcgtg			
			agetgetatg			
			ctggcccagg			
			cgtagtgggc			
			gtccaccacc			
			acgctcagag			
			cggctcatgc			
			gagtctgtac			
			cccctccca			
			cccactgtgc			
			gccccagcc			
			tccatgcaca			
			tccagccctt			
			gcccggacag			
			gaggetgtgt			
			cggcggcgac			
			aggetgatet			
			atgategeea			
			gageteacea			
			atgctgctga			
		- 3 3 - 3				

#### WO 01/02561



		ctacaacatc				
tgggagattg	tgggccagca	gggaggtggc	ctgtcggtgc	tgcggacctt	ccgcctgatg	3000
cgggtgctga	agctggtgcg	cttcctgccg	gccctgcagc	gccagctcgt	ggtgctcatg	3060
aagaccatgg	acaacgtggc	caccttctgc	atgctcctca	tgctgttcat	cttcatcttc	3120
agcatcctgg	gcatgcatct	ctttggttgc	aagttcgcat	ctgaacggga	tggggacacg	3180
		cgactccctg				
		taaagtcctc				
		cctcatgact				
		attccaggca				
		tgtggatggt				
		ggaactacga				
		acaccccaag				
ggctctggct	ctcgacgtac	cagtagcagt	gggtccgctg	agcctggagc	tgcccaccat	3660
		tgcccgcagc				
		cagcaggaac				
		gaggtccctg				
		ggaccgggcc				
		caagagttcc				
		cggccggagc				
		ggcccgcacc				
		aaatctgagc				
		ccgagagcga				
cagtcaaggt	ttcgtctcct	gtgtcaccgg	atcatcaccc	acaagatgtt	tgaccatgtg	4260
		caactgtatc				
ccccacagcg	ctgagcgcat	cttcctgacc	ctctccaact	acatcttcac	ggcagtcttt	4380
ctagctgaaa	tgacagtgaa	ggtggtggca	ctgggctggt	gctttgggga	gcaggcctac	4440
ctgcgcagca	gctggaatgt	gctggacggc	ttgctggtgc	tcatctccgt	catcgacatc	4500
		cagcggcacc				
		actcagggtc				
		cctcaaaccc				
ttcttcatca	tttttggaat	tctcggggtg	cagctcttca	aagggaagtt	cttcgtgtgt	4740
		catcactaac				
		ctttgacaac				
		ggttgacatc				
		ccacaacccc				
		cctgaacatg				
		ggaggaggag				
aggctggaga	aaaagagaag	gagtaaggag	aagcagatgg	ccgaagccca	gtgcaagccc	5160
		attccggctc				
		tgtcatcggg				
caccagcagc	cccagatcct	ggacgaggct	ctgaagatct	gcaattacat	ctttaccgtc	5340
atctttgtct	ttgagtcagt	tttcaaactt	gtggcctttg	cgttccgccg	tttcttccag	5400
gacaggtgga	accagctgga	cctggctatt	gtgcttctgt	ccatcatggg	catcacactg	5460
		gtcgctgccc				
		tctgaagetg				
		cctgcccag				
ctgtttttca	tctttgcagc	tctgggcgtg	gagetetttg	gagacetgga	gtgtgatgag	5700
acacaccctt	grgagggctt	gggtcggcat	gccaccttta	ggaactttgg	tatggccttt	5760



```
etgacectet teegagtete caetggtgae aactggaatg gtattatgaa ggaceettee 5820
egggaetgtg accaggagte cacctgetae aacactgtea teteccetat etactttgtg 5880
teettegtge tgaeggeeea gtttgtgetg gteaacgtgg teatagetgt getgatgaag 5940
cacctggaag aaagcaacaa agaggccaag gaggaggccg agctcgaggc cgagctggag 6000
ctggagatga agacgeteag ecegeagece caeteceege tgggeagece ettectetgg 6060
cccggggtgg agggtgtcaa cagtactgac agccctaagc ctggggctcc acacaccact 6120
gaggaggtgc cagtccccct aggaccagac ctgctgactg tgaggaagtc tggtgtcagc 6240
cggacgcact ctctgcccaa tgacagctac atgtgccgca atgggagcac tgctgagaga 6300
tccctaggac acaggggctg ggggctcccc aaagcccagt caggctccat cttgtccgtt 6360
cacteceaac cageagacac cagetgeate etacagette ecaaagatgt geactatetg 6420
ctccagcctc atggggctcc cacctggggc gccatcccta aactaccccc acctggccgc 6480
tecectetgg eteagaggee teteaggege caggeageaa taaggaetga eteeetggat 6540
gtgcagggcc tgggtagccg ggaagacctg ttgtcagagg tgagtgggcc ctcctgccct 6600
ctgacceggt cctcatcctt ctggggcggg tcgagcatcc aggtgcagca gcgttccggc 6660
atecagagea aagteteeaa geacateege etgeeageee ettgeecagg cetggaacee 6720
agetgggeea aggaceetee agagaceaga ageagettag agetggaeae ggagetgage 6780
tggatttcag gagacetect teccagcage caggaagaac ceetgtteec aegggacetg 6840
aagaagtgct acagtgtaga gacccagagc tgcaggcgca ggcctgggtt ctggctagat 6900
gaacagegga gacactecat tgctgtcage tgtctggaca geggetecea acceegeeta 6960
tgtccaagcc cctcaagcct cgggggccaa cctcttgggg gtcctgggag ccggcctaag 7020
aaaaaactca gcccacccag tatctctata gaccccccgg agagccaggg ctctcggccc 7080
ccatgcagtc ctggtgtctg cctcaggagg agggcgccgg ccagtgactc taaggatccc 7140
teggteteca gececettga cageaegget gecteaceet eeccaaagaa agacaegetg 7200
agtotototg gtttgtotto tgacccaaca gacatggaco cotgagtoot acccactoto 7260
ceccateace thetecace gggtgcagat cetacgteeg ceteetggge agegthtetg 7320
aaaagtccca cgtaagcagc aagcagccac gaggcacctc acctgccttc ttcagtggct 7380
ggtggggatg acgagcagaa cttccggaga gtcgatctga agagaacaca gccctggagc 7440
ccetgcctcc gggaagaagg aaaaggagaa gcccagtgtg gccaaggctc ccgacaccag 7500
gagctgttgg gagaagcaat acgtttgtgc agaatctcta
<210> 24
<211> 2287
<212> PRT
```

<213> rat

<400> 24

Met Leu Pro His Arg Val Pro Arg Cys Val Arg Thr Pro Pro Leu Arg 10

Gly Ser Ala Arg Pro Ser Ser Asp Pro Pro Gly Pro Arg Leu Ala Arg

Gly Trp Thr Arg Arg Arg Met Glu Arg Ala Pro Arg Ser Arg Asp Ser

Pro Val Ala Ser Arg Ser Ser Thr Thr Cys Pro Gly Pro Gly Ala Ala 55

#### WO.01/02561



11/023	<b>J.</b>												•		200/00	,
Gly 65	Ala	Gly	Ser	Thr	Glu 70	Lys	Asp	Pro	Gly	Ser 75	Ala	Asp	Ser	Glu	Ala 80	
Glu	Gly	Leu	Pro	Tyr 85	Pro	Ala	Leu	Ala	Pro 90	Val	Val	Phe	Phe	Tyr 95	Leu	
Ser	Gln	Asp	Ser 100	Arg	Pro	Arg	Ser	Trp 105	Cys	Leu	Arg	Thr	Val 110	Сув	Asn	
Pro	Trp	Phe 115	Glu	Arg	Val	Ser	Met 120	Leu	Val	Ile	Leu	Leu 125	Asn	Cys	Val	
Thr	Leu 130	Gly	Met	Phe	Arg	Pro 135	Сув	Glu	Asp	Ile	Ala 140	Сув	Asp	ser	Gln	
Arg 145	Суз	Arg	Ile	Leu	Gln 150	Ala	Phe	Asp	Asp	Phe 155	Ile	Phe	Ala	Phe	Phe 160	
Ala	Val	Glu	Met	Val 165	Val	ГÀв	Met	Val	Ala 170	Leu	Gly	Ile	Phe	Gly 175	Lys	
Lys	Суз	Tyr	Leu 180	Gly	Asp	Thr	Trp	Asn 185	Arg	Leu	Asp	Phe	Phe 190	Ile	Val	
Ile	Ala	Gly 195	Met	Leu	Glu	Tyr	Ser 200	Leu	Asp	Leu	Gln	Asn 205	Val	Ser	Phe	
Ser	Ala 210	Val	Arg	Thr	Val	Arg 215	Val	Leu	Arg	Pro	Leu 220	Arg	Ala	Ile	Asn	
Arg 225	Val	Pro	Ser	Met	Arg 230	Ile	Leu	Val	Thr	Leu 235	Leu	Leu	Asp	Thr	Leu 240	
Pro	Met	Leu	Gly	Asn 245	Val	Leu	Leu	Leu	Суs 250	Phe	Phe	Val	Phe	Phe 255	Ile	
Phe	Gly	Ile	Val 260	_	Val	Gln	Leu	Trp 265	Ala	Gly	Leu	Leu	Arg 270	Asn	Arg	
Cys	Phe	Leu 275		Glu	Asn	Phe	Ser 280	Leu	Pro	Leu	Ser	Val 285	Asp	Leu	Glu	
Pro	Tyr 290		Gln	Thr	Glu	Asn 295	Glu	Asp	Glu	Ser	Pro 300	Phe	Ile	Сув	Ser	
Gln 305		Arg	Glu	Asn	Gly 310	Met	Arg	Ser	Сув	Arg 315	Ser	Val	Pro	Thr	Leu 320	

#### · WO 01/02561



Arg Gly Glu	-			Сув 330		Leu	Asp	-	Glu 335	Thr
		 	 	•	_		_			_

- Tyr Asn Ser Ser Ser Asn Thr Thr Cys Val Asn Trp Asn Gln Tyr Tyr 340 345 350
- Thr Asn Cys Ser Ala Gly Glu His Asn Pro Phe Lys Gly Ala Ile Asn 355 . 360 365
- Phe Asp Asn Ile Gly Tyr Ala Trp Ile Ala Ile Phe Gln Val Ile Thr 370 380
- Leu Glu Gly Trp Val Asp Ile Met Tyr Phe Val Met Asp Ala His Ser 385 390 395 400
- Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile Val Gly Ser Phe
  405 410 415
- Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr Gln Phe Ser Glu 420 425 430
- Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln Arg Val Arg Phe
  435 440 445
- Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys 450 455 460
- Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu Arg Lys Ala Ala 465 470 475 480
- Arg Arg Leu Ala Gln Val Ser Arg Ala Ile Gly Val Arg Ala Gly Leu
  485 490 495
- Leu Ser Ser Pro Val Ala Arg Ser Gly Gln Glu Pro Gln Pro Ser Gly 500 505 510
- Ser Cys Thr Arg Ser His Arg Arg Leu Ser Val His His Leu Val His 515 520 525
- His His His His His His His Tyr His Leu Gly Asn Gly Thr Leu 530 540
- Arg Val Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg Asp Ala Asn Gly 545 550 555 560
- Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro Thr Pro Ser Gly 565 570 575



01/02561														P		A00/00
	Gly	Pro	Pro	Arg 580	Gly	Ala	Glu	Ser	Val 585	His	Ser	Phe	Tyr	His 590	Ala	Asp
	Cys	His	Leu 595	Glu	Pro	Val	Arg	Сув 600	Gln	Ala	Pro	Pro	Pro 605	Arg	Cys	Pro
	Ser	Glu 610	Ala	Ser	Gly	Arg	Thr 615	Val	Gly	Ser	Gly	Lys 620	Val	Tyr	Pro	Thr
	Val 625	His	Thr	Ser	Pro	Pro 630	Pro	Glu	Ile	Leu	Lув 635	Asp	Lys	Ala	Leu	Val 640
	Glu	Val	Ala	Pro	Ser 645	Pro	Gly	Pro	Pro	Thr 650	Leu	Thr	Ser	Phe	Asn 655	Ile
	Pro	Pro	Gly	Pro 660	Phe	Ser	Ser	Met	His 665	Lys	Leu	Leu	Glu	Thr 670	Gln	Ser
	Thr	Gly	Ala 675	Cys	His	Ser	Ser	680 CAa	Lys	Ile	Ser	Ser	Pro 685	Cys	Ser	Lys
	-	690					695		Asp			700	-	_		_
	705					710			Ala		715					720
	•				725				Thr	730	_				735	
		_	_	740				_	Arg 745					750		
			755					760	Phe	-	J		765	-	•	
		770	-			_	775	_	Tyr		Ī	780	_			
	785					790			Met		795					800
					805				Glu	810					815	
	ser	ьeu	rne	: ATG	rea	GIU	mec	ьeu	Leu	гÃg	ren	Leu	val	TYT	ĠΤΆ	KLO



- Phe Gly Tyr Ile Lys Asn Pro Tyr Asn Ile Phe Asp Gly Val Ile Val 835 840 845
- Val Ile Ser Val Trp Glu Ile Val Gly Gln Gln Gly Gly Leu Ser 850 855 860
- Val Leu Arg Thr Phe Arg Leu Met Arg Val Leu Lys Leu Val Arg Phe 865 870 875 880
- Leu Pro Ala Leu Gln Arg Gln Leu Val Val Leu Met Lys Thr Met Asp 885 890 895
- Asn Val Ala Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe 900 905 910
- Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ala Ser Glu Arg 915 920 925
- Asp Gly Asp Thr Leu Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp 930 940
- Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Lys 945 950 955 960
- Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp Ala Ala Leu Tyr 965 970 975
- Phe Ile Ala Leu Met Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu 980 985 990
- Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Thr Lys 995 1000 1005
- Ser Glu Ser Glu Pro Asp Phe Phe Ser Pro Ser Val Asp Gly Asp Gly 1010 1015 1020
- Asp Arg Lys Lys Arg Leu Ala Leu Val Ala Leu Gly Glu His Ala Glu 1025 1030 1035 1040
- Leu Arg Lys Ser Leu Leu Pro Pro Leu Ile Ile His Thr Ala Ala Thr
  1045 1050 1055
- Pro Met Ser His Pro Lys Ser Ser Ser Thr Gly Val Gly Glu Ala Leu 1060 1065 1070
- Gly Ser Gly Ser Arg Arg Thr Ser Ser Ser Gly Ser Ala Glu Pro Gly
  1075 1080 1085



- Ala Ala His His Glu Met Lys Cys Pro Pro Ser Ala Arg Ser Ser Pro 1090 1095 1100
- His Ser Pro Trp Ser Ala Ala Ser Ser Trp Thr Ser Arg Arg Ser Ser 1105 1110 1115 1120
- Arg Asn Ser Leu Gly Arg Ala Pro Ser Leu Lys Arg Arg Ser Pro Ser 1125. 1130 1135
- Gly Glu Arg Arg Ser Leu Leu Ser Gly Glu Gly Gln Glu Ser Gln Asp 1140 1145 1150
- Glu Glu Glu Ser Ser Glu Glu Asp Arg Ala Ser Pro Ala Gly Ser Asp 1155 1160 1165
- His Arg His Arg Gly Ser Leu Glu Arg Glu Ala Lys Ser Ser Phe Asp 1170 1180
- Leu Pro Asp Thr Leu Gln Val Pro Gly Leu His Arg Thr Ala Ser Gly 1185 1190 1195 1200
- Arg Ser Ser Ala Ser Glu His Gln Asp Cys Asn Gly Lys Ser Ala Ser 1205 1210 1215
- Gly Arg Leu Ala Arg Thr Leu Arg Thr Asp Asp Pro Gln Leu Asp Gly
  1220 1225 1230
- Asp Asp Asp Asn Asp Glu Gly Asn Leu Ser Lys Gly Glu Arg Ile Gln 1235 1240 1245
- Ala Trp Val Arg Ser Arg Leu Pro Ala Cys Cys Arg Glu Arg Asp Ser 1250 1255 1260
- Trp Ser Ala Tyr Ile Phe Pro Pro Gln Ser Arg Phe Arg Leu Leu Cys 1265 1270 1275 1280
- His Arg Ile Ile Thr His Lys Met Phe Asp His Val Val Leu Val Ile 1285 1290 1295
- Ile Phe Leu Asn Cys Ile Thr Ile Ala Met Glu Arg Pro Lys Ile Asp 1300 1305 1310
- Pro His Ser Ala Glu Arg Ile Phe Leu Thr Leu Ser Asn Tyr Ile Phe 1315 1320 1325
- Thr Ala Val Phe Leu Ala Glu Met Thr Val Lys Val Val Ala Leu Gly
  1330 1335 1340



- Trp Cys Phe Gly Glu Gln Ala Tyr Leu Arg Ser Ser Trp Asn Val Leu 1345 1350 1355 1360
- Asp Gly Leu Leu Val Leu Ile Ser Val Ile Asp Ile Leu Val Ser Met
  1365 1370 1375
- Val Ser Asp Ser Gly Thr Lys Ile Leu Gly Met Leu Arg Val Leu Arg 1380 1385 1390
- Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Gln Gly
  1395 1400 1405
- Leu Lys Leu Val Val Glu Thr Leu Met Ser Ser Leu Lys Pro Ile Gly 1410 1415 1420
- Asn Ile Val Val Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu 1425 1430 1435 1440
- Gly Val Gln Leu Phe Lys Gly Lys Phe Phe Val Cys Gln Gly Glu Asp 1445 1450 1455
- Thr Arg Asn Ile Thr Asn Lys Ser Asp Cys Ala Glu Ala Ser Tyr Arg 1460 1465 1470
- Trp Val Arg His Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met 1475 1480 1485
- Ser Leu Phe Val Leu Ala Ser Lys Asp Gly Trp Val Asp Ile Met Tyr 1490 1495 1500
- Asp Gly Leu Asp Ala Val Gly Val Asp Gln Gln Pro Ile Met Asn His 1505 1510 1515 1520
- Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ala 1525 1530 1535
- Phe Phe Val Leu Asn Met Phe Val Gly Val Val Val Glu Asn Phe His 1540 1545 1550
- Lys Cys Arg Gln His Gln Glu Glu Glu Glu Ala Arg Arg Glu Glu 1555 1560 1565
- Lys Arg Leu Arg Arg Leu Glu Lys Lys Arg Arg Ser Lys Glu Lys Gln 1570 1575 1580
- Met Ala Glu Ala Gln Cys Lys Pro Tyr Tyr Ser Asp Tyr Ser Arg Phe 1585 1590 1595 1600



- Arg Leu Leu Val His His Leu Cys Thr Ser His Tyr Leu Asp Leu Phe 1605 1610 1615
- Ile Thr Gly Val Ile Gly Leu Asn Val Val Thr Met Ala Met Glu His 1620 1625 1630
- Tyr Gln Gln Pro Gln Ile Leu Asp Glu Ala Leu Lys Ile Cys Asn Tyr 1635 1640 1645
- Ile Phe Thr Val Ile Phe Val Phe Glu Ser Val Phe Lys Leu Val Ala 1650 1655 1660
- Phe Ala Phe Arg Arg Phe Phe Gln Asp Arg Trp Asn Gln Leu Asp Leu · 1665 1670 1680
- Ala Ile Val Leu Leu Ser Ile Met Gly Ile Thr Leu Glu Glu Ile Glu 1685 1690 1695
- Val Asn Leu Ser Leu Pro Ile Asn Pro Thr Ile Ile Arg Ile Met Arg 1700 1705 1710
- Val Leu Arg Ile Ala Arg Val Leu Lys Leu Leu Lys Met Ala Val Gly
  1715 1720 1725
- Met Arg Ala Leu Leu His Thr Val Met Gln Ala Leu Pro Gln Val Gly 1730 1740
- Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe Ile Phe Ala Ala Leu 1745 1750 1755 1760
- Gly Val Glu Leu Phe Gly Asp Leu Glu Cys Asp Glu Thr His Pro Cys 1765 1770 1775
- Glu Gly Leu Gly Arg His Ala Thr Phe Arg Asn Phe Gly Met Ala Phe 1780 1785 1790
- Leu Thr Leu Phe Arg Val Ser Thr Gly Asp Asn Trp Asn Gly Ile Met 1795 1800 1805
- Lys Asp Pro Ser Arg Asp Cys Asp Gln Glu Ser Thr Cys Tyr Asn Thr 1810 1815 1820
- Val Ile Ser Pro Ile Tyr Phe Val Ser Phe Val Leu Thr Ala Gln Phe 1825 1830 1835 1840
- Val Leu Val Asn Val Val Ile Ala Val Leu Met Lys His Leu Glu Glu 1845 1850 1855



- Ser Asn Lys Glu Ala Lys Glu Glu Ala Glu Leu Glu Ala Glu Leu Glu 1860 1865 1870
- Leu Glu Met Lys Thr Leu Ser Pro Gln Pro His Ser Pro Leu Gly Ser 1875 1880 1885
- Pro Phe Leu Trp Pro Gly Val Glu Gly Val Asn Ser Thr Asp Ser Pro 1890 1895 1900
- Lys Pro Gly Ala Pro His Thr Thr Ala His Ile Gly Ala Ala Ser Gly 1905 1910 1915 1920
- Phe Ser Leu Glu His Pro Thr Met Val Pro His Pro Glu Glu Val Pro 1925 1930 1935
- Val Pro Leu Gly Pro Asp Leu Leu Thr Val Arg Lys Ser Gly Val Ser 1940 1945 1950
- Arg Thr His Ser Leu Pro Asn Asp Ser Tyr Met Cys Arg Asn Gly Ser 1955 1960 1965
- Thr Ala Glu Arg Ser Leu Gly His Arg Gly Trp Gly Leu Pro Lys Ala 1970 1975 1980
- Gln Ser Gly Ser Ile Leu Ser Val His Ser Gln Pro Ala Asp Thr Ser 1985 1990 1995 2000
- Cys Ile Leu Gln Leu Pro Lys Asp Val His Tyr Leu Leu Gln Pro His
  2005 2010 2015
- Gly Ala Pro Thr Trp Gly Ala Ile Pro Lys Leu Pro Pro Pro Gly Arg
  2020 2025 2030
- Ser Pro Leu Ala Gln Arg Pro Leu Arg Arg Gln Ala Ala Ile Arg Thr 2035 2040 2045
- Asp Ser Leu Asp Val Gln Gly Leu Gly Ser Arg Glu Asp Leu Leu Ser 2050 2055 2060
- Glu Val Ser Gly Pro Ser Cys Pro Leu Thr Arg Ser Ser Ser Phe Trp 2065 2070 2075 2080
- Gly Gly Ser Ser Ile Gln Val Gln Gln Arg Ser Gly Ile Gln Ser Lys 2085 2090 2095
- Val Ser Lys His Ile Arg Leu Pro Ala Pro Cys Pro Gly Leu Glu Pro 2100 2105 2110



Ser Trp Ala Lys Asp Pro Pro Glu Thr Arg Ser Ser Leu Glu Leu Asp 2115 2120 2125

Thr Glu Leu Ser Trp Ile Ser Gly Asp Leu Leu Pro Ser Ser Gln Glu 2130 2135 2140

Glu Pro Leu Phe Pro Arg Asp Leu Lys Lys Cys Tyr Ser Val Glu Thr 2145 2150 2155 2160

Gln Ser Cys Arg Arg Pro Gly Phe Trp Leu Asp Glu Gln Arg Arg 2165 2170 2175

His Ser Ile Ala Val Ser Cys Leu Asp Ser Gly Ser Gln Pro Arg Leu 2180 2185 2190

Cys Pro Ser Pro Ser Ser Leu Gly Gly Gln Pro Leu Gly Gly Pro Gly
2195 2200 2205

Ser Arg Pro Lys Lys Leu Ser Pro Pro Ser Ile Ser Ile Asp Pro 2210 2215 2220

Pro Glu Ser Gln Gly Ser Arg Pro Pro Cys Ser Pro Gly Val Cys Leu 2225 2230 2235 2240

Arg Arg Ala Pro Ala Ser Asp Ser Lys Asp Pro Ser Val Ser Ser 2245 2250 2255

Pro Leu Asp Ser Thr Ala Ala Ser Pro Ser Pro Lys Lys Asp Thr Leu 2260 2265 2270

Ser Leu Ser Gly Leu Ser Ser Asp Pro Thr Asp Met Asp Pro Glx 2275 2280 2285

<210> 25

<211> 8447

<212> DNA

<213> rat

<400> 25

cgggataatt ctgtctcatt accataggca cacaataaaa catctttacc atttctctaa 60 actcagccat tggccaaagc cagaaggaag acctgtgcat ttgcatctgg ggatccgatc 120 ctgactgatg ctctaggttg ctgcgtatac agtggaggag actgtgagaa aggaccatag 180 tagtcaagga agaaagcatc ctgggacaga gccacaatca cgagatgatt cctaccaatg 240 aacctcttcg gactgggtc cagtgacage gccgcccggg ctatgccacg gggacgccg 300 tagccaccgg agcgggtga gatgcggagg gtacgcgcg ttactgcgcg cctgggacc 360 tttgaacttg agctctgtgg gctccgagc cctagggctc ccgcaaccct tcgcctcggc 420





					atttgtctct	
					cgctccgcct	
					ctccgcaggt	
					gggtgcccct	
					gccctggggc	
					agagcccagg	
					acccagetet	
ggctgccaca	gtcttcttct	gcctcgggca	aaccacgcgg	ccgcgcagct	ggtgcctccg	900
actggtttgt	aacccgtggt	tcgagcacgt	cagcatgctg	gtcatcatgc	tgaactgcgt	960
					gttgcagcat	
cttggaggcc	ttcgacgact	tcatctttgc	cttcttcgcc	gtggagatgg	tgatcaagat	1080
ggtggctttg	gggctgtttg	ggcaaaaatg	ctacctgggt	gacacctgga	acaggctgga	1140
cttcttcatt	gtcatggcgg	gcatgatgga	gtactctctg	gacggacaca	aggtgagcct	1200
ctctgccatc	cgaaccgtgc	gtgtgctgcg	gcccctccgc	gccatcaacc	gagtccccag	1260
tatgcggatc	ctggtcactc	tgctgctgga	cacgctgccc	atgcttggga	atgtcctcct	1320
cctctgcttc	ttcgtcttct	tcatcttcgg	cattgttggg	gtccagctct	gggctggcct	1380
					tgaccttctt	
gcggccatac	taccagacgg	aggagggtga	ggagaaccct	ttcatctgct	cctcccgccg	1500
tgacaacggc	atgcagaagt	gctcgcacat	ccccagccgc	cgtgagcttc	gagtgcagtg	1560
					ctggccgcaa	
cgcctgtatc	aactggaacc	agtattacaa	cgtgtgccgc	tcgggggaat	tcaaccctca	1680
					tccaggtcat	
					cgttctacaa	
					acctgtgcct	
ggtggtgata	gccacacagt	tctcagagac	aaagcaaagg	gaaaaccagc	tgatgcgaga	1920
					agcccggcag	
					aacgccgtag	
cctgcgtctt	tatgcccgct	ggcagagccg	ctggcgtaag	aaggtggatc	ccagcagtac	2100
cgtgcatggc	caaggccctg	ggcggcggcc	acgacgggca	ggcaggcgta	cagcttcagt	2160
gcaccatctg	gtctaccacc	accaccacca	ccatcaccac	cattaccact	ttagccacgg	2220
tggcccacgc	aggcccagcc	cagagccagg	tgctggtgac	aacaggttgg	tcagggcctg	2280
tgcgccaccc	tcgccgccat	ccccaggcca	tgggccacca	gactctgagt	ctgtgcacag	2340
tatctaccat	gctgactgcc	acgtggaggg	gccgcaggaa	cgagcccgag	tggcacactc	2400
catagccact	gctgctagcc	tcaagctggc	ctcaggtttg	ggtaccatga	actaccccac	2460
catcctacct	tcaggaacag	tcaacagcaa	aggtggcacc	agctcacgac	ccaaggggct	2520
acgaggtgct	ggcgccccag	gggctgcagt	acacageeet	ctgagcctgg	gaagccccag	2580
accctatgag	aagatccagg	atgtggtggg	agaacaagga	ctaggccgag	cctctagcca	2640
					cgctgacctg	
					ttgaattcag	
tggctcagag	agcggggact	cggatgccca	cggagtctat	gagtttaccc	aggatgtacg	2820
gcatggggat	tgtcgggacc	ctgtgcagca	gccccatgaa	gtgggcacac	caggccacag	2880
caatgagcgg	cggcggacac	cactgcggaa	ggcctcacaa	ccaggaggga	taggccacct	2940
ctgggcatcc	ttcagtggca	agctacgtcg	cattgtagac	agcaagtact	tcaaccgagg	3000
					atgaacagcc	
					tgtttgcctt	
					acccctacaa	
					aggcagacgg	
tggccagtct	gtgctgcgca	ccttcaggct	gctgcgggtg	ctgaagctgg	tgcgcttcct	3300



gccggccctg	cggcgccagc	tegtggtget	catgaggacc	atggacaacg	tggccacctt	3360
ctgcatgctc	ctcatgctgt	tcatcttcat	cttcagcatc	ctgggcatgc	acctgttcgg	3420
ctgtaagttc	agcctgaaga	cagactctgg	agacaccgtc	cctgacagga	agaacttcga	3480
ctccctactg	tgggccatcg	tcaccgtgtt	tcagatcttg	acacaggaag	actggaacgt	3540
ggttctgtac	aacggcatgg	cctccacttc	gtcctgggcc	gccctttact	ttqtqqcct	3600
catgaccttt	gggaactatg	tgctcttcaa	cctgctggta	gccatcctgg	tqqaaqqttt	3660
ccaggcagag	ggtgacgcca	ccagatetga	caccgacgag	gataagacgt	ctacccaget	3720
agagggagat	ttcgataagc	tcagagatct	tcgagccaca	gagatgaaga	totattcact	3780
ggcagtgacc	cctaacgggc	acctagaggg	ccgaggcagc	ctaccaccac	ccctcatcac	3840
tcacacggca	gctacgccta	tgcctactcc	caaaagctcc	ccaaacctgg	acgtggccca	3900
tgctctcctq	gactctcggc	qcaqcaqcaq	cggctctgtg	gaccccage	tagaggacca	3960
gaagtetetg	qccaqcctcc	qcaqctcccc	ttgcacccca	tagaacccca	acagcactag	4020
gagcagcagg	cactccaatt	ggaacagcct	gggccgcgca	cccagcetca	aacgccgcag	4080
ccagtgtggg	gagegegagt	ccctactctc	tggagagggg	aagggagga	cccatcacca	4140
qqccqaqqac	agcagaccaa	gcacgggaac	ccacccaggg	acctcaccaa	accccasac	4200
cacqccactq	caacatacca	agtcattgga	ccaccgcagc	acoctooacc	tatatacaca	4260
acqqcctqcq	cctcctacca	tccaagttca	tgactgcaac	aaacaaataa	taaccctacc	4320
cagcgagttc	tttctgcgca	tegacageca	caaggaggat	gcagcggagt	ttgatgatga	4380
catagaggat	agetgetget	tecetetaca	caaagtgctg	gaaccctato	caccccagta	4440
qtqccqtaqc	cgggagtcct	gaaccctata	tctcttccca	ccacagaaca	gactacacat	4500
ctcctqccaq	aaagtcatcg	cacacaagat	gtttgaccac	gtggtccttg	tetteatett	4560
cctcaactqt	atcaccatto	ctctggagag	gccagacatt	gacccaggca	gcactgagcg	4620
ggccttcctc	agcgtctcca	actacatctt	cacagccatc	ttcataataa	adatostoot	4680
gaaggtggta	accetaggae	tactatagaa	tgaacatgcc	tacctacage	ccacttccaa	4740
tatactagac	agactactta	tectggtate	cctggttgac	atcatcotoo	ccatoocctc	4800
agctggcggt	gccaagatcc	taggcgtcct	gcgtgtcgtg	cacctactac	ggacctgag	4860
qcctctqaqq	gtcatcagcc	gagetecagg	cctcaagctg	attatagaga	ctctcetetc	4920
atcoctcago	cccattogga	acatcotcct	catctgctgc	geettettea	tcatctttca	4980
catcctcggg	gtgcagcttt	tcaagggcaa	attctactac	tacaaaaaca	cagataccag	5040
gaatatcacc	accaaggccg	agtgccatgc	tgcccactac	cactagatas	cagacaccag	5100
caactttgac	aacctgggtc	aggcgctgat	gtctctgttc	atactatest	ctaaggatgg	5160
ctgggtaaac	atcatotato	acoogctoga	tgccgtgggc	atcgaccage	accentaca	5220
gaaccacaac	ccctggatgc	tectctactt	catctccttc	ctactcatca	tcagcttctt	5280
catactcaac	atatttataa	acataataat	ggagaacttc	cacaagtgcc	dacadesee	5340
ggaggctgag	gaggetegge	accadaada	gaaacggctg	caacacctaa	33ca3cacca	5400
caggaaggcc	Cadcaccaac	cctactacgc	agactattca	cacactccc	actecateca	5460
ttcgctgtgc	accagccact	acctggacct	cttcatcacc	ttcatcatct	acctcaatat	5520
catcaccatq	tecatogage	actacaacca	gcccaagtcc	ctagatgagg	ccctcaagta	5580
ctgcaactac	gtctttacca	tcatcttcat	ctttgaggct	gcactgaage	tagtageett	5640
tagattecaa	aggttettea	aggacaggtg	gaaccagetg	gacttggcca	teatectect	5700
atccatcato	ggcattgcgc	tggaggagat	tgagatgaac	accacactac	ccatcaatcc	5760
caccatcatc	cgcatcatgc	gtgtgcttca	aatcgcccgt	gtactassec	tactgaaget	5820
ggccacaggc	atgegegeet	toctocatac	tgtggttcaa	actotacete	addtadddae	5880
ccttaatctt	cttttcatoc	tectatttt	tatctatgct	accetagasa	tagaactatt	5940
tgggaggeta	gagtgcagcg	aggataaccc	ctgcgagggc	ctdadcadd	-33-3-cyc	6000
caccaacttc	gacatagacet	tecteacact	gttccgagtg	tccactgggg	acaactagaa	6060
toggattato	aaggataccc	tecataaata	tacccgtgag	gacaagcact	acctcaacta	6120
cctgcccaca	ctctcaccca	tctacttcot	caccttcatg	ctaataactc	agttcotoct	6180
						3230



```
ggtcaatgtg gtggtggccg tgctcatgaa gcacctggag gagagcaaca aggaggcccg 6240
cgaggatgca gagatggacg ccgagatcga gctggagatg gcacaggggt ccacagccca 6300
gcccccacct acagcacagg aaagccaagg tacccagcca gacaccccga acctcctggt 6360
cgtgcgaaaa gtatctgtgt ccaggatgct ctcgctgccc aatgacagct acatgttcag 6420
geoggtgget cocgeggetg coccacatte ceacceactg caggaagtgg agatggagac 6480
ctacacagge ceggtcacet etgetcacte gecacecetg gageceegeg cetettteca 6540
ggtcccatca gccgcgtcct ccccagccag ggtcagtgac cccctttgtg ccctttcacc 6600
coggggtaca cocceptete tgagtetete acggatacte tgeagacagg aggccatgca 6660
ctctgagtcc ctggaaggga aggttgatga tgttggagga gacagcatcc cagactacac 6720
agagectget gaaaatatgt ccaegageea ggeateaaca ggtgeeeega ggteeeetee 6780
gtgetecceg egacetgeca gegteegtae eegeaageae aegtttggge aaegetgeat 6840
ctccagccgc cctcccaccc tgggaggaga tgaggctgaa gcagcagacc cagcagatga 6900
ggaggtcagc cacatcacca gctcagccca cccctggccg gctacagagc cccacagccc 6960
tgaggcctcc ccaacagcct ctcctgtgaa aggcacaatg ggcagtgggc gggacccacg 7020
caggttctgc agtgtagatg ctcagagctt cctggacaaa ccaggtcggc cagatgcaca 7080
acggtggtcc tcagtggaac tggataacgg agaaagccac ctagagtccg gggaagtgag 7140
gggccgggcc tcagagctcg aaccagctct tgggtcacga aggaagaaga agatgagccc 7200
tecetgeate tecattgaac eteceactaa ggatgaggge tettecegge eccetgeage 7260
cgaaggaggc aacactacec tgaggegceg aaccccatec tgtgaggetg ecctecatag 7320
ggactgccca gagcctacag aaggcccagg caccggaggg gaccctgtag ccaagggtga 7380
gegetgggge caggeetett geegageaga geatetgaet gteeceaact ttgeetttga 7440
gcctctggac atgggcggac ctggtggaga ctgtttcttg gacagtgacc aaagtgtgac 7500
cccagaaccc agagtttcct ctttgggggc tatagtgcct ctgatactag aaactgaact 7560
ttotatgocc totoctgact goccagagaa ggaacaagga ctgtacctca ctgtgcccca 7620
gaccccttg aagaaaccag ggtctacccc agccactcct gccccagatg acagtggaga 7680
tgagectgtg tagatgggge tgegtgteea cagggetttg geattgaggt tgtttggetee 7740
tgcagggtgg tagggccatg agtggaccct gcttaggccc cactaaggca gagggaccgg 7800
gagataacca teecaggaga ggeageagae atecegtete tgeaccatga cacaggagea 7860
gcctcgggcc ccacgagcct ccctcgtggt gattcaggtt tgggttttcc tgagttttaa 7920
ccaccaccag aagctgtacc aggaccaggt catcagtete aggaggagag getgtgteet 7980
gggaaggacc agtaatteet cacaggcace acagetecat ecatgtgaca cacaggttte 8040
cgacagggag tacagettga geetgtgtac attgggteet geagecaceg cacceatat 8100
caccttegtt cacagtectg tttetgteca ceaeteggea teetteeete teacagtgee 8160
cotecccat tecatecect tagatggtet agaactttgc agtgacectg ggaagtactg 8220
acceatgeaa taagacattg cagteecaae tgaggtgggg etteecatee atteeagget 8280
gttgggctca acattcattt gacatccatt tgctttatgt catccgtttc tacaaattca 8340
ggttaaatgt tgcaataatc tgatgcagaa aacttggctt cctaagtcaa agctgagggg 8400
aggggagggg aggggcaagg caaatctgaa taaacactaa cttattg
```

```
<210> 26
<211> 2359
<212> PRT
```

<213> rat

Met Thr Glu Gly Thr Leu Ala Ala Asp Glu Val Arg Val Pro Leu Gly

1 5 10 15



Ala Ser	Pro	Pro	Ala	Pro	Ala	Ala	Pro	Val	Arg	Ala	Ser	Pro	Ala	Ser
	20				25					30				


- Pro Gly Ala Pro Gly Arg Glu Glu Glu Gly Gly Ser Gly Ser Gly Val
  35 40 45
- Leu Ala Pro Glu Ser Pro Gly Thr Glu Cys Gly Ala Asp Leu Gly Ala
  50 55 60
- Asp Glu Glu Gln Pro Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe
  65 70 75 80
- Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu Arg Leu 85 90 95
- Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile Met Leu 100 105 110
- Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys 115 120 125
- Arg Ser Glu Arg Cys Ser Ile Leu Glu Ala Phe Asp Asp Phe Ile Phe 130 135 140
- Ala Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu 145 150 155 160
- Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe 165 170 175
- Phe Ile Val Met Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Lys 180 185 190
- Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg 195 200 205
- Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu 210 215 220
- Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Cys Phe Phe Val 225 230 235
- Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu 245 250 255
- Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu 260 265 270



Thr	Phe	Leu	Arg	Pro	Tyr	Tyr	Gln	Thr	Glu	Glu	Gly	Glu	Glu	Asn	Pro
		275					280					285			

- Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys Ser His 290 295 300
- Ile Pro Ser Arg Arg Glu Leu Arg Val Gln Cys Thr Leu Gly Trp Glu 305 310 315 320
- Ala Tyr Gly Gln Pro Gln Ala Glu Asp Gly Gly Ala Gly Arg Asn Ala 325 330 335
- Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly Glu Phe 340 345 350
- Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala Trp 355 360 365
- Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp Ile Met 370 380
- Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile 385 390 395
- Leu Leu Ile Ile Met Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val 405 410 415
- Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Asn Gln Leu 420 425 430
- Met Arg Glu Gln Arg Ala Arg Tyr Leu Ser Asn Asp Ser Thr Leu Ala 435 440 445
- Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Val 450 455 460
- Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu Tyr Ala 465 470 475 480
- Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ser Thr Val
- His Gly Gln Gly Pro Gly Arg Arg Pro Arg Arg Ala Gly Arg Arg Thr 500 505 510





Gly Ala Gly Asp Asn Arg Leu Val Arg Ala Cys Ala Pro Pro Ser Pro 545 550 555

Pro Ser Pro Gly His Gly Pro Pro Asp Ser Glu Ser Val His Ser Ile 565 570 575

Tyr His Ala Asp Cys His Val Glu Gly Pro Gln Glu Arg Ala Arg Val 580 585 590

Ala His Ser Ile Ala Thr Ala Ala Ser Leu Lys Leu Ala Ser Gly Leu 595 600

Gly Thr Met Asn Tyr Pro Thr Ile Leu Pro Ser Gly Thr Val Asn Ser 610 615 620

Lys Gly Gly Thr Ser Ser Arg Pro Lys Gly Leu Arg Gly Ala Gly Ala 625 630 635 640

Pro Gly Ala Ala Val His Ser Pro Leu Ser Leu Gly Ser Pro Arg Pro 645 650 655

Tyr Glu Lys Ile Gln Asp Val Val Gly Glu Gln Gly Leu Gly Arg Ala 660 665 670

Ser Ser His Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro Ser Pro 675 680 685

Gln Ala Gly Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr Cys Ala 690 695 700

Ser Ala Leu Glu Asp Pro Glu Phe Glu Phe Ser Gly Ser Glu Ser Gly 705 710 715 720

Asp Ser Asp Ala His Gly Val Tyr Glu Phe Thr Gln Asp Val Arg His
725 730 735

Gly Asp Cys Arg Asp Pro Val Gln Gln Pro His Glu Val Gly Thr Pro
740 745 750

Gly His Ser Asn Glu Arg Arg Arg Thr Pro Leu Arg Lys Ala Ser Gln 755 760 765

Pro Gly Gly Ile Gly His Leu Trp Ala Ser Phe Ser Gly Lys Leu Arg 770 775 780

### · WO 01/02561



Arg	Ile	Val	Asp	Ser	Lys	Tyr	Phe	Asn	Arg	Gly	Ile	Met	Ala	Ala	Ile
785					790					795					800

- Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr His Glu Gln Pro Glu 805 810 815
- Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile Val Phe Thr Ser Met 820 825 830
- Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala Cys Gly Pro Leu Gly 835 840 845
- Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly Ile Val Val Ile 850 855 860
- Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly Gly Gln Ser Val Leu 865 870 875 880
- Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu Val Arg Phe Leu Pro
- Ala Leu Arg Arg Gln Leu Val Val Leu Met Arg Thr Met Asp Asn Val 900 905 910
- Ala Thr Phe Cys Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser Ile 915 920 925
- Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser Leu Lys Thr Asp Ser 930 935 940
- Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp Ala 945 950 955 960
- Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Val Val 965 970 975
- Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp Ala Ala Leu Tyr Phe 980 985 990
- Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu Val 995 1000 1005
- Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly Asp Ala Thr Arg Ser 1010 1015 1020
- Asp Thr Asp Glu Asp Lys Thr Ser Thr Gln Leu Glu Gly Asp Phe Asp 1025 1030 1035 1040



- Lys Leu Arg Asp Leu Arg Ala Thr Glu Met Lys Met Tyr Ser Leu Ala 1045 1050 1055
- Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly Ser Leu Pro Pro 1060 1065 1070
- Leu Ile Thr His Thr Ala Ala Thr Pro Met Pro Thr Pro Lys Ser Ser 1075 1080 1085
- Pro Asn Leu Asp Val Ala His Ala Leu Leu Asp Ser Arg Arg Ser Ser 1090 1095 1100
- Ser Gly Ser Val Asp Pro Gln Leu Gly Asp Gln Lys Ser Leu Ala Ser 1105 1110 1115 1120
- Leu Arg Ser Ser Pro Cys Thr Pro Trp Gly Pro Asn Ser Ala Gly Ser 1125 1130 1135
- Ser Arg Arg Ser Ser Trp Asn Ser Leu Gly Arg Ala Pro Ser Leu Lys
  1140 1145 1150
- Arg Arg Ser Gln Cys Gly Glu Arg Glu Ser Leu Leu Ser Gly Glu Gly
  1155 1160 1165
- Lys Gly Ser Thr Asp Asp Glu Ala Glu Asp Ser Arg Pro Ser Thr Gly
  1170 1175 1180
- Thr His Pro Gly Ala Ser Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg 1185 1190 1195 1200
- Ala Glu Ser Leu Asp His Arg Ser Thr Leu Asp Leu Cys Pro Pro Arg 1205 1210 1215
- Pro Ala Pro Pro Ala Val Gln Val His Asp Cys Asn Gly Gln Met Val 1220 1225 1230
- Ala Leu Pro Ser Glu Phe Phe Leu Arg Ile Asp Ser His Lys Glu Asp 1235 1240 1245
- Ala Ala Glu Phe Asp Asp Asp Ile Glu Asp Ser Cys Cys Phe Arg Leu 1250 1255 1260
- His Lys Val Leu Glu Pro Tyr Ala Pro Gln Trp Cys Arg Ser Arg Glu 1265 1270 1275 1280
- Ser Trp Ala Leu Tyr Leu Phe Pro Pro Gln Asn Arg Leu Arg Val Ser 1285 1290 1295



- Cys Gln Lys Val Ile Ala His Lys Met Phe Asp His Val Val Leu Val 1300 1305 1310
- Phe Ile Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu Arg Pro Asp Ile 1315 1320 1325
- Asp Pro Gly Ser Thr Glu Arg Ala Phe Leu Ser Val Ser Asn Tyr Ile 1330 1335 1340
- Phe Thr Ala Ile Phe Val Val Glu Met Met Val Lys Val Val Ala Leu 1345 1350 1355 1360
- Gly Leu Leu Trp Gly Glu His Ala Tyr Leu Gln Ser Ser Trp Asn Val 1365 1370 1375
- Leu Asp Gly Leu Leu Val Leu Val Ser Leu Val Asp Ile Ile Val Ala 1380 1385 1390
- Met Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu Arg Val Val 1395 1400 1405
- Arg Leu Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Pro 1410 1415 1420
- Gly Leu Lys Leu Val Val Glu Thr Leu Ile Ser Ser Leu Arg Pro Ile 1425 1430 1435 1440
- Gly Asn Ile Val Leu Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile 1445 1450 1455
- Leu Gly Val Gln Leu Phe Lys Gly Lys Phe Tyr Tyr Cys Glu Gly Thr 1460 1465 1470
- Asp Thr Arg Asn Ile Thr Thr Lys Ala Glu Cys His Ala Ala His Tyr 1475 1480 1485
- Arg Trp Val Arg Arg Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu 1490 1495 1500
- Met Ser Leu Phe Val Leu Ser Ser Lys Asp Gly Trp Val Asn Ile Met 1505 1510 1515 1520
- Tyr Asp Gly Leu Asp Ala Val Gly Ile Asp Gln Gln Pro Val Gln Asn 1525 1530 1535
- His Asn Pro Trp Met Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val 1540 1545 1550




- Ser Phe Phe Val Leu Asn Met Phe Val Gly Val Val Glu Asn Phe 1555 1560 1565
- His Lys Cys Arg Gln His Gln Glu Ala Glu Glu Ala Arg Arg Glu 1570 1575 1580
- Glu Lys Arg Leu Arg Arg Leu Glu Arg Arg Arg Arg Lys Ala Gln Arg 1585 1590 1595 1600
- Arg Pro Tyr Tyr Ala Asp Tyr Ser His Thr Arg Arg Ser Ile His Ser 1605 1610 1615
- Leu Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Cys 1620 1625 1630
- Leu Asn Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser 1635 1640 1645
- Leu Asp Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val Phe 1650 1655 1660
- Val Phe Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg Phe 1665 1670 1675 1680
- Phe Lys Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser 1685 1690 1695
- Ile Met Gly Ile Ala Leu Glu Glu Ile Glu Met Asn Ala Ala Leu Pro 1700 1705 1710
- Ile Asn Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg 1715 1720 1725
- Val Leu Lys Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp 1730 1735 1740
- Thr Val Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe 1745 1750 1755 1760
- Met Leu Phe Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly
  1765 1770 1775
- Arg Leu Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His 1780 1785 1790
- Ala Thr Phe Thr Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val 1795 1800 1805



- Ser Thr Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu 1810 1815 1820
- Cys Thr Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser 1825 1830 1835 1840
- Pro Val Tyr Phe Val Thr Phe Met Leu Val Ala Gln Phe Val Leu Val 1845 . 1850 1855
- Asn Val Val Val Ala Val Leu Met Lys His Leu Glu Glu Ser Asn Lys 1860 1865 1870
- Glu Ala Arg Glu Asp Ala Glu Met Asp Ala Glu Ile Glu Leu Glu Met 1875 1880 1885
- Ala Gln Gly Ser Thr Ala Gln Pro Pro Pro Thr Ala Gln Glu Ser Gln 1890 1895 1900
- Gly Thr Gln Pro Asp Thr Pro Asn Leu Leu Val Val Arg Lys Val Ser 1905 1910 1915 1920
- Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe Arg Pro 1925 1930 1935
- Val Ala Pro Ala Ala Pro His Ser His Pro Leu Gln Glu Val Glu 1940 1945 1950
- Met Glu Thr Tyr Thr Gly Pro Val Thr Ser Ala His Ser Pro Pro Leu 1955 1960 1965
- Glu Pro Arg Ala Ser Phe Gln Val Pro Ser Ala Ala Ser Ser Pro Ala 1970 1975 1980
- Arg Val Ser Asp Pro Leu Cys Ala Leu Ser Pro Arg Gly Thr Pro Arg 1985 1990 1995 2000
- Ser Leu Ser Leu Ser Arg Ile Leu Cys Arg Gln Glu Ala Met His Ser 2005 2010 2015
- Glu Ser Leu Glu Gly Lys Val Asp Asp Val Gly Gly Asp Ser Ile Pro 2020 2025 2030
- Asp Tyr Thr Glu Pro Ala Glu Asn Met Ser Thr Ser Gln Ala Ser Thr 2035 2040 2045
- Gly Ala Pro Arg Ser Pro Pro Cys Ser Pro Arg Pro Ala Ser Val Arg 2050 2055 2060





- Thr Leu Gly Gly Asp Glu Ala Glu Ala Ala Asp Pro Ala Asp Glu Glu 2085 2090 2095
- Val Ser His Ile Thr Ser Ser Ala His Pro Trp Pro Ala Thr Glu Pro 2100 2105 2110
- His Ser Pro Glu Ala Ser Pro Thr Ala Ser Pro Val Lys Gly Thr Met
  2115 2120 2125
- Gly Ser Gly Arg Asp Pro Arg Arg Phe Cys Ser Val Asp Ala Gln Ser 2130 2135 2140
- Phe Leu Asp Lys Pro Gly Arg Pro Asp Ala Gln Arg Trp Ser Ser Val 2145 2150 2155 2160
- Glu Leu Asp Asn Gly Glu Ser His Leu Glu Ser Gly Glu Val Arg Gly
  2165 2170 2175
- Arg Ala Ser Glu Leu Glu Pro Ala Leu Gly Ser Arg Arg Lys Lys 2180 2185 2190
- Met Ser Pro Pro Cys Ile Ser Ile Glu Pro Pro Thr Lys Asp Glu Gly
  2195 2200 2205
- Ser Ser Arg Pro Pro Ala Ala Glu Gly Gly Asn Thr Thr Leu Arg Arg 2210 2215 2220
- Arg Thr Pro Ser Cys Glu Ala Ala Leu His Arg Asp Cys Pro Glu Pro 2225 2230 2235 2240
- Thr Glu Gly Pro Gly Thr Gly Gly Asp Pro Val Ala Lys Gly Glu Arg 2245 2250 2255
- Trp Gly Gln Ala Ser Cys Arg Ala Glu His Leu Thr Val Pro Asn Phe 2260 2265 2270
- Ala Phe Glu Pro Leu Asp Met Gly Gly Pro Gly Gly Asp Cys Phe Leu 2275 2280 2285
- Asp Ser Asp Gln Ser Val Thr Pro Glu Pro Arg Val Ser Ser Leu Gly 2290 2295 2300
- Ala Ile Val Pro Leu Ile Leu Glu Thr Glu Leu Ser Met Pro Ser Pro 2305 2310 2315 2320





Asp Cys Pro Glu Lys Glu Gln Gly Leu Tyr Leu Thr Val Pro Gln Thr
2325 2330 2335

Pro Leu Lys Lys Pro Gly Ser Thr Pro Ala Thr Pro Ala Pro Asp Asp 2340 2345 2350

Ser Gly Asp Glu Pro Val Glx 2355

<210> 27

<211> 5735

<212> DNA

<213> rat

<400> 27

ceggettegg egeegtgeee ggeeacgtee atgeeaaggg etecetgete caegetgaea 60 tggctgacag caacttaccg ccctcatctg cagcagccc ggcccccgag ccgggaatca 120 ctgagcagec ggggccccgg agtecccctc catcccctcc aggcctggag gagccattgg 180 aaggaaccaa ccctgacgtc ccacatccag acctggctcc tgttgctttc ttctgcctgc 240 gecagaceae gageceaegg aactggtgea teaagatggt ttgtaaceeg tggttegagt 300 gtgtgagcat gctggttatt ctgctgaact gtgtgaccct gggcatgtac cagccatgtg 360 atgacatgga gtgcctgtcg gaccgttgca agatcctgca ggtcttcgat gacttcatct 420 teatettett tgecatggag atggtgetta agatggtgge eetgggeatt tttggeaaga 480 agtgetacet eggagacaca tggaacegee tggatttett cattgteatg geagggatgg 540 ttgagtactc tctggaccta cagaacatca acctgtcagc catccgcact gtgcgtgtcc 600 tgaggeetet caaageeate aacegtgtae ceageetgeg gateetggtg aacetgetge 660 tegacaeget geccatgetg gggaaegtge teetgetetg titettegte tietteatet 720 teggeateat tggegtgeag etetgggeag geetgetaeg gaacegetge tteetggaag 780 aaaacttcac catacaaggg gatgtggccc tgccccctta ttaccaacca gaggaggatg 840 acgagatgee etttatetge teeetgactg gggacaatgg cateatggge tgecacgaga 900 tecececaet gaaggageag ggeegggaag tetgeetgte caaagatgat gtgtatgaet 960 teggggeggg gegeeaggae etcaaegeea geggtetgtg egteaaetgg aaeegetaet 1020 acaacgtotg cogcacgggc aacgccaacc ctcacaaggg cgccatcaac tttgacaaca 1080 ttggctatgc ctggattgtg attttccagg tgatcactct ggaaggctgg gtggagatca 1140 tgtactatgt gatggaegea cattettet acaactteat tetgeteate atagtggget 1200 cettetteat gateaacttg tgeetegtte teatageaac ceagttetet gagaceaage 1260 aacggaacca ccggctgatg ctggagcaac gccagcgcta cctgtcctcc agcacggtgg 1320 ccagttacgc tgagcccggt gattgctatg aggagatctt ccaatatgtc tgtcacatcc 1380 ttegeaaage caagegeegt geectaggee tetaccagge cetgeagaac eggegeeagg 1440 ccatgggccc ggggacacca gccctgcca agcctgggcc ccatgccaag gagcccagcc 1500 actogaaget gtgcccacga cacagecece tggaceceae tececacaca etggtgcage 1560 ccatctctgc cattctggcc tcttacccca gcagctgccc tcactgccag cacgaggcag 1620 geaggeggee etetggeetg ggeageactg acteaggeea ggaaggetea ggttetggtg 1680 getetgeaga ggeegaagee aatggggatg gaeteeagag eagagaggat ggggteteet 1740 cggacctggg gaaggaggag gaacaggagg acggggcagc ccgactgtgt ggggatgtat 1800 ggcgcgagac acgaaaaaag ctgcggggca tcgtggacag caagtacttc aacagaggta 1860 tcatgatggc tatcctggtg aacacagtca gcatgggcat cgagcaccac gaacagcccg 1920

# : WO 01/02561



aggagctgac	caacatcctg	gagatctgca	atgtggtctt	caccagtatg	tttgccctgg	1980
agatgatcct	gaaactggcc	gcctttgggc	tcttcgacta	cctgcggaac	ccttacaaca	2040
tctttgacag	catcatcgtc	atcatcagca	tctgggaaat	cgtggggcag	gcggacagtg	2100
gcctgtctgt	gctgcgcact	teceggttge	tgcgggtgct	gaagctagtg	cgcttcatgc	2160
cggcgctgcg	ccagctcgtg	gtgctcatga	agaccatgga	caacgtggcc	accttctgca	2220
tgctactcat	gctgttcatc	ttcatcttca	gcatccttgg	gatcgatatc	tttggctgca	2280
aattcagcct	ccgcacggac	acgggagaca	ccgttcctga	caggaagaac	ttcgattcct	2340
tactgtgggc	catcgtcaca	gtgttccaga	tcctcactca	ggaggactgg	aacgttgtcc	2400
tgtacaatgg	catggcctcc	accacccct	gggcctccct	ctattttgtt	gccctcatga	2460
cctttggcaa	ctacgttctc	ttcaatctcc	tggtggctat	cctggtagag	ggtttccagg	2520
ctgagggtga	tgctaatcgt	tcctactctg	atgaggacca	gageteatee	aatttagagg	2580
agttagacaa	gctcccagag	ggcctggaca	acaggagaga	tctcaagctc	tgcccaatac	2640
ccatgacacc	caatggacac	ctggacccta	gcctccctct	gggtgcgcat	ctgggtcctg	2700
ctggtaccat	gggtactgcc	ccccgcctct	cactgcagcc	agacccggta	ctggtggccc	2760
gggactctcg	gaaaagcagt	tactggtccc	tgggcaggat	gagctatgat	cagcgatect	2820
tgtccagctc	ccggagctcc	tactacggcc	ctgggggccg	cagtgggacc	tgggctagcc	2880
gccgctccag	ctggaacagc	ctgaaacaca	agccgccctc	agctgagcat	gagtccttac	2940
tgtctgggga	gggtggaggt	agctgcgtca	gggcctgtga	aggcgcccgg	gaggaggcgc	3000
caactcgcac	cgcacccctg	catgctccac	accggcacca	cgcgcaccat	ggaccccacc	3060
tggcacaccg	tcaccgacac	caccgccgga	ctctgtccct	cgataccagg	gactctgttg	3120
acctgggaga	gctggtgccc	gtggtgggtg	cccactcacg	ggccgcttgg	aggggggcgg	3180
gtcaggcccc	tgggcacgag	gactgcaatg	gcagaatgcc	caacatggcc	aaggatgtct	3240
tcaccaagat	ggatgaccgc	cgcgaccgcg	gggaggacga	ggaggagatc	gactataccc	3300
tgtgtttccg	ggtccgcaag	atgatttgct	gtgtgtacaa	gccggactgg	tgcgaagtcc	3360
gcgaggactg	gtcggtctac	ctcttctccc	ccgagaacaa	gttccggatc	ctgtgtcaga	3420
ctatcattgc	tcacaagctt	tttgactacg	tggtcttggc	ctttatcttc	ctcaactgta	3480
tcaccattgc	tctggagaga	ccccagattg	aagctggtag	cactgagcgc	atcttcctca	3540
cggtgtctaa	ctacatcttc	acagccatct	tegtgggega	gatgacactg	aaggtggttt	3600
ctctgggcct	gtactttggt	gagcaggcgt	acctgcgtac	ggactggaat	gtactggatg	3660
gtttcctggt	ctttgtgtcc	atcatcgata	tcgtagtgtc	cgtggcctct	gctgggggag	3720
ccaagattct	gggggtcctg	cggctcctgc	gtaccttacg	tcctttgaga	gttatcagcc	3780
gggcccctgg	gctgaagctg	gtggtagaga	cgctcatctc	ctccctcaag	cccattggga	3840
acatcgtcct	catctgctgt	gccttcttca	tcatcttcgg	catcctgggg	gtgcagcttt	3900
tcaaaggcaa	gttctaccat	tgtttgggag	tggacacccg	aaacatcacc	aaccgatctg	3960
actgcgtggc	ggccaactac	cgctgggtgc	atcacaaata	caactttgac	aacctgggcc	4020
aggcattgat	gtccctcttt	gtcttggcct	ccaaggacgg	ctgggtgaac	atcatgtata	4080
atggattaga	tgctgttgct	gtggaccagc	agcccgtgac	gaaccacaac	ccctggatgc	4140
tactgtactt	catttegtte	ctgctcatcg	tcagettett	tgtgctcaac	atgtttgtgg	4200
gegtggtegt	ggagaacttc	cacaagtgcc	ggcagcacca	ggaggctgag	gaggcgcgga	4260
ggcgtgagga	gaaacggctg	cggcgcctgg	aaaagaagcg	ccgttacgct	cagaggctgc	4320
cctactatgc	tacctactgt	cccacaaggc	tgctcatcca	ctccatgtgc	accagccact	4380
acctggacat	cttcattacc	ttcatcatct	gcctcaatgt	tgtcaccatg	tccctggagc	4440
actacaacca	gcctacatcc	ctagagacag	cccttaagta	ctgcaactac	atgttcacca	4500
ctgtgtttgt	gctggaggct	gtgctgaagc	tggtggcatt	tggcctgagg	cgtttcttca	4560
aggaccgatg	gaaccagctg	gacctggcca	ttgtgctgct	gtccgtcatg	ggcatcacac	4620
tggaggagat	cgagatcaat	geegeeette	ccatcaaccc	caccatcatc	cgtatcatgc	4680
gtgttctgcg	tategeeegg	gtgttgaagc	tattgaagat	ggccacagga	atgcgggccc	4740
tgctggacac	agtggtacag	gctctgcccc	aggtgggcaa	cctgggcctg	ctcttcatgc	4800



```
tgctcttctt catctatgct gctctgggag tggagctctt cggaaagctg gtctgcaatg 4860
acgagaaccc gtgtgagggt atgagccggc acgccacett tgaaaactct gctagggcct 4920
tectcaeget ettecaggte tecacaggeg ataactggaa tggaattatg aaggacaece 4980
tgcgagactg tacccatgat gagcgcacgt gcctaagcag cctgcagttt gtgtcaccgc 5040
totactttgt gagottegtg cteacagete agttegtget cateaacgtg gtggtggeeg 5100
tgctgatgaa acatctggat gacagcaaca aggaggccca ggaggatgca gagatggatg 5160
etgagatega getggagatg geccatgget ceggeceetg ceetggeece tgecetggte 5220
cetgecectg cecetgeece tgeceetgtt etggeeegag gtgeceaeta gttacetggg 5280
geteggggge gatggategg gaggggeagg tgetggagge acacegagag teacetgtge 5340
geactgetat caggtgetgg acacegagag teacetgtge eggeactget attetecage 5400
ccaggagacc ctgtggctgg acagggtctc tttaatcatc aaggactcct tggaggggga 5460
getgaecate attgaeaace tgtetgggte egtetteeae caetaegeet caetgaegge 5520
tgtggcaagt gtcaccatga caagcaagag gtgcagctgg ctgagacaga ggccttctcc 5580
ctgaactcag acaggtette atecatectg ctgggggatg acetgagtet tgaggacece 5640
acggcctcgc acagggcccc aaaggagagc aagggtgaac aataaagagc ctccggagcc 5700
catgcaggct ggagacctgg atgaatgcaa aaaaa
<210> 28
<211> 1792
<212> PRT
<213> rat
```

<400> 28

Met Ala Asp Ser Asn Leu Pro Pro Ser Ser Ala Ala Ala Pro Ala Pro 1 5 10 15

Glu Pro Gly Ile Thr Glu Gln Pro Gly Pro Arg Ser Pro Pro Pro Ser 20 25 30

Pro Pro Gly Leu Glu Glu Pro Leu Glu Gly Thr Asn Pro Asp Val Pro 35 40 45

His Pro Asp Leu Ala Pro Val Ala Phe Phe Cys Leu Arg Gln Thr Thr
50 55 60

Ser Pro Arg Asn Trp Cys Ile Lys Met Val Cys Asn Pro Trp Phe Glu 65 70 75 80

Cys Val Ser Met Leu Val Ile Leu Leu Asn Cys Val Thr Leu Gly Met 85 90 95

Tyr Gln Pro Cys Asp Asp Met Glu Cys Leu Ser Asp Arg Cys Lys Ile 100 105 110

Leu Gln Val Phe Asp Asp Phe Ile Phe Ile Phe Phe Ala Met Glu Met
115 120 125

Val Leu Lys Met Val Ala Leu Gly Ile Phe Gly Lys Lys Cys Tyr Leu

Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe Ile Val Met Ala Gly Met 145 150 155 160

140

Val Glu Tyr Ser Leu Asp Leu Gln Asn Ile Asn Leu Ser Ala Ile Arg 165 170 175

Thr Val Arg Val Leu Arg Pro Leu Lys Ala Ile Asn Arg Val Pro Ser 180 185 190

Leu Arg Ile Leu Val Asn Leu Leu Leu Asp Thr Leu Pro Met Leu Gly
195 200 205

Asn Val Leu Leu Cys Phe Phe Val Phe Phe Ile Phe Gly Ile Ile 210 215 220

Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg Cys Phe Leu Glu 225 230 235 240

Glu Asn Phe Thr Ile Gln Gly Asp Val Ala Leu Pro Pro Tyr Tyr Gln 245 250 255

Pro Glu Glu Asp Asp Glu Met Pro Phe Ile Cys Ser Leu Thr Gly Asp 260 265 270

Asn Gly Ile Met Gly Cys His Glu Ile Pro Pro Leu Lys Glu Gln Gly 275 280 285

Arg Glu Val Cys Leu Ser Lys Asp Asp Val Tyr Asp Phe Gly Ala Gly 290 295 300

Arg Gln Asp Leu Asn Ala Ser Gly Leu Cys Val Asn Trp Asn Arg Tyr 305 310 315 320

Tyr Asn Val Cys Arg Thr Gly Asn Ala Asn Pro His Lys Gly Ala Ile 325 330 335

Asn Phe Asp Asn Ile Gly Tyr Ala Trp Ile Val Ile Phe Gln Val Ile 340 345 350

Thr Leu Glu Gly Trp Val Glu Ile Met Tyr Tyr Val Met Asp Ala His 355 360 365

Ser Phe Tyr Asn Phe Ile Leu Leu Ile Ile Val Gly Ser Phe Phe Met 370 380

Ile Asn Leu Cys Leu Val Leu Ile Ala Thr Gln Phe Ser Glu Thr Lys

A00/00794

385	390	395	400

Gln Arg Asn His Arg Leu Met Leu Glu Gln Arg Gln Arg Tyr Leu Ser 405 410 415

Ser Ser Thr Val Ala Ser Tyr Ala Glu Pro Gly Asp Cys Tyr Glu Glu
420 425 430

Ile Phe Gln Tyr Val Cys His Ile Leu Arg Lys Ala Lys Arg Arg Ala 435 440 445

Leu Gly Leu Tyr Gln Ala Leu Gln Asn Arg Arg Gln Ala Met Gly Pro 450 460

Gly Thr Pro Ala Pro Ala Lys Pro Gly Pro His Ala Lys Glu Pro Ser 465 470 475 480

His Ser Lys Leu Cys Pro Arg His Ser Pro Leu Asp Pro Thr Pro His 485 490 495

Thr Leu Val Gln Pro Ile Ser Ala Ile Leu Ala Ser Tyr Pro Ser Ser 500 505 510

Cys Pro His Cys Gln His Glu Ala Gly Arg Arg Pro Ser Gly Leu Gly 515 520 525

Ser Thr Asp Ser Gly Gln Glu Gly Ser Gly Ser Gly Gly Ser Ala Glu 530 535 540

Ala Glu Ala Asn Gly Asp Gly Leu Gln Ser Arg Glu Asp Gly Val Ser 545 550 555 560

Ser Asp Leu Gly Lys Glu Glu Glu Glu Glu Asp Gly Ala Ala Arg Leu 565 570 575

Cys Gly Asp Val Trp Arg Glu Thr Arg Lys Lys Leu Arg Gly Ile Val 580 585

Asp Ser Lys Tyr Phe Asn Arg Gly Ile Met Met Ala Ile Leu Val Asn 595 600 605

Thr Val Ser Met Gly Ile Glu His His Glu Gln Pro Glu Glu Leu Thr
610 620

Asn Ile Leu Glu Ile Cys Asn Val Val Phe Thr Ser Met Phe Ala Leu 625 630 635 640

Glu Met Ile Leu Lys Leu Ala Ala Phe Gly Leu Phe Asp Tyr Leu Arg





650

Asn Pro Tyr Asn Ile Phe Asp Ser Ile Ile Val Ile Ile Ser Ile Trp
660 665 670

Glu Ile Val Gly Gln Ala Asp Ser Gly Leu Ser Val Leu Arg Thr Ser 675 680 685

Arg Leu Leu Arg Val Leu Lys Leu Val Arg Phe Met Pro Ala Leu Arg 690 695 700

Gln Leu Val Val Leu Met Lys Thr Met Asp Asn Val Ala Thr Phe Cys 705 710 715 720

Met Leu Leu Met Leu Phe Ile Phe Ile Phe Ser Ile Leu Gly Ile Asp
725 730 735

Ile Phe Gly Cys Lys Phe Ser Leu Arg Thr Asp Thr Gly Asp Thr Val 740 745 750

Pro Asp Arg Lys Asn Phe Asp Ser Leu Leu Trp Ala Ile Val Thr Val 755 760 765

Phe Gln Ile Leu Thr Gln Glu Asp Trp Asn Val Val Leu Tyr Asn Gly
770 780

Met Ala Ser Thr Thr Pro Trp Ala Ser Leu Tyr Phe Val Ala Leu Met 785 790 795 800

Thr Phe Gly Asn Tyr Val Leu Phe Asn Leu Leu Val Ala Ile Leu Val 805 810 815

Glu Gly Phe Gln Ala Glu Gly Asp Ala Asn Arg Ser Tyr Ser Asp Glu 820 825 830

Asp Gln Ser Ser Asn Leu Glu Glu Leu Asp Lys Leu Pro Glu Gly 835 840 845

Leu Asp Asn Arg Arg Asp Leu Lys Leu Cys Pro Ile Pro Met Thr Pro 850 855 860

Asn Gly His Leu Asp Pro Ser Leu Pro Leu Gly Ala His Leu Gly Pro 865 870 875 880

Ala Gly Thr Met Gly Thr Ala Pro Arg Leu Ser Leu Gln Pro Asp Pro 885 890 895

Val Leu Val Ala Arg Asp Ser Arg Lys Ser Ser Tyr Trp Ser Leu Gly



900 905 910

Arg Met Ser Tyr Asp Gln Arg Ser Leu Ser Ser Ser Arg Ser Ser Tyr 915 920 925

Tyr Gly Pro Gly Gly Arg Ser Gly Thr Trp Ala Ser Arg Arg Ser Ser 930 935 940

Trp Asn Ser Leu Lys His Lys Pro Pro Ser Ala Glu His Glu Ser Leu 945 950 955 960

Leu Ser Gly Glu Gly Gly Ser Cys Val Arg Ala Cys Glu Gly Ala 965 970 975

Arg Glu Glu Ala Pro Thr Arg Thr Ala Pro Leu His Ala Pro His Arg 980 985 990

His His Ala His His Gly Pro His Leu Ala His Arg His Arg His His 995 1000 1005

Arg Arg Thr Leu Ser Leu Asp Thr Arg Asp Ser Val Asp Leu Gly Glu 1010 1015 1020

Leu Val Pro Val Val Gly Ala His Ser Arg Ala Ala Trp Arg Gly Ala 1025 1030 1035 1040

Gly Gln Ala Pro Gly His Glu Asp Cys Asn Gly Arg Met Pro Asn Met
1045 1050 1055

Ala Lys Asp Val Phe Thr Lys Met Asp Asp Arg Asp Arg Gly Glu 1060 1065 1070

Asp Glu Glu Ile Asp Tyr Thr Leu Cys Phe Arg Val Arg Lys Met 1075 1080 1085

Ile Cys Cys Val Tyr Lys Pro Asp Trp Cys Glu Val Arg Glu Asp Trp
1090 1095 1100

Ser Val Tyr Leu Phe Ser Pro Glu Asn Lys Phe Arg Ile Leu Cys Gln 1105 1110 1115 1120

Thr Ile Ile Ala His Lys Leu Phe Asp Tyr Val Val Leu Ala Phe Ile 1125 1130 1135

Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu Arg Pro Gln Ile Glu Ala 1140 1145 1150

Gly Ser Thr Glu Arg Ile Phe Leu Thr Val Ser Asn Tyr Ile Phe Thr



1155 1160 1165

Ala Ile Phe Val Gly Glu Met Thr Leu Lys Val Val Ser Leu Gly Leu 1170 1175 1180

Tyr Phe Gly Glu Gln Ala Tyr Leu Arg Thr Asp Trp Asn Val Leu Asp 1185 1190 1195 1200

Gly Phe Leu Val Phe Val Ser Ile Ile Asp Ile Val Val Ser Val Ala 1205 1210 1215

Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu Arg Leu Leu Arg Thr 1220 1225 1230

Leu Arg Pro Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val 1235 1240 1245

Val Glu Thr Leu Ile Ser Ser Leu Lys Pro Ile Gly Asn Ile Val Leu 1250 1255 1260

Ile Cys Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu 1265 1270 1275 1280

Phe Lys Gly Lys Phe Tyr His Cys Leu Gly Val Asp Thr Arg Asn Ile 1285 1290 1295

Thr Asn Arg Ser Asp Cys Val Ala Ala Asn Tyr Arg Trp Val His His 1300 1305 1310

Lys Tyr Asn Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val 1315 1320 1325

Leu Ala Ser Lys Asp Gly Trp Val Asn Ile Met Tyr Asn Gly Leu Asp 1330 1335 1340

Ala Val Ala Val Asp Gln Gln Pro Val Thr Asn His Asn Pro Trp Met 1345 1350 1355 1360

Leu Leu Tyr Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Phe Val Leu 1365 1370 1375

Asn Met Phe Val Gly Val Val Glu Asn Phe His Lys Cys Arg Gln 1380 1385 1390

His Gln Glu Ala Glu Glu Ala Arg Arg Glu Glu Lys Arg Leu Arg 1395 1400 1405

Arg Leu Glu Lys Lys Arg Arg Tyr Ala Gln Arg Leu Pro Tyr Tyr Ala



1410 1415 1420

Thr Tyr Cys Pro Thr Arg Leu Leu Ile His Ser Met Cys Thr Ser His 1425 1430 1435 1440

Tyr Leu Asp Ile Phe Ile Thr Phe Ile Ile Cys Leu Asn Val Val Thr 1445 1450 1455

Met Ser Leu Glu His Tyr Asn Gln Pro Thr Ser Leu Glu Thr Ala Leu 1460 1465 1470

Lys Tyr Cys Asn Tyr Met Phe Thr Thr Val Phe Val Leu Glu Ala Val 1475 1480 1485

Leu Lys Leu Val Ala Phe Gly Leu Arg Arg Phe Phe Lys Asp Arg Trp 1490 1495 1500

Asn Gln Leu Asp Leu Ala Ile Val Leu Ser Val Met Gly Ile Thr 1505 1510 1515 1520

Leu Glu Glu Ile Glu Ile Asn Ala Ala Leu Pro Ile Asn Pro Thr Ile
1525 1530 1535

Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu Lys Leu Leu 1540 1550

Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val Val Gln Ala 1555 1560 1565

Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu Leu Phe Phe 1570 1575 1580

Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Lys Leu Val Cys Asn 1585 1590 1595 1600

Asp Glu Asn Pro Cys Glu Gly Met Ser Arg His Ala Thr Phe Glu Asn 1605 1610 1615

Ser Ala Arg Ala Phe Leu Thr Leu Phe Gln Val Ser Thr Gly Asp Asn 1620 1625 1630

Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Asp Cys Thr His Asp Glu 1635 1640 1645

Arg Thr Cys Leu Ser Ser Leu Gln Phe Val Ser Pro Leu Tyr Phe Val 1650 1655 1660

Ser Phe Val Leu Thr Ala Gln Phe Val Leu Ile Asn Val Val Val Ala





1665

0 1675

Val Leu Met Lys His Leu Asp Asp Ser Asn Lys Glu Ala Gln Glu Asp 1685 1690 1695

Ala Glu Met Asp Ala Glu Ile Glu Leu Glu Met Ala His Gly Ser Gly
1700 1705 1710

Pro Cys Pro Gly Pro Cys Pro Gly Pro Cys Pro Cys Pro Cys Pro Cys 1715 1720 1725

Pro Cys Ser Gly Pro Arg Cys Pro Leu Val Thr Trp Gly Ser Gly Ala 1730 1735 1740

Met Asp Arg Glu Gly Gln Val Leu Glu Ala His Arg Glu Ser Pro Val 1745 1750 1755 1760

Arg Thr Ala Ile Arg Cys Trp Thr Pro Arg Val Thr Cys Ala Gly Thr 1765 1770 1775

Ala Ile Leu Gln Pro Arg Arg Pro Cys Gly Trp Thr Gly Ser Leu Glx 1780 1785 1790

<210> 29

<211> 540

<212> DNA

<213> rat

<400> 29

aagettetet gagecaggea getgetatga ggagetaete aagtaeetgg tgtacateet 60 cegaaaagea geecgaagge tggeceaggt etetaggget ataggegtge gggetggget 120 geteageage ceagtggee gtagtgggea ggageeecag eecagtggea getgeaeteg 180 eteacaceetg egtetgtetg teeaceacet ggtecaceae cateaceae aceateaeea 240 etacacacet gggtetegea geteagget teecegggee ageecaagga teeaggaeag 300 ggatgeeate gggtetegee ggeteatget aceaceaee tetacaceae eteecetegg 360 gggeeeteeg agggteggg agtetgtaea eagettetae eatgetgaet geeaettgga 420 geeagteegt tgeeaggeae eeceteecag atgeeeateg gaggeatetg gtaggaetgt 480 gggtagtggg aaggtatee eeaetgtgea taceageeet eeaeeagaga 540

<210> 30

<211> 2212

<212> DNA

<213> HUMAN

```
WO 01/02561
```



```
<400> 30
gtgaggggga gccggccggc tggcccggga agccccaggg gcgcagggga agcgggactc 60
gegeegggeg gggttteeet gegeeeegge geeeegggg cageatgeee etgegggeag 120
ggggagetgg gctgaactgg coetcoeggg ggetcagett gcgccctaga gcccaccaga 180
tgtgcccccg coggggcccc cgggttgcgt gaggacacct cctctgaggg gcgccgcttg 240
cccctctccg gatcgcccgg ggccccggct ggccagagga tggacgagga ggaggatgga 300
gegggegeeg aggagteggg acageceegg agetteatge ggeteaacga cetgtegggg 360
gccgggggcc ggccggggcc ggggtcagca gaaaaggacc cgggcagcgc ggactccgag 420
geggaggggc tgccgtaccc ggcgctggcc ccggtggttt tcttctactt gagccaggac 480
agcegecege ggagetggtg tetecgeaeg gtetgtaace cetggtttga gegeateage 540
atgttggtca teetteteaa etgegtgace etgggeatgt teeggeeatg egaggacate 600
geetgtgact cecagegotg ceggatectg caggeetttg atgaetteat etttgeette 660
tttgccgtgg agatggtggt gaagatggtg gccttgggca tctttgggaa aaagtgttac 720
ctgggagaca cttggaaccg gcttgacttt ttcatcgtca tcgcagggat gctggagtac 780
tegetggace tgcagaacgt cagettetca getgtcagga cagtcegtgt getgegaceg 840
ctcagggcca ttaaccgggt gcccagcatg cgcatcettg tcacgttgct gctggatacg 900
ctgcccatgc tgggcaacgt cctgctgctc tgcttcttcg tcttcttcat cttcggcatc 960
gtcggcgtcc agctgtgggc agggctgctt cggaaccgat gcttcctacc tgagaatttc 1020
agecteccec tgagegtgga cetggagege tattaceaga cagagaaega ggatgagage 1080
cccttcatct gctcccagcc acgcgagaac ggcatgcggt cctgcagaag cgtgcccacg 1140
ctgcgcgggg acgggggggg tggcccacct tgcggtctgg actatgaggc ctacaacaqc 1200
tecageaaca ceacetgtgt caactggaac cagtactaca ceaactgete agegggggag 1260
cacaacccct tcaagggcgc catcaacttt gacaacattg gctatgcctg gategccatc 1320
ttccaggtca tcacgctgga gggctgggtc gacatcatgt actttgtgat ggatgctcat 1380
tccttctaca atttcatcta cttcatcctc ctcatcatcg tgggctcctt cttcatgatc 1440
aacetgtgee tggtggtgat tgeeacgeag tteteagaga ceaageageg ggaaageeag 1500
ctgatgeggg agcagegtgt geggtteetg tecaaegeea geaecetgge tagettetet 1560
gageceggea getgetatga ggagetgete aagtacetgg tgtacateet tegtaaggea 1620
gecegeagge tggeteaggt etetegggea geaggtgtge gggttggget geteageage 1680
ccagcacccc tcgggggcca ggagacccag cccagcagca gctgctctcg ctcccaccgc 1740
egectateeg tecaceacet ggtgcaceac caccaceace ateaceacea ctaccacetg 1800
ggcaatggga cgctcagggc cccccgggcc agcccggaga tccaggacag ggatgccaat 1860
gggtcccgcc ggctcatgct gccaccaccc tcgacgcctg ccctctccgg ggcccccct 1920
ggtggcgcag agtctgtgca cagcttctac catgccgact gccacttaga gccagtccgc 1980
tgccaggcgc cccctcccag gtccccatct gaggcatccg gcaggactgt gggcagcggg 2040
aaggtgtatc ccaccgtgca caccagccct ccaccggaga cgctgaagga gaaggcacta 2100
gtagaggtgg ctgccagctc tgggccccca accctcacca gcctcaacat cccacccggg 2160
ccctacagct ccatgcacaa gctgctggag acacagagta caggtgcctg cc
<210> 31
<211> 644
<212> PRT
<213> HUMAN
```


<400> 31

Met Asp Glu Glu Glu Asp Gly Ala Glu Glu Glu Ser Gly Gln Pro



- Arg Ser Phe Met Arg Leu Asn Asp Leu Ser Gly Ala Gly Gly Arg Pro 20 25 30
- Gly Pro Gly Ser Ala Glu Lys Asp Pro Gly Ser Ala Asp Ser Glu Ala 35 40 45
- Glu Gly Leu Pro Tyr Pro Ala Leu Ala Pro Val Val Phe Phe Tyr Leu
  50 55 60
- Ser Gln Asp Ser Arg Pro Arg Ser Trp Cys Leu Arg Thr Val Cys Asn 65 70 75 80
- Pro Trp Phe Glu Arg Ile Ser Met Leu Val Ile Leu Leu Asn Cys Val 85 90 95
- Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Ile Ala Cys Asp Ser Gln 100 105 110
- Arg Cys Arg Ile Leu Gln Ala Phe Asp Asp Phe Ile Phe Ala Phe Phe 115 120 125
- Ala Val Glu Met Val Val Lys Met Val Ala Leu Gly Ile Phe Gly Lys 130 140
- Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe Phe Ile Val 145 150 155 160
- Ile Ala Gly Met Leu Glu Tyr Ser Leu Asp Leu Gln Asn Val Ser Phe 165 170 175
- Ser Ala Val Arg Thr Val Arg Val Leu Arg Pro Leu Arg Ala Ile Asn 180 185 190
- Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu Asp Thr Leu 195 200 205
- Pro Met Leu Gly Asn Val Leu Leu Cys Phe Phe Val Phe Phe Ile 210 215 220
- Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu Arg Asn Arg 225 230 235
- Cys Phe Leu Pro Glu Asn Phe Ser Leu Pro Leu Ser Val Asp Leu Glu 245 250 255
- Arg Tyr Tyr Gln Thr Glu Asn Glu Asp Glu Ser Pro Phe Ile Cys Ser 260 265 270





Arg Gly Asp Gly Gly Gly Pro Pro Cys Gly Leu Asp Tyr Glu Ala 290 295 300

Tyr Asn Ser Ser Ser Asn Thr Thr Cys Val Asn Trp Asn Gln Tyr Tyr 305 310 315 320

Thr Asn Cys Ser Ala Gly Glu His Asn Pro Phe Lys Gly Ala Ile Asn 325 330 335

Phe Asp Asn Ile Gly Tyr Ala Trp Ile Ala Ile Phe Gln Val Ile Thr 340 345 350

Leu Glu Gly Trp Val Asp Ile Met Tyr Phe Val Met Asp Ala His Ser 355 360 365

Phe Tyr Asn Phe Ile Tyr Phe Ile Leu Leu Ile Ile Val Gly Ser Phe 370 375 380

Phe Met Ile Asn Leu Cys Leu Val Val Ile Ala Thr Gln Phe Ser Glu 385 390 395 400

Thr Lys Gln Arg Glu Ser Gln Leu Met Arg Glu Gln Arg Val Arg Phe
405 410 415

Leu Ser Asn Ala Ser Thr Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys
420 425 430

Tyr Glu Glu Leu Leu Lys Tyr Leu Val Tyr Ile Leu Arg Lys Ala Ala 435 440 445

Arg Arg Leu Ala Gln Val Ser Arg Ala Ala Gly Val Arg Val Gly Leu 450 455 460

Leu Ser Ser Pro Ala Pro Leu Gly Gly Gln Glu Thr Gln Pro Ser Ser 465 470 475 480

Ser Cys Ser Arg Ser His Arg Arg Leu Ser Val His His Leu Val His 485 490 495

His His His His His His His Tyr His Leu Gly Asn Gly Thr Leu 500 505 510

Arg Ala Pro Arg Ala Ser Pro Glu Ile Gln Asp Arg Asp Ala Asn Gly 515 520 525



Ser Arg Arg Leu Met Leu Pro Pro Pro Ser Thr Pro Ala Leu Ser Gly 530 540

Ala Pro Pro Gly Gly Ala Glu Ser Val His Ser Phe Tyr His Ala Asp 545 550 555 560

Cys His Leu Glu Pro Val Arg Cys Gln Ala Pro Pro Pro Arg Ser Pro 565 570 575

Ser Glu Ala Ser Gly Arg Thr Val Gly Ser Gly Lys Val Tyr Pro Thr 580 585 590

Val His Thr Ser Pro Pro Pro Glu Thr Leu Lys Glu Lys Ala Leu Val 595 600 605

Glu Val Ala Ala Ser Ser Gly Pro Pro Thr Leu Thr Ser Leu Asn Ile 610 615 620

Pro Pro Gly Pro Tyr Ser Ser Met His Lys Leu Leu Glu Thr Gln Ser 625 630 635 640

Thr Gly Ala Cys

<210> 32

<211> 1608

<212> DNA

<213> HUMAN

#### <400> 32

atgecegegg ggaegeegee ggeeageaga gegaggtget geeggeegee aceatgaeeg 60 agggcgcacg ggccgccgac gaggtccggg tgcccctggg cgcgccgccc cctggccctg 120 cggcgttggt gggggcgtcc ccggagagcc ccgggggcgcc gggacgcgag gcggagcggg 180 ggtccgaget eggegtgtca ceeteegaga geeeggegge egagegegge geggagetgg 240 gtgccgacga ggagcagege gtcccgtace eggeettgge ggecaeggte ttettetgce 300 teggteagae caegeggeeg egeagetggt geeteegget ggtetgeaac ceatggtteg 360 agcacgtgag catgctggta atcatgctca actgcgtgac cctgggcatg ttccggccct 420 gtgaggacgt tgagtgcggc tccgagcgct gcaacatcct ggaggccttt gacgccttca 480 ttttegeett ttttgeggtg gagatggtea teaagatggt ggeettgggg etgtteggge 540 agaagtgtta cctgggtgac acgtggaaca ggctggattt cttcatcgtc gtggcgggca 600 tgatggagta ctcgttggac ggacacaacg tgagcctctc ggctatcagg accgtgcggg 660 tgctgcggcc cctccgcgcc atcaaccgcg tgcctagcat gcggatcctg gtcactctgc 720 tgctggatac gctgcccatg ctcgggaacg tccttctgct gtgcttcttc gtcttcttca 780 tttteggcat cgttggcgtc cagctctggg ctggcctcct gcggaaccgc tgcttcctgg 840 acagtgcctt tgtcaggaac aacaacctga ccttcctgcg gccgtactac cagacggagg 900 agggcgagga gaacccgttc atctgctcct cacgccgaga caacggcatg cagaagtgct 960 egcacatece eggeegeege gagetgegea tgeeetgeae eetgggetgg gaggeetaca 1020



```
cgcagccgca ggccgagggg gtgggcgctg cacgcaacgc ctgcatcaac tggaaccagt 1080 actacaacgt gtgccgctcg ggtgactcca acccccacaa cggtgccatc aacttcgaca 1140 acatcggcta cgcctggatc gccatcttcc aggtgatcac gctggaaggc tgggtggaca 1200 tcatgtacta cgtcatggac gcccactcat tctacaactt catctattc atcctgctca 1260 tcatcgtggg ctccttctc atgatcaacc tgtgcctggt ggtgattgcc acgcagttct 1320 cggagacgaa gcagcggaag agtcagctga tgcgggagca gcgggcacgc cacctgtcca 1380 acgacagcac gctggcaagc ttctccgagc ctggcagctg ctacgaagag ctgctgaagt 1440 acgtgggcca catattccgc aaggtcaagc ggcgcagctt gcgccagcttac gcccgctggc 1500 agagccgctg gcgcaagaag gtggaccca gtggcagct gcgccagggt cccggggacc 1560 gccagcgccg ggcaggagg cacacagcct cggtgcacca cctggtcc 1608 <210> 33 <211> 518 <212> PRT <213> HUMAN
```

<400> 33

Met Thr Glu Gly Ala Arg Ala Ala Asp Glu Val Arg Val Pro Leu Gly

1 10 15 ...

Ala Pro Pro Pro Gly Pro Ala Ala Leu Val Gly Ala Ser Pro Glu Ser 20 25 30

Pro Gly Ala Pro Gly Arg Glu Ala Glu Arg Gly Ser Glu Leu Gly Val
35 40 45

Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu Gly Ala
50 55 60

Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr Val Phe 65 70 75 80

Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu Arg Leu 85 90 95

Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile Met Leu 100 105 110

Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val Glu Cys 115 120 125

Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe Ile Phe 130 135 140

Ala Phe Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu Gly Leu 145 150 155 160

Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu Asp Phe

170

Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly His Asn 180 185 190

- Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro Leu Arg 195 200 205
- Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu Leu Leu 210 215 220
- Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe Phe Val 225 230 235
- Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly Leu Leu 245 250 255
- Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn Asn Leu 260 265 270
- Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Glu Glu Glu Asn Pro 275 280 285
- Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys Ser His 290 295 300
- Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly Trp Glu 305 310 315 320
- Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg Asn Ala 325 330 335
- Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly Asp Ser 340 345 350
- Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr Ala Trp 355 360 365
- Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp Ile Met 370 375 380
- Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr Phe Ile 385 390 395 400
- Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys Leu Val
  405 410 415
- Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser Gln Leu

Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr Leu Ala

Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys Tyr Val

Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu Tyr Ala

Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ala Val Gln

Gly Gln Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His Thr Ala 505

Ser Val His His Leu Val 515

<210> 34

<211> 1080

<212> DNA

<213> HUMAN

<400> 34

geagtgteat gtetetaggg aggatgaget atgaceageg etecetgtee ageteegga 60 getectaeta egggeeatgg ggeegeageg eggeetggge cageegtege tecagetgga 120 acageeteaa geacaageeg eegteggegg ageatgagte cetgetetet geggagegeg 180 geggeggege cegggtetge gaggttgeeg eggacgaggg geegeegegg geegeaccec 240 tgcacacccc acacgcccac cacattcatc acgggcccca tctggcgcac cgccaccgcc 300 accacegeeg gacgetgtee etegacaaca gggaeteggt ggaeetggee gagetggtge 360 ccgcggtggg cgcccacccc cgggccgcct ggagggcggc aggcccggcc cccgggcatg 420 aggactgcaa tggcaggatg cccagcatcg ccaaagacgt cttcaccaag atgggcgacc 480 gcggggatcg cggggaggat gaggaggaaa tcgactacac cctgtgcttc cgcgtccgca 540 agatgatcga cgtctataag cccgactggt gcgaggtccg cgaagactgg tctgtctacc 600 tettetetee egagaacagg tteegggtee tgtgteagae cattattgee cacaaactet 660 tegactacgt egteetggee tteatettte teaactgeat caccategee etggagegge 720 ctcagatcga ggccggcagc accgaacgca tctttctcac cgtgtccaac tacatcttca 780 cggccatctt cgtgggcgag atgacattga aggtagtctc gctgggcctg tacttcggcg 840 agcaggcgta cctacgcagc agctggaacg tgctggatgg ctttcttgtc ttcgtgtcca 900 teategacat egtggtgtee etggeeteag eegggggage caagatettg ggggteetee 960 gagtettgeg geteetgege accetaegee ceetgegtgt cateageegg gegeegggee 1020 tgaagetggt ggtggagaca eteateteet eeeteaagee categgeaac ategtgetea 1080

<210> 35 <211> 359



<212> PRT <213> HUMAN

<400> 35

Ser Val Met Ser Leu Gly Arg Met Ser Tyr Asp Gln Arg Ser Leu Ser 1 5 10 15

Ser Ser Arg Ser Ser Tyr Tyr Gly Pro Trp Gly Arg Ser Ala Ala Trp

Ala Ser Arg Arg Ser Ser Trp Asn Ser Leu Lys His Lys Pro Pro Ser 35 40 45

Ala Glu His Glu Ser Leu Leu Ser Ala Glu Arg Gly Gly Gly Ala Arg
50 55 60

Val Cys Glu Val Ala Ala Asp Glu Gly Pro Pro Arg Ala Ala Pro Leu 65 70 75 80

His Thr Pro His Ala His His Ile His His Gly Pro His Leu Ala His 85 90 95

Arg His Arg His His Arg Arg Thr Leu Ser Leu Asp Asn Arg Asp Ser 100 105 110

Val Asp Leu Ala Glu Leu Val Pro Ala Val Gly Ala His Pro Arg Ala 115 120 125

Ala Trp Arg Ala Ala Gly Pro Ala Pro Gly His Glu Asp Cys Asn Gly 130 135 140

Arg Met Pro Ser Ile Ala Lys Asp Val Phe Thr Lys Met Gly Asp Arg 145 150 155 160

Gly Asp Arg Gly Glu Asp Glu Glu Glu Ile Asp Tyr Thr Leu Cys Phe 165 170 175

Arg Val Arg Lys Met Ile Asp Val Tyr Lys Pro Asp Trp Cys Glu Val

Arg Glu Asp Trp Ser Val Tyr Leu Phe Ser Pro Glu Asn Arg Phe Arg

Val Leu Cys Gln Thr Ile Ile Ala His Lys Leu Phe Asp Tyr Val Val 210 215 220

Leu Ala Phe Ile Phe Leu Asn Cys Ile Thr Ile Ala Leu Glu Arg Pro 230 235 240



Gln Ile Glu Ala Gly Ser Thr Glu Arg Ile Phe Leu Thr Val Ser Asn 245 250 255

Tyr lle Phe Thr Ala Ile Phe Val Gly Glu Met Thr Leu Lys Val Val 260 265 270

Ser Leu Gly Leu Tyr Phe Gly Glu Gln Ala Tyr Leu Arg Ser Ser Trp 275 280 285

Asn Val Leu Asp Gly Phe Leu Val Phe Val Ser Ile Ile Asp Ile Val 290 295 300

Val Ser Leu Ala Ser Ala Gly Gly Ala Lys Ile Leu Gly Val Leu Arg 305 310 315 320

Val Leu Arg Leu Arg Thr Leu Arg Pro Leu Arg Val Ile Ser Arg 325 330 335

Ala Pro Gly Leu Lys Leu Val Val Glu Thr Leu Ile Ser Ser Leu Lys 340 345 350

Pro Ile Gly Asn Ile Val Leu 355